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Abstract.
The ELM erythroleukaemia is novel in that long-term survival of leukaemic 
cells in culture (ELM-D cells) is dependent on contact with a bone marrow-derived 
stromal feeder cell layer. A collaborative study has shown that the transmembrane 
form of stem cell factor is a crucial component of the stromal cell-derived survival 
signal. A number of stroma-independent (ELM-I) mutants have been derived that 
vary in their tumorigenicity and their ability to differentiate in vitro in response to 
erythropoietin and IL-3. The work in this thesis has attempted to define the genetic 
changes responsible for these different phenotypes. At the p53 locus in the primary 
leukaemic cells, one copy of the gene has been lost whilst the other contains an 18bp 
deletion, implicating its mutation as an early step in the development of the 
leukaemia. Changes in ets gene expression have also been found. The Fli-1 locus is 
rearranged in the primary tumour due to the insertion of a retrovirus upstream of one 
Fli-1 allele. However, this does not result in Fli-1 gene activation in any of the ELM- 
D or ELM-I cell lines, except one, which significantly is the only cell line to have lost 
the ability to differentiate in response to erythropoietin. In addition, up-regulation of 
another ets family member, erg, is associated with stromal cell-independent growth 
since all ELM-I mutants have moderate levels of erg mRNA, whereas only low or 
undetectable levels are found in primary leukaemic cells in vivo or in ELM-D cells in 
vitro. This up-regulation of erg mRNA seems to be important for stromal cell- 
independent growth since ELM-D cells, which exhibit short-term viability after 
separation from stromal cells, show elevated expression of the erg gene. This seems 
to be made permanent in ELM-I mutants since, unlike ELM-D cells, they do not 
down-regulate erg mRNA when grown in contact with stromal cells. These 
experiments suggest that alterations in ets gene expression may affect both the 
survival and the differentiation of erythroid cells. Future work designed to assess the 
validity of this hypothesis is discussed.
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PART 1: INTRODUCTION.
2CHAPTER 1: The Control of Erythropoiesis.
1.1: Haemopoiesis and leukaemia.
During normal steady-state haemopoiesis in the mouse, blood cells are 
continually being renewed, as old cells are removed by the liver and replaced by a 
tightly controlled system of proliferation and differentiation of cells within the bone 
marrow and the spleen (Figure 1.1) (for a review, see Dexter and Spooncer, 1987). It 
has been estimated that in humans 3.7xlOn blood cells need to be produced per day to 
replace those lost by natural wastage: injury, infection and haematological stress 
increases and modifies this demand for cell production. All these mature cells are 
derived from a small number of pluripotent stem cells in the haemopoietic organs. 
These cells are able to undergo indefinite self-renewal, but also generate cells that are 
more restricted in terms of their developmental potential. These are essentially of two 
types: the lymphoid precursor cell is only able to produce mature lymphocytes, of 
both the T and B lineages, whilst the multipotential myeloid precursor cell can 
generate all the remaining blood cells i.e. mast cells, erythrocytes, neutrophils, 
macrophages, eosinophils and megakaryocytes (that form platelets). Throughout this 
thesis, 'myeloid' is defined as all the non-lymphoid cells and their precursors in 
recognition of the existence of a common precursor cell, including erythroid cells but 
excluding pluripotent stem cells.
The precursors produce daughter cells that become committed to one 
particular lineage. It is at this stage of differentiation when cell numbers are rapidly 
expanded, such that the number of mature cells formed per precursor is immense. 
These cells respond to maturation signals that activate lineage-specific genes which 
give the mature cell its characteristic properties. This whole process is responsive to 
a large number of cytokines and regulatory molecules that stimulate or repress the 
proliferation, survival and maturation of specific cell types. In steady-state 
haemopoiesis, it appears that a significant proportion of this control is exerted locally 
by the production of these regulators by stromal and haemopoietic cells in the
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3haemopoietic organs. Thus, to a certain extent, these organs act autonomously. 
However, a crucial facet of the system is that it must be able to respond to the needs 
of the animal in times of stress, for example during chronic infection or injury- 
induced blood loss. The precursor and progenitor cell populations are able to respond 
to cytokines produced as a consequence of these events, such that the number and 
type of blood cell produced meets these requirements. Furthermore, it also seems 
likely that stress-induced regulators also alter the spectrum of cytokines produced in 
the haemopoietic microenvironment. These two distinct control mechanisms has 
meant that the role of different regulatory molecules, either in 'emergency' or steady- 
state haemopoiesis, is often a matter of some controversy; an in vitro response of 
progenitors cells to a particular cytokine does not define the exact role of that 
molecule in vivo, but simply indicates the cell's ability to respond. The question of 
when and why the cell needs or utilises this property remains, in many cases, 
unanswered.
In leukaemia, the normal control of haemopoiesis is disrupted. Progenitor, 
precursor or stem cells proliferate uncontrollably and become insensitive to 
maturation signals due to the accumulation of mutational events that alter the function 
of particular oncogenes and tumour suppressor genes (reviewed in Sawyers et al, 
1991). Erythroleukaemias, the subject of this thesis, are relatively unusual in humans, 
representing less than 5% of leukaemias (Villeval et al, 1986). However, their study 
in animal model systems has given important insights into the multistage nature of 
cancer and the function of several genes that are also involved in human 
tumorigenesis.
This introductory section will concentrate on describing the molecules that 
may be involved in regulating normal murine erythropoiesis, and then detail 
erythroleukaemia systems that have been used to identify genes capable of abrogating 
this control. The current hypotheses concerning the role of these genes in normal 
cells will then be described in an attempt to understand why they are targeted during 
the development of erythroleukaemias. I will then describe the ELM cell system
4which has provided a unique opportunity to examine the role of stromal cells in 
erythropoiesis and to identify the effect particular genes have on tumour progression 
within this lineage.
1.2: Erythropoiesis.
Distinct committed erythroid progenitors have been identified called the 
colony-forming unit-erythroid (CFU-E), a mature progenitor, and the burst-forming 
unit-erythroid (BFU-E), a more primitive cell (Figure 1.2). Within these two groups 
are cells at different stages of maturation, thus representing a continuum of 
development from the earliest unipotent progenitor cell to the mature erythrocyte. 
The earliest BFU-E cell is a lineage-restricted product of a myeloid precursor, a cell 
that has the potential to generate all other myeloid cells and is itself derived from a 
pluripotent stem cell. The existence of CFU-E cells was implied by the observation 
that small colonies of between eight and sixty haemoglobinised cells form when 
murine haemopoietic cells are cultured in semi-solid media solely in the presence of 
low levels of purified erythropoietin (epo) for four days (Stephenson et al, 1974). 
Each colony is believed to be derived from a single, rapidly-dividing CFU-E 
progenitor. In similar clonogenic assays, larger grouped colonies called 'bursts' 
appear after five to seven days, although the amount of epo incorporated in the assay 
has to be considerably higher (Gregory and Eaves, 1978). These bursts are derived 
from single late BFU-E cells, with earlier BFU-E forming larger bursts, taking longer 
to do so and requiring additional growth factors. BFU-E cells divide less frequently 
than CFU-E progenitors, but have the potential to generate more erythrocytes. The 
size of the CFU-E population is closely dependent on the serum epo levels. The 
survival, proliferation and maturation of the BFU-E cells, on the other hand, appears 
to be much less responsive to epo, but instead is probably responsive to a large 
number of molecules produced locally in the haemopoietic compartments to create an 
inductive microenvironment. Components of this are discussed below.
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5The purification of these erythroid progenitor cells (Sawada et al, 1990; Koury 
et al, 1984; Nijhof et al, 1987) and the molecular cloning of the erythropoietin gene, 
and subsequent production of the recombinant protein (Jacobs et al, 1985; Lin et al, 
1985), have been very important in understanding the later stages of erythropoiesis. 
CFU-E cells, in response to epo, develop through several morphologically distinct 
intermediate cell types, namely proerythroblast, erythroblast and reticulocyte, before 
the mature erythrocyte is formed. Gradually during maturation erythroid-specific 
genes are switched on that produce the proteins required in a functional erythrocyte 
e.g. a- and p-globins (reviewed in Krantz, 1991). Expression of these genes is 
dependent at least in part on the binding of the GATA-1 zinc-fmger transcription 
factor to recognition sequences in their promoters; mature erythrocytes are not formed 
from cells lacking this protein (Pevny et al, 1991). However, the processes that 
determine whether a cell becomes committed towards erythrocyte production, and 
how erythroid-specific gene expression is coordinately regulated, remain largely 
unresolved. Finally, after this lengthy process of expansion and differentiation, the 
nucleus is removed and the mature red blood cell passes into the blood stream to
perform its critical function as an oxygen transporter.
1.3: Regulation of erythropoiesis: Growth factors and the microenvironment. 
1.3.1: Erythropoietin.
Erythropoietin (epo), the principal factor regulating changes in erythropoiesis 
in the mouse, is a small glycoprotein released into the blood by the kidney, and to a
lesser extent by the liver (reviewed in Krantz, 1991). By a combination of
transcriptional activation through an enhancer 3' to the epo gene (Pugh et al, 1991), 
and stabilisation of the epo mRNA (Goldberg et al, 1991), tissue hypoxia increases 
epo production. Epo binds to the epo receptor (epoR) expressed on erythroid 
progenitors (D'Andrea et al, 1989a), which is a member of the large 'class T cytokine 
receptor family that lack intrinsic kinase activity and probably transduce signals by 
interacting with other membrane-associated proteins (reviewed in Bazan, 1990). In
6particular, epoR is structurally-related to the interleukin-2 receptor P-chain, which 
forms part of an oligomeric complex that permits high affinity binding of the ligand 
and transduces a signal (Saragovi and Malek, 1990). The putative complex formed by 
ligand-associated epoR proteins generates second messengers in responsive CFU-E 
cells that prevent apoptosis (Koury and Bondurant, 1990), the process of programmed 
cell death characterised by membrane blebbing, chromatin condensation, DNA 
fragmentation and eventual cellular disintegration (reviewed in Bursch et al, 1992). 
As the CFU-E mature into erythroblasts their survival no longer requires epo, and epo 
receptors are lost from the cell surface (Figure 1.2) (Landschulz et al, 1989). Thus, 
epo allows more progenitor cells to mature through this stage of differentiation.
However, this is probably an over-simplistic view of the role of epo in 
haemopoiesis. It is likely that epo also stimulates less mature progenitors; erythroid 
'bursts' can form in clonogenic assays simply on the addition of purified epo to the 
media (Gregory and Eaves, 1978), whilst the number of cycling human BFU-E cells 
in vivo is increased during epo infusion (Dessypris and Krantz, 1984). Interestingly, a 
truncated form of the epo receptor gene (epoRT) that lacks part of the cytoplasmic 
domain is preferentially expressed on earlier progenitors, stimulation of which is 
unable to block apoptosis but can still transduce a mitogenic signal (Figure 1.2) 
(Nakamura et al, 1992). Loss of this domain in epoRT may alter the ability of the 
receptor to form homo- and heterodimers, a property which is believed to be 
necessary for signal transduction. This may affect the second messenger systems that 
are stimulated by the two receptor forms, and thus, produce distinct responses 
(Watowich et al, 1992; D'Andrea et al, 1989b).
As well blocking apoptosis and acting as a mitogen, it is likely that epo can 
also independently direct the transcription of erythroid-specific genes, since highly 
proliferative erythroleukaemia cell lines that do not undergo apoptosis can be induced 
to express these genes when treated with epo (Weiss et al, 1989). This may involve 
up-regulation of GATA-1 gene expression, which, interestingly, is able to enhance the 
expression of the epoR gene, thus forming a positive feedback loop to enhance
7differentiation induction by epo (Chiba et al, 1991; Zon et al, 1991). It is not known 
exactly how this loop is broken later in erythroid differentiation when epoR 
expression is down-regulated. However, it has been proposed that the epo-induced 
increase in the level of GATA-1 protein, from the low basal levels seen in earlier 
progenitor cells, is necessary to switch on erythroid-specific genes (Chiba et al, 1991; 
Sposi et al, 1992).
Surprisingly, numerous other cell types outwith the erythroid lineage express 
epo receptors. Multipotential haemopoietic stem cells express low levels of epoR 
mRNA, detectable only by PCR, and it is debatable as to whether a functional 
receptor is translated and translocated to the membrane (Heberlein et al, 1992). 
Indeed, it has been proposed that a major control point in the cell surface expression 
of epoR may be at the level of translocation to the membrane (Migliaccio et al, 1991). 
However, functional, cell-surface epo receptors have been detected on 
megakaryocytes (Fraser et al, 1989), B-lymphocytes (Kimata et al, 1991) and 
endothelial cells (Anagnostou et al, 1990) and treatment with epo produces distinct 
responses, the physiological role of which is not understood.
1.3.2: The haemopoietic microenvironment and erythropoiesis.
Endocrine stimulation of erythroid progenitors by epo is, without question, the 
key regulatory process that determines the number of mature erythrocytes produced in 
an adult mouse. However, epo alone is not sufficient to support long-term 
erythropoiesis and other regulatory molecules must be essential for the lineage 
commitment, survival, proliferation and maturation of early progenitor cells that 
eventually give rise to the epo-responsive CFU-E cell population. Many factors have 
been identified that stimulate early progenitor cells, but their role in normal steady- 
state erythropoiesis must be considered in the context of the structural organisation of 
the haemopoietic compartments. In the marrow, haemopoietic cells from all the 
different cell lineages are intimately associated with stromal tissue, a network of cells 
and extracellular matrix which not only physically supports the haemopoietic cells but
8is also crucial in regulating their maturation (reviewed in Chabannon and Torok- 
Storb, 1992, and Quesenberry, 1992). The bone marrow stroma contains several cell 
types including fibroblasts, macrophages, endothelial cells and T and B lymphocytes. 
It has been known for many years that haemopoietic cells from different lineages 
proliferate in defined zones of the bone marrow (Lord et al, 1975; Lambertsen and 
Weiss, 1984). These observations led to the proposal that the stroma itself is 
compartmentalized into a series of haemopoietic microenvironments. Each is thought 
to commit its resident pluripotent stem cell to a particular lineage by stimulating the 
stem cell and progenitor cells with a cocktail of cytokines and regulatory molecules 
produced locally by distinct stromal cells (Trentin, 1970).
Due to the highly structured nature of the stroma it has been difficult to initiate 
in vitro studies that accurately reflect the in vivo situation. However, much of what 
we do know concerning the haemopoietic microenvironment has come from 
investigating long-term bone marrow cultures (LTBMC).
1.3.3: Long-term bone marrow culture.
When cultured in the appropriate conditions, bone marrow cells give rise to a 
complex adherent layer of stromal cells into which immature progenitor cells seed 
where they proliferate and differentiate into mature myeloid blood cells in the absence 
of exogenous factors (reviewed in Quesenberry, 1992). Modifying the culture 
conditions results in the production of pre B and B cells (Whitlock and Witte, 1982), 
probably as a result of changes in the constituents of the stroma and/or cytokine 
production (Johnson and Dorshkind, 1986). Others have shown that T cell precursors 
can also be generated (Touw and Lowenberg, 1984); thus by slight variations in the 
culture conditions all the mature cells of the blood can be formed. In murine 
LTBMCs, production of haemopoietic cells continues for up to a year, suggesting that 
multipotential stem cells with a high proliferative capacity are supported by the 
adherent layer.
9The presence of the adherent stromal cells is absolutely required for long-term 
haemopoiesis in vivo. Furthermore, direct contact (Dexter et al, 1977), or at least 
extremely close association (Verfaille, 1992), is also required, implying that cytokines 
and other regulatory molecules are concentrated locally on the surface of the stroma. 
BFU-E cells are identifiable in these cultures, but no mature erythrocytes are 
produced unless erythropoietin is added (Eliason et al, 1979; Tsai et al, 1986). Thus, 
with respect to erythropoiesis, all factors required to generate and support BFU-E 
cells are present in the adherent cell layer in LTBMCs, which probably quite 
accurately reflects the importance of stromal cells in erythropoiesis in vivo.
1.3.4: Erythropoietin and the microenvironment.
Several observations suggest that epo may not be acting solely as an endocrine 
factor, but may also be produced locally by cells of the haemopoietic organs. First, 
structures called erythroblastic islands have been identified in vivo, and also in vitro 
in LTBMCs. Originally reported by Bessis (1958), these consist of maturing 
erythroblasts clustered around a central macrophage, with more mature cells more 
distal. Evidence has been presented from in situ hybridisation experiments, which 
suggests that a subset of macrophages in LTBMCs and in vivo can express the epo 
gene, implying that erythropoiesis can be regulated by short range, or cell-to-cell, 
interactions within the bone marrow between epo and its receptor (Rich, 1988; Vogt 
et al, 1991). This result has been supported by sensitive PCR experiments that have 
enabled detection of epo mRNA in bone marrow cells. Recent evidence suggests that 
cells other than macrophages may also express the epo gene in the haemopoietic 
organs. If bone marrow cells are pre-incubated for 36 hours with antisense epo 
oligonucleotides, there is a decrease in the number of mixed erythroid/non-erythroid 
colonies formed in subsequent epo/interleukin-3-stimulated 'burst'-forming assays 
compared to controls containing epo sense sequences (Hermine et al, 1991). 
However, the number of colonies consisting entirely of erythroid cells is unaffected 
by the oligonucleotides. This result suggested that locally-produced epo was essential
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for the survival of epo-responsive multipotential myeloid precursor cells, but not for 
BFU-E cells, during the pre-incubation stage. Surprisingly, inclusion of epo protein in 
the antisense pre-incubation did not prevent the inhibition of colony formation, which 
the authors suggest is evidence that epo and its receptor are produced by the same cell 
and interact internally, analogous to the gp55:epoR interaction seen in Friend virus- 
infected erythroid progenitors (see section 2.3.2) (Hermine et al, 1991; Yoshimura et 
al, 1990a). Nevertheless, antisense experiments are always subject to problems of 
specificity: it is possible that the antisense epo oligonucleotides used in these 
experiments affect the expression of other genes involved in multipotential progenitor 
survival and not just the epo gene. Thus, whilst the role epo plays in the stromal 
microenvironment remains unclear, it seems unlikely that it is acting solely as an 
endocrine factor.
1.3.5: The role of IL-3 and GM-CSF in erythropoiesis.
Two haemopoietic cytokines, interleukin-3 (IL-3) (Ihle et al, 1983; Yokota et 
al, 1984) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Burgess 
et al, 1977; Gasson et al, 1984), have a wide variety of effects, stimulating the 
progenitor cells from all myeloid lineages (reviewed in Arai et al, 1990). Use of 
either of these factors in combination with low levels of epo greatly enhances the 
number and size of 'bursts' of haemoglobin-containing cells formed from bone 
marrow cells in clonogenic assays compared to when epo was used alone. Using 
them both together with epo has an even more dramatic effect, and the concentration 
of epo used in the experiment can be reduced to near physiological levels (Sonoda et 
al, 1988). Using highly purified blood-borne BFU-E cells, Sawada et al (1990) 
concluded that developing erythroid cells are initially IL-3/GM-CSF-responsive, but 
that this is then lost as the cells mature into the epo-dependent CFU-E stage. The 
pleiotropic effect of these two cytokines has been demonstrated in vivo by 
administering them to experimental animals and showing a huge expansion of 
myeloid progenitor cells, including BFU-E and CFU-E (Metcalf et al, 1986; Donahue
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et al, 1986). Furthermore, transplantation of bone marrow cells, infected with a 
retrovirus over-expressing the IL-3 gene, into lethally-irradiated syngeneic hosts, 
generates a non-neoplastic myeloproliferative syndrome in mice, again dramatically 
increasing the BFU-E and CFU-E numbers (Chang et al, 1989).
However, the role of these factors in vivo is a matter of some controversy. 
Although, GM-CSF protein and mRNA is readily detectable in the stromal cell layer 
of LTBMCs that have been exposed to radiation (Gualtieri et al, 1984; Alberico et al,
1987), or interleukin-1 (IL-1) (a multifunctional inflammatory mediator) (Yang et al,
1988), it has been very difficult to detect in unstimulated stroma. However, using 
highly sensitive PCR protocols, Kittler et al (1992) have shown that IL-3 and GM- 
CSF mRNA are present at very low levels in unstimulated stromal cells. These levels 
of expression, however, would suggest that haemopoietic cells are only ever exposed 
to suboptimal concentrations of these factors in the medium. However, LTBMC 
stroma is able to support the growth of factor-dependent haemopoietic cell lines, an 
effect that is abrogated by the inclusion of antibodies directed against IL-3 or GM- 
CSF in the culture (Alberico et al, 1987; Kittler et al, 1992). Furthermore, recent 
work implies that components of the extracellular matrix (ECM) may be involved in 
binding and presenting growth factors to target cells such that their effective 
concentration locally is increased dramatically. Gordon et al (1987) and Roberts et al 
(1988) have shown that sulphated glycosaminoglycans, the major component of 
which is heparan sulphate, adsorb both GM-CSF and IL-3, retaining them in an active 
form. In LTBMCs this may explain the necessity for the extremely close association 
between haemopoietic cells and the stroma in blood cell development (Verfaille, 
1992). In vivo, this could create microenvironmental niches that direct the maturation 
of specific cell types.
Despite this evidence, it is still debatable whether EL-3 and GM-CSF are 
involved in erythropoiesis under normal steady-state conditions. Zipori (1990) and 
Arai et al (1990) have argued that the sole function of these cytokines is as 
components of 'emergency' haemopoiesis associated with immune defence. IL-3 and
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GM-CSF are produced by activated T cells (Arai et al, 1990) and support the 
proliferation of mature haemopoietic cells, such as neutrophils and macrophages 
(Gasson et al, 1984; Vairo and Hamilton, 1991). Their effect on progenitor cells may 
also be important in supplementing mature blood cells at the sites of infection by 
stimulating the proliferation of blood-borne progenitors. Infection would also be 
likely to induce IL-3 and GM-CSF production by certain immune-responsive cells in 
the bone marrow, and thereby increase blood cell production; alternatively, other 
factors, such as IL-1, circulating in the blood as a result of infection could stimulate 
their production from bone marrow stromal cells (Arai et al, 1990; Yang et al, 1988).
A recent report suggests that GM-CSF may even indirectly down-regulate 
erythropoiesis in some situations (Wang et al, 1992a). Burst formation by BFU-E 
cells is reduced in GM-CSF/epo-containing medium if macrophages are added. GM- 
CSF induces the secretion of TNF-a by stromal cells and macrophages. TNF-a is a 
negative regulator of erythropoiesis (see section 1.3.8.5 below), and is able to negate 
the positive stimulatory effect of GM-CSF on erythroid progenitors. Combining this 
with the known stimulation of other myeloid lineages by GM-CSF (that are relatively 
insensitive to TNF-a), in vivo, there will be a shift in the lineage-commitment of 
multipotent myeloid precursor cells away from the erythroid lineage at times when 
GM-CSF production is high, and there are a large number of macrophages present. 
This is indeed seen during chronic infection, with anaemia often accompanying 
increases in macrophage production.
1.3.6: Stem cell factor; an essential component of the haemopoietic 
microenvironment.
13.6.1: The white-spotting and Steel loci.
The importance of the stromal microenvironment in the development, 
maintenance and regulation of haemopoiesis is illustrated by Steel (S[) and white- 
spotting (W) mutant mice. Mutations at a single autosomal locus in these animals 
results in altered coat colouration, defective gonad development, varying degrees of
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anaemia and a reduction in the number of mast cells (reviewed in Russell, 1979). 
Numerous distinct alleles have been identified (e.g. SI, Sld, W, and W42) which, in a 
homozygous state, generally cause embryonic lethality due to severe anaemia. 
Heterozygotes (e.g. SI/+) or compound heterozygotes (Sl/Sl^) are still viable and can 
reach maturity, but still exhibit the phenotype to varying degrees. Despite the 
similarities between the SI and W mice, two distinct cell populations are affected. 
This was demonstrated in vivo by a series of experiments performed by McCulloch 
and co-workers (McCulloch et al, 1964, 1965): these showed that haemopoietic stem 
cells from a SI, but not a W, heterozygote could rescue a lethally-irradiated normal 
mouse, whilst normal haemopoietic cells could cure a W mutant, but not a SI, mouse. 
Furthermore, stromal cell feeder layers generated from a SI mouse are unable to 
support long-term stem cell growth in LTBMCs, whereas stromal cells from a W 
mouse are unaffected by their mutation (Dexter and Moore, 1977). Thus, in SI mice 
the microenvironment is deficient in providing support for progenitor cells of the 
haemopoietic system, whilst in W mutants it is the progenitors themselves that are 
defective.
1.3.6.2: The white-spotting locus encodes the c-kit receptor.
The products of these two loci have now been identified. The W locus on 
chromosome 5 codes for the c-kit protein, a tyrosine kinase receptor containing five 
extracellular immunoglobulin-like repeats that is closely related to the receptors for 
platelet-derived growth factor and colony-stimulating factor-1 (Geissler et al, 1988; 
Chabot et al, 1988; Qiu et al, 1988). All W mutations result in a marked reduction in 
the kinase activity of the receptor, either by directly reducing the level of c-kit mRNA 
or by the presence of inactivating point mutations in the c-kit coding region (Nocka et 
al, 1989, 1990a; Tan et al, 1990; Reith et al, 1991; Dubreuil et al, 1990). As 
expected, expression of functional c-kit receptors rescues the defect of W mutant cells 
(Alexander et al, 1991), whilst injection of anti-kit antibodies into normal wild-type 
mice mimics, at least to some extent, the effect of mutation within the c-kit gene seen
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in W mice (Ogawa et al, 1991). Surprisingly, W mutants are known that have point 
mutations in c-kit but only exhibit some of the phenotypic abnormalities described 
above (Reith et al, 1990). Furthermore, c-kit mutations are present in humans 
suffering from piebaldism, a genetic disease which alters skin pigmentation but has no 
effect on haemopoiesis and gonad development (Giebel and Spritz, 1991; Fleischman 
et al, 1991). Thus, some c-kit mutations only affect certain cell types implying tissue- 
specific roles for certain domains in the c-kit protein. Interestingly, in contrast to the 
W mutations, other abnormalities in c-kit can be oncogenic; the HZ4 feline sarcoma 
virus contains a transduced cellular gene which encodes a mutated, truncated version 
of the receptor, termed v-kit (Besmer et al, 1986), which is thought to possess 
constitutive tyrosine kinase activity.
1.3.6.3: Stem cell factor, a ligand for c-kit.
The Steel locus on chromosome 10 encodes stem cell factor (SCF), a protein 
that acts as a ligand for c-kit, binding via the three amino-terminal immunoglobulin­
like repeats in the receptor: SCF is also referred to as mast cell growth factor, kit 
ligand and Steel factor (Huang et al, 1990; Anderson et al, 1990; Nocka et al, 1990b; 
Williams et al, 1990a; Copeland et al, 1990; Zsebo et al, 1990a, 1990b; Martin et al, 
1990; reviewed in Witte, 1990; Blechman et al, 1993; Lev et al, 1993). Expectedly, 
infusion of SI mice with SCF produces a marked reduction in the severity of their 
anaemia and increases their mast cell number (Zsebo et al, 1990b). As is the case 
with a number of other cytokines such as transforming growth factor-a (TGF-a) 
(reviewed by Massague, 1990), SCF is produced as a transmembrane (TM), as well as 
a soluble, form (Flanagan and Leder, 1990; Huang et al, 1990, 1992). Alternative 
splicing of the SCF mRNA determines if it is retained in the membrane or if a 
proteolytic cleavage site is included that can be digested to efficiently release soluble 
SCF. The expression of these two forms is regulated in a tissue-specific manner, and 
cleavage can be induced by extracellular stimuli, an effect, which in the case of TGF- 
a , is mediated by the cytoplasmic tail of the protein (Huang et al, 1992; Bosenberg et
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al, 1992). Both forms of SCF stimulate cell proliferation, but cells expressing TM 
SCF are able to adhere to c-kit-expressing cells (Flanagan etal, 1991).
The importance of TM-SCF in vivo has been implied by studying certain Steel 
mutants. Mice homozygous for the Steel-Dickie allele (Sl^) develop to adulthood and 
show a classic Steel phenotype but seem to have no reduction in the amount of SCF 
mRNA produced. However, these animals produce no TM SCF as a result of a 
deletion that removes the TM and intracellular domains of the gene, but still produce 
biologically-active soluble SCF (Flanagan et al, 1991; Brannan et al, 1991; Huang et 
al, 1992). This is highly suggestive that direct cell-cell interactions mediated by TM 
SCF and c-kit are necessary for the development of the murine haemopoietic system. 
It is possible that these interactions are required to direct stem cells and progenitors 
from the yolk sac to the liver, and then to the bone marrow and spleen, during 
embryogenesis. It is at the time of these migrations that the SlfW phenotype becomes 
apparent, and indeed, SCF is expressed in increasing amounts along the appropriate 
migratory pathways to the homing sites (Matsui et al, 1990; Keshet et al, 1991), 
whilst c-kit is present on the migrating cells (Orr-Urteger et al, 1990; Keshet et al,
1991). Furthermore, it has been proposed that the TM SCF has different stimulatory 
properties from the soluble form. Dolci and her co-workers (1991) showed that 
soluble SCF is relatively limited in its ability to support the long-term survival of 
primordial germ cells in culture whilst the TM form was much more proficient. Steel 
et al (1992) have suggested that the same may be true for embryonic melanoblasts. 
Furthermore, TM SCF not only establishes cell-cell adhesion in LTBMCs but also 
maintains haemopoietic progenitors in culture much longer than soluble SCF (Toksoz 
et al, 1992). Differences in a cells response to soluble versus TM growth factors 
could occur through several mechanisms including (a) changes in receptor 
internalisation (Blume-Jensen et al, 1991), (b) generation of different intracellular 
messages, or (c) establishing other stimulatory interactions between receptors and 
ligands such as IL-3, GM-CSF or components of the ECM as a result of juxtaposing 
the two cell types.
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There is some evidence that the cytoplasmic region of SCF may play an 
important role in vivo. The Steel17H allele is only a weak mutant: homozygotes 
survive and only exhibit mild anaemia and coat colour changes, and intriguingly, only 
male animals are sterile. This allele has lost 68 nucleotides from its mRNA as a 
consequence of a splicing defect, resulting in the loss of 23 amino acids and a frame 
shift in the cytoplasmic region of the protein. Whether the phenotype affects either 
the processing of this protein to the membrane, or its cleavage to produce the soluble 
form, is uncertain, but it raises important questions concerning signalling into stromal 
cells, and the sex-specificity of TM SCF (Brannan et al, 1992).
The Sl/W phenotype in embryonic-lethal homozygotes appears to be a 
consequence of a block in cell survival and migration during development. The 
heterozygotes phenotype could be interpreted as a reduction in the number of stem 
cells reaching the target organs. However, in adult mice, SCF still plays a central role 
in haemopoiesis (reviewed in Broxmeyer et al, 1991a). Normal haemopoietic cells 
are unable to rescue SI heterozygotes, whilst injection of normal adult mice with anti­
kit antibodies causes a rapid reduction in the number of myeloid progenitor cells, 
including BFU-E and CFU-E, followed eventually by loss of the mature cells from 
these lineages (Ogawa et al, 1991). Furthermore, antisense c-kit oligomers drastically 
inhibit burst formation by BFU-E cells (Ratajczak et al, 1992). Thus, myeloid and 
erythroid progenitor cells present in adult animals appear to be dependent on SCF for 
survival. This has been supported using in vitro clonogenic assays and purified 
soluble SCF. Alone, SCF has little effect on progenitor cells, although it can induce 
proliferation and maturation of mast cells (Nocka et al, 1990b; Tsai et al, 1991a). 
However in combination with other cytokines, SCF has a potent synergistic effect on 
progenitors. With GM-CSF or granulocyte colony-stimulating factor (G-CSF) it 
.stimulates the formation of myeloid colonies (Ulich et al, 1991). Interleukin-7 (IL-7), 
a lymphoid-specific cytokine, and SCF combine to stimulate pre-B cells, a surprising 
result considering that B-lymphopoiesis is unaffected in W mice or by anti-kit 
antibodies in vivo (McNiece et al, 1991). As would be expected, in combination with
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epo, SCF dramatically increases erythroid ’burst' formation (Martin et al, 1990; 
Anderson et al, 1990; Nocka et al, 1990b; Broxmeyer et al, 1991b; Dai et al, 1991). 
Furthermore, multipotent myeloid precursor cells are also highly responsive to SCF 
(Broxmeyer et al, 1991b; Carow et al, 1991), although it is still questionable as to 
whether SCF is able to directly stimulate pluripotent haemopoietic stem cells 
(Broxmeyer et al, 1991a; Wineman et al, 1993). In many cases, the concentration of 
cytokine required to elicit this synergism with SCF is extremely low, comparable to 
levels seen in vivo. Therefore, a model has been proposed in which SCF acts to 
'prime' cells to respond to local or circulating factors, such as IL-3 and epo 
respectively, at the physiologically relevant level (Lowry et al, 1992).
Thus, in summary, unlike GM-CSF and IL-3 and many other factors whose 
involvement in steady-state erythropoiesis has only been inferred by in vitro 
experiments, the results discussed here with the SlfW mutants demonstrate that SCF is 
an essential component of the haemopoietic microenvironment controlling blood cell 
production. The different properties of the two forms of the growth factor (either 
soluble or membrane-anchored) imply that direct cell-cell contact between progenitor 
cells and the stroma, mediated by TM SCF, may be central to this control.
1.3.7: Integrins and the extracellular matrix.
The ECM of the haemopoietic organs plays a dual role in erythropoiesis. 
First, it acts as an anchorage site for progenitor cells. CFU-E, and to a lesser extent 
BFU-E, adhere to fibronectin (Fn) (Weinstein et al, 1989), whereas granulocyte 
progenitors preferentially bind to haemonectin, a separate component of the ECM 
(Campbell et al, 1987). Both are able to bind to collagen type I (Koenigsmann et al,
1992). These differences in the adhesive properties of specific progenitor cell 
populations, may be essential to direct them to distinct microenvironments that permit 
further maturation. To allow the erythrocytes to enter the blood stream, as the CFU-E 
mature, the number of Fn receptors decreases and adhesion is lost (Vuillet-Gaugler et 
al, 1990).
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The second possible function is as a direct stimulant of cell proliferation 
and/or survival. For example, Fn induces a modest increase of erythroid 'burst' 
formation in vitro, an effect that may be mediated by signal transduction through the 
Fn receptor (Werb et al, 1989). Indeed, ECM receptor proteins (integrins) are now 
believed to initiate intracellular signals that influence cell growth, differentiation and 
morphology (reviewed in Damsky and Werb, 1992). The Fn receptor is not the only 
integrin expressed during erythropoiesis: many other adhesion molecules have been 
detected on erythroid progenitor cells and their expression is modified as they mature 
(Papayannopoulou and Brice, 1992). The exact role of these interactions during 
erythropoiesis remains to be elucidated, but it seems likely that they affect the 
processes of maturation and proliferation as part of an inductive microenvironment 
for erythropoiesis.
The ECM also plays an important indirect role in haemopoiesis. As discussed 
above, GM-CSF and IL-3 bind to heparan sulphate where they are retained in an 
active form. Other studies suggest that interaction with the ECM is important in the 
effective presentation of growth factors to cells. For example, basic fibroblast growth 
factor also binds to heparan sulphate, but unlike IL-3 and GM-CSF, this is necessary 
to enable it to bind to its high affinity receptor on target cells (Yayon et al, 1991). 
Leukaemia inhibitory factor, on the other hand, can be secreted in two forms from 
embryonic fibroblasts. One is a soluble molecule whilst the other contains a unique 
amino-terminus, as a consequence of transcription from an alternative promoter, that 
causes it to become immobilised on the ECM (Rathjen et al, 1990). Alternatively, as 
for SCF, growth factors can be produced as membrane proteins, which along with the 
mechanisms discussed here, have the effect of concentrating growth factors on a 
relatively immobile two-dimensional surface. It seems highly likely that this is 
essential to restrict regulation of cell growth and development to a small area of the 
bone marrow and to permit the establishment of many heterogeneous lineage-specific 
niches.
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1.3.8: Other erythropoietic regulators.
Several other molecules are able to influence erythrocyte production, by 
stimulating or inhibiting cell proliferation, maturation or survival. A number of these 
that are believed to exert a direct effect on erythroid progenitors are discussed below, 
although their exact role in the context of the haemopoietic microenvironment is often 
a matter of some controversy.
13.8.1: Erythroid-potentiating activity.
Erythroid-potentiating activity (EPA) was originally purified from the 
conditioned-medium of a T-lymphoblast cell line which had the ability to synergise 
with epo to induce erythroid 'burst' formation in vitro (Westbrook et al, 1984; Gasson 
et al, 1985). In vivo administration of recombinant protein to anaemic mice causes an 
increase in the number of erythroid precursors in the spleen, and erythrocytes in the 
blood (Niskanen et al, 1988). EPA is expressed in the haemopoietic organs and is 
produced in an active form by stromal and erythroleukaemia cells (Hayakawa et al, 
1990; Avalos et al, 1988). EPA signals via specific receptor molecules on progenitor 
cells to up-regulate erythropoietin receptor expression (Fraser et al, 1988). 
Surprisingly, EPA is identical to a member of the family of tissue inhibitors of 
metalloproteinases-1, which as their name suggests were isolated due to their ability 
to prevent ECM degradation by metalloproteinases (Docherty et al, 1988). In view of 
the importance of the ECM in haemopoiesis, this molecule could also affect 
erythropoiesis indirectly through a local restructuring of the microenvironment.
1.3.8.2: Burst-promoting activity (BPA).
Daniak and Cohen (1982) identified an activity in conditioned-medium from 
B-lymphocytes that acted synergistically with epo to induce erythroid 'burst' 
formation in vitro. Although the gene for this protein has yet to be cloned, it was 
shown that the activity is caused by an integral membrane protein, termed BPA, 
present in exfoliated vesicles from the B-cells interacting with early erythroid
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progenitors (Feldman et al, 1987). This represents a unique mechanism whereby the 
close proximity of two cell types, but not necessarily direct contact, is sufficient to 
exchange growth regulatory signals present in the membranes. As with all these 
factors, the exact role of BPA in vivo is unknown, but its association with an immune 
cell suggests it may be involved in 'emergency' haemopoiesis induced on infection. 
However, B-cells are also believed to be a component of the haemopoietic stroma 
(Quesenberry, 1992) and thus, BPA may be involved in establishing an erythropoietic 
microenvironment.
1.3.8.3: Steroids: thyroid hormone and retinoic acid.
Anaemia is frequently a complication of hypothyroidism in humans, 
responding only to thyroid hormone (T3) replacement therapy (Fein and Rivlin, 
1975). This hormone stimulates erythropoietin production (Peschle et al, 1971), but 
also appears to have a more direct effect on immature erythroid cells, acting to 
increase epo/IL-3-induced erythroid 'burst' formation in in vitro assays (Dainiak et al, 
1978). Dainiak and his co-workers later suggested that this was due to T3 inducing 
the production of erythropoietic growth factors by accessory cells, probably 
lymphocytes, and not as a direct effect on the erythroid progenitors themselves 
(Dainiak et al, 1986). However, a more detailed recent study (Schroeder et al, 1992) 
using pure populations of chick erythroid cells, suggests that this is probably not a full 
explanation. These experiments were performed on erythroid progenitors reversibly 
transformed with a temperature-sensitive (ts) v-sea oncogene. At the non-permissive 
temperature when the cells were no longer transformed, treatment with T3 weakly 
accelerated the differentiation of the progenitors, but induced premature cell death in 
more mature cell types. The same phenomenon was also observed in erythroid 
progenitors isolated by virtue of their ability to grow in TGF-a, suggesting that the ts- 
v-sea oncogene was not involved in the effect.
Interestingly, retinoic acid (RA) produced a similar response to T3 in these 
experiments, but was much more potent, and furthermore, exhibited a synergistic
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effect when used in combination with T3 (Schroeder et al, 1992). As in hypothyroid 
individuals, there is often a correlation between retinol (vitamin A) deficiency and 
anaemia (Koeffler and Amatruda, 1985). The similarity in the responses elicited by 
T3 and RA is probably due to the functional similarity of their receptors, both 
signalling via nearly identical response elements (reviewed in Beato, 1989), whilst it 
has been proposed that the observed synergism between these two steroids is possibly 
an indication of heterodimerisation of the two receptors (Schroeder et al, 1992; 
Hudson et al, 1990). The importance of these two factors in normal erythropoiesis in 
vivo is supported not only by the correlations between deficiency and anaemia, but 
also by the oncogenic effect v-erbA, a mutated form of the T3 receptor carried by the 
avian erythroblastosis virus (AEV) (section 2.2.1). As its name suggests AEV 
induces erythroleukaemias in chickens, with the v-erbA protein preventing RA and 
T3-mediated signals, blocking the expression of certain erythroid-specific genes, and 
thus, disrupting differentiation.
1.3.8.4: Activin.
Eto and his co-workers (1987) purified a protein, termed erythroid 
differentiation factor (EDF), from a phorbol ester-treated monocytic cell line, that was 
able to induce the differentiation of murine erythroleukaemia cells and enhance the 
growth of normal erythroid precursors in vitro and when administered to mice in vivo 
(Yu et al, 1987; Broxmeyer et al, 1988; Shiozaki et al, 1990a). EDF has also been 
shown to have a stimulatory effect on megakaryocytic differentiation (Fujimoto et al, 
1991) and the growth of multipotential progenitor cells (Broxmeyer et al, 1988). It 
has been demonstrated that EDF is identical to activin (Murata et al, 1988), a protein 
that is known to enhance the secretion of follicle-stimulating hormone from pituitary 
cells (Vale et al, 1986; Ling et al, 1986) and appears to be involved in determining 
cell fate in early embryos (reviewed in Wylie, 1990). There are several observations 
that imply that activin/EDF plays a physiological role in normal steady-state 
erythropoiesis. First, Yamashita and his colleagues (1992) have demonstrated that
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murine bone marrow stromal cells express the gene, and respond to cytokines, like 
interleukin-1, to increase production. Second, Shiozaki et al (1992), who confirmed 
this observation, went on to show that the protein was produced in an active form by 
these cells. More importantly, they demonstrated that follistatin (a specific binding 
protein that blocks activin function) induces a decrease of the erythroid progenitor 
cell population (BFU-E and CFU-E) when administered to mice. Surprisingly, 
however, the number of mature erythrocytes produced was unchanged. This implies 
that activin has a role in controlling steady-state erythropoiesis, but that other factors 
can compensate if it is inhibited.
1.3.8.5: Negative effect of tumour necrosis factor-a.
Macrophages reduce in vitro colony formation by CFU-E cells whilst infusion 
of macrophages into mice that have been infected with the Friend virus (see section 
2.3 below), that have a large increase in CFU-E numbers, results in the reversal of the 
disease state (Marcelletti and Furmanski, 1978). Indeed, during Friend disease 
macrophages become infected and their ability to suppress erythropoiesis is lost 
(Marcelletti and Furmanski, 1979). Furthermore, it is now generally accepted that the 
anaemia that often accompanies chronic infection, is due to macrophage proliferation 
(see section 1.3.5). Macrophages release a large number of cytokines, including 
interleukin-1-a (IL-l-a) which mediates this erythrosuppressive effect by synergising 
with tumour necrosis factor-a, induced in soluble or membrane bound forms 
(Massague, 1990) by stromal cells and macrophages in response to IL -la  and GM- 
CSF (see above) (Furmanski and Johnson, 1990; Wang et al, 1992a). EL-l-a release 
increases at times of infection so shunting haemopoiesis toward the production 
immune defence cells at the expense of erythrocytes.
1.4: Summary.
Alterations in the level of production of mature red blood cells that are needed 
to meet the requirements of the animal, are almost exclusively controlled by the
23
hormone erythropoietin, which enhances the survival of erythroid progenitors already 
in the process of differentiation. Only at times of infection or blood loss are other 
growth factors, such as IL-3, GM-CSF and TNF-a, likely to affect erythrocyte 
production. However, the viability, proliferation and lineage commitment of the 
progenitors is largely determined by the nature of the local microenvironment which 
contains a complex combination of growth factors, extracellular matrix components 
and cell adhesion molecules produced by haemopoietic and stromal cells. The study 
of these interactions has only been possible using genetically-defective mice (Steel 
and white-spotting mutants) and complex in vitro systems, like LTBMCs. To further 
understand the role of the microenvironment, it would be advantageous to generate 
cell systems in which complexity is reduced by decreasing the number of cell types in 
the culture, whilst maintaining the physiological dependence on stroma interaction. 
The availability of these simplified coculture systems would also permit an 
investigation into the role of stroma in leukaemia: one could hypothesise that a cell 
able to proliferate outside the haemopoietic microenvironment would have a 
considerable advantage over its normal counterparts. Identifying genetic alterations 
which are able to overcome stromal cell-dependence, would not only give an insight 
into the signal transduction pathways activated by stromal cell interaction, but may 
show that overcoming the control exerted by the microenvironment can be a crucial 
part of leukaemic progression.
CHAPTER 2: Models for Erythroleukaemia in Experimental
Animals.
2.1: Retrovirally-induced leukaemias: An overview.
Leukaemia can be defined as the uncontrolled proliferation or expansion of 
haemopoietic cells that lose the ability to differentiate normally to mature blood cells. 
This implies that the developing leukaemic cell must become insensitive to the
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normal signals that regulate its proliferation, survival and maturation. This is 
dependent on the accumulation of stable genetic mutations that activate proto­
oncogenes and disrupt the inhibitory effects of tumour suppressor gene products. In 
humans, these genetic alterations are either inherited or arise spontaneously, probably 
to some extent as the consequence of exposure to environmental mutagens and 
carcinogens throughout life. Many animal model systems have been developed to 
study tumorigenesis, in which a defined treatment will repeatedly generate 
malignancies of a specific type. These have been essential in the identification of 
genes targeted in tumour progression and the definition of their role in disrupting 
normal growth and development.
Important advances in understanding normal and malignant haemopoiesis 
have come from the study of murine and avian leukaemia viruses (reviewed in Teich 
et alt 1982). These can be divided into two classes determined by their structure and 
leukaemogenicity. The first group, termed the acute transforming retroviruses, 
rapidly induce leukaemias within two to three weeks of infection. They lack the 
classical gag-pol-env genomic structure of a retrovirus since viral genes have been 
replaced by transduced, mutated cellular genes that are crucial for leukaemogenicity 
e.g. the avian erythroblastosis and E26 viruses, and Abelson murine leukaemia virus. 
Loss of viral genes usually results in the virus becoming replication-defective, and 
inclusion of 'helper' viruses to compensate for the defective functions usually 
decreases latency. Integration of these viruses into host DNA furthers tumour 
progression by mutating or activating host genes. The slow transforming retroviruses 
require a longer incubation period due to the absence of a transduced oncogene. 
These depend mainly on insertional mutagenesis or recombination with host 
sequences to generate leukaemias; for example, Friend murine leukaemia virus and 
avian leukaemia virus. Identification of genes deregulated or inactivated by these 
integrations has demonstrated the involvement of many known and novel genes in 
tumour progression (reviewed in Peters, 1990).
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2.2: Avian leukaemia viruses and erythroleukaemias.
Many acute transforming retroviruses have been isolated that are able to 
induce leukaemias in chickens, the phenotype of which is determined by the 
transduced host sequences present in the viral genome. Of particular interest to this 
study are the replication-defective avian erythroblastosis virus strain ES4 (AEV-ES4) 
and E26, both of which rapidly induce tumours that appear to be derived, at least in 
part, from cells of the erythroid lineage. Understanding these viruses has led to many 
important discoveries concerning oncogenes and the mechanisms by which they 
transform erythroid cells. Both viruses carry transduced sequences derived from two 
host genes that cooperate by two distinct mechanisms in the development of the 
leukaemia.
2.2.1: The AEV-ES4 virus.
AEV-ES4, which induces rapid and fatal erythroblastosis in chicks, expresses 
v-erbA and v-erbB, oncogenic forms of the thyroid hormone (T3) receptor and 
epidermal growth factor (EGF) receptor respectively (Sap et al, 1986; Weinberger et 
al, 1986; Downward et al, 1984): each plays a separate role in generating the 
phenotype of the leukaemic cells (Figure 2.1). V-erbB is capable of increasing the 
self-renewal potential of early erythroid progenitor cells (BFU-E) in chicks, a 
property which can also be conferred by infection with viruses carrying a wide variety 
of activated kinase-type oncogenes (Klinken, 1988). However, v-erbB-transformed 
cells have also lost their dependence on epo for survival and differentiation, and will 
mature spontaneously into erythrocytes (reviewed in Hayman and Beug, 1992). 
Interestingly, this loss of epo-dependence appears to be mediated by mutations in the 
carboxy-terminus of v-erbB, whereas self-renewal can be induced experimentally 
simply by over-expressing the c-erbB gene (Khazaie et al, 1988). This often occurs 
in erythroleukaemias induced with the replication-competent slow-transforming 
retrovirus avian leukaemia virus, in which c-erbB is deregulated as a consequence of 
insertion of the retrovirus upstream of the host c-erbB gene (Fung et al, 1983).
Figure 2.1: Structure and function of erythroleukaemogenic 
retroviruses.
AEV (ES4). 
LTR v-erbA v-erbB LTR
Blocks erythroid differentiation by 
interfering with steroid hormone 
signaling.
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growth factor independent growth 
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LTR
SFFV.
v-myb v-ets
Fusion of v-myb and v-ets required 
to transform multipotential precursor 
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epoR gene expression.
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▼
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activates, epoR.
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molecule that activates epoR.
All retroviruses can act as insertional mutagens. Particular insertions will be selected 
for during tumour progression e.g. activation of ets genes in Friend erythroleukaemia. 
For further description of these viruses, see text.
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However, in many of these tumours c-erbB mRNA undergoes altered processing to 
produce proteins lacking the extracellular domain which may be important in the 
development of the leukaemia (Nilsen et al, 1985).
The EGF receptor is expressed on a subset of chicken BFU-E cells and it has 
been demonstrated that transforming growth factor-a (TGF-a), which signals through 
the EGF receptor (Lax et al, 1988), stimulates the self-renewal of these cells (Pain et 
al, 1991). Thus, v-erbB will stimulate this signalling pathway in the absence of the 
growth factor. However, EGF receptors have not been detected on mammalian 
haemopoietic cells (von Ruden and Wagner, 1988). Nevertheless, v-erbB is still able 
to transform murine BFU-E cells (Miller et al, 1990); it also induces 
hyperproliferation of mast cells and myeloid progenitors that eventually leads to 
myeloid leukaemia (von Ruden et al, 1992). In view of these observations, it is 
interesting to note that (a) cell types affected by v-erbB expression in the mouse are 
all SCF-responsive, and (b) c-kit and the EGF receptor are both kinase-type receptors 
that share common signal transduction molecules (von Ruden et al, 1992). Therefore, 
in mice, the v-erbB protein could possibly encourage SCF-independent growth of 
haemopoietic progenitors by constitutive activation of signal pathways used by SCF. 
However, there have been no reports implicating the EGF receptor in mammalian 
haemopoietic malignancies.
V-erbB is capable of inducing erythroleukaemias in chicks in the absence of v- 
erbA (Frykberg et al, 1983; Yamamoto et al, 1983). However, disease latency is 
reduced significantly if v-erbA is included in the virus. This oncogene appears to 
block the spontaneous differentiation of v-er&B-transformed erythroid cells by 
preventing the expression of erythroid specific genes (Schroeder et al, 1990; 
Fuerstenberg et al, 1992). This effect is thought to involve the dominant-negative 
inhibition of steroid hormone-mediated differentiation signals, in particular, those 
signalling through the retinoic acid receptor (see section 1.3.8.3 above) (Sharif and 
Privalsky, 1991; Desbois et al, 1991). The mutations in the gene prevent its product 
from transactivating target genes in the presence of T3, and moreover, by competing
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for recognition sequences in promoters and/or enhancers, prevent c-erbA and the 
retinoic acid receptor from transactivating their target genes.
2.2.2: Fusion of myb and ets in the E26 retrovirus.
The E26 retrovirus generates leukaemias that exhibit both a myeloid and an 
erythroid component due to transformation of a precursor cell that has potential to 
differentiate along the myeloid or erythroid lineages (Graf et al, 1992). This virus has 
an unusual tripartite genomic structure in which viral gag sequences are fused to a 
truncated c-myb gene {v-myb), which in turn is fused to a sequence termed the E26 
/ransformation-specific region, or v-ets (Figure 2.1) (Nunn et al, 1983; Leprince et al, 
1983), with both v-ets and v-myb being derived from cellular transcription factors. 
Alone, the v-myb and v-ets components of the E26 retrovirus are not leukaemogenic; 
however, they are able to transform haemopoietic cells in vitro, v-myb affecting 
myeloid and erythroid cells whilst v-ets only affects erythroid progenitors. When 
both genes are used together, but as separate proteins, transformation is potentiated 
but the transformed erythroid cells appear to be more mature than cells expressing the 
myb-ets fusion protein. Furthermore, this combination is still not leukaemogenic in 
vivo (Nunn and Hunter, 1989; Metz and Graf, 1991a). Only when the two genes are 
physically fused in a way similar to that found in the original virus is 
leukaemogenicity restored (Metz and Graf, 1991b). Exactly why fusion of the two 
parts is necessary is unclear, but it seems likely that each component in some way 
alters the properties of the other. This would create a molecule that has a unique 
DNA binding specificity, and possibly has modified interactions with regulatory 
molecules, such that it is able to control the transcription of a distinct set of genes 
essential in the transformation of the multipotent progenitor cell.
An artificial murine retrovirus, ME26, which contains the gag-myb-ets fusion 
gene from E26 in an Abelson murine leukaemia virus-derived vector, can, like E26, 
transform multipotential progenitors and induce erythroid and myeloid leukaemias in 
newborn, but not adult, mice (Yuan et al, 1988). Erythroleukaemic cells from these
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animals could be readily established as permanent epo-dependent cell lines, which 
looked considerably more immature than leukaemic cells from a Friend virus-infected 
mouse (see section 2.3 below). Ruscetti et al (1992) suggested that these cells more 
closely resembled multipotential precursors than erythroid-specific progenitors, and 
proposed that ME26 may be inducing them to become epo-responsive. Consistent 
with this idea, they showed that when an IL-3-dependent murine cell line, FDCP-2, 
was infected with ME26 they could grow in the presence of epo or IL-3: uninfected or 
F-MuLV-infected control cells grew only in IL-3. Co-transfection experiments 
performed by Ruscetti’s group in FDCP-2 cells imply that this ME26-specific effect is 
mediated by the GATA-1 gene, the expression of which is up-regulated by the gag- 
myb-ets fusion protein (Aurigemma et al, 1992). This may be a direct effect on the 
GATA-1 promoter which contains binding sites that may be recognised by myb and 
ets proteins (Nicolis et al, 1991). GATA-1 is able to stimulate transcription of the 
epoR gene through GATA-1 sites upstream of the gene, an effect that is potentiated 
by interaction of the myb-ets fusion protein with the epoR promoter. Increased epoR 
protein in immature cell types may mediate an epo-induced hyperproliferative state, 
that could ultimately develop into an erythroleukaemia (Aurigemma et al, 1992). 
Although this is an attractive hypothesis, it is unlikely that it fully explains the 
leukaemogenicity of E26 or ME26. For instance, ME26 infection acts as a mitogenic 
stimuli to fibroblasts in the absence of growth factors and without activating epoR 
expression, presumably as a result of activating other target genes (Yuan et al, 1988; 
Aurigemma et al, 1992).
2.3: Friend virus-induced erythroleukaemias.
2.3.1: Rapid induction of erythroblastosis in Friend virus-infected mice.
Few of the murine retroviruses induce erythroleukaemias; most affect 
lymphoid cells or other myeloid lineages. However, the Friend virus (FV) 
specifically transforms erythroid progenitor cells (for review, see Ben-David and 
Bernstein, 1991; Kabat, 1989). The original isolate (FV-A) was obtained from a cell-
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free spleen extract from an adult mouse that had developed erythroleukaemia 
following inoculation with Ehrlich mouse carcinoma cells (Friend, 1957). Injection 
of this extract into other susceptible hosts resulted in a rapid enlargement of the 
spleen (splenomegaly), and often the liver (hepatomegaly), and induced anaemia due 
to the large numbers of undifferentiated erythroid progenitor cells in the blood 
(Tambourin et al, 1979). It is likely that most haemopoietic cells become infected by 
virus, but it is only the epo-responsive erythroid progenitor cells i.e. the CFU-E and 
late BFU-E populations, that are affected. However, this may be potentiated by FV 
infection of macrophages preventing TNF-a-mediated erythrosuppression 
(Marcelletti and Furmanski, 1979). Rauscher virus, an independently-isolated virus 
from mice injected with ascites tumour cells, is very similar in structure to FV-A. It 
induces a similar disease, although late after infection leukaemic lymphoid cells are 
often detectable (Rauscher, 1962; Teich et al, 1982). Derivatives of FV-A, termed 
FV-P, were found to induce splenomegaly characterised by polycythaemia (an over­
production of red blood cells), rather than anaemia (Mirand, 1967; Sassa et al, 1968). 
Cells infected by FV-P have completely lost their dependence on epo for growth and 
differentiation (Mirand, 1967), whereas FV-A is unable to induce total epo- 
independence and requires additional exogenous growth factor to terminally 
differentiate. In vivo, the concentration of epo is insufficient to cope with the 
excessive expansion of the erythroid progenitor compartment induced on FV-A 
infection, and progenitors are released into the blood in an undifferentiated state.
Thus, the early stages of Friend disease are characterised by a polyclonal 
expansion of erythroid progenitor cells that still differentiate and whose self-renewal 
capacity is limited (Figure 2.1). Only by replication and re-infection can the disease 
be maintained. It is only late in the disease when truly leukaemic cells evolve that are 
blocked in differentiation and have become immortalised. The identification and 
molecular analysis of these cells will be discussed at greater length below.
Numerous genetic loci control susceptibility to FV infection and seem to act 
by either blocking replication (e.g the Fv-1 locus (Pryciak and Varmus, 1992)) or by
Figure 2.2: Multistage Friend erythroleukaemia. 
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reducing the number of erythroid progenitor cells available for infection. For 
example, the Fv-2 locus controls the expression of a secreted protein, called the 
negative regulatory protein, that dramatically reduces the number of cycling BFU-E 
cells, without affecting progenitors from other lineages or, surprisingly, the number of 
mature erythrocytes released into the blood (Axelrad et al, 1981; Del Rizzo et al,
1988). Similarly, Steel and W mutant mice, that have a paucity of haemopoietic 
progenitor cells (see above), are also resistant to FV infection.
2.3.2: The Friend virus and its oncogene.
Both FV-A and FV-P are a mix of two types of viruses: a replication-defective 
spleen focus-forming virus (SFFV), and, to allow propagation of the infection, a 
replication-competent Friend murine leukaemia virus (F-MuLV) (Figure 2.1) (Kabat,
1989). F-MuLV is dispensable if large SFFV titres are used, as the need for 
replication and re-infection is no longer required (Wolff and Ruscetti, 1985; Wolff et 
al, 1986). Furthermore, transgenic mice harbouring the SFFV genome develop 
erythroid neoplasms (Aizawa et al, 1990). Thus, SFFV is able to act as an acute- 
transforming retrovirus, although surprisingly it does not contain a transduced cellular 
gene. Instead, it contains a rearranged envelope {env) gene that has lost its packaging 
properties (explaining the requirement for a helper-virus), but is essential for the 
erythroblastosis in the initial stage of the Friend disease (Figures 2.1 and 2.2) (Wolff 
and Ruscetti, 1988). Transgenic mice expressing this gene, termed gp55, develop 
erythroleukaemia as readily as those expressing the whole virus (Aizawa et al, 1990). 
Gp55 contains an extracytoplasmic region derived from the endogenous Friend mink 
cell focus-forming (MCF) viral env protein and a transmembrane domain from the 
env protein of F-MuLV. The cleavage site found between the gp70 and pl5(E) 
portions of other retroviral env proteins is missing from the gp55 gene, and thus, it 
codes for a membrane-spanning fusion protein. Furthermore, a single base insertion 
in the pl5(E)-derived portion causes a shift in the reading frame that truncates the 
gp55 protein due to premature termination. The deletion and base insertion are found
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in the gp55 genes from all SFFV isolates, implying a functional importance for its 
leukaemogenicity (Clark and Mak, 1983). Unlike the env proteins from F-MuLV, the 
gp55 protein is processed inefficiently and 95% is retained in the endoplasmic 
reticulum. It is here that gp55 interacts with the epo receptor, altering its metabolism 
and, more importantly, inducing a proliferative signal in the absence of epo 
(Yoshimura et al, 1990a). However, Ferro et al (1993) have produced data which 
contradicts this conclusion to some extent, in that only SFFV-infected cells which 
transport gp55 to the cell surface can become epo-independent. Nevertheless, the 
gp55/epoR interaction has been effectively confirmed by two experiments. Ruscetti 
et al (1990) were able to generate factor-independence in an epo-dependent cell line, 
HCD-57, simply by transfecting in the gp55 gene from the FV-P strain. Similarly, Li 
and co-workers (1990) generated factor-independence in the IL-3-dependent 
lymphoid cell line, Ba/F3, by co-transfecting vectors expressing the epoR gene and 
gp55 from FV-P.
The interaction between gp55 and epoR is highly specific: gp55 shows no 
ability to complex with other closely-related growth factor receptors, such as the IL-3 
receptor (IL-3R). The interaction with epoR appears to be via an extracellular domain 
on the receptor distinct from the epo binding site, and also via the membrane- 
spanning domain (Zon et al, 1992; D'Andrea, 1992). This has been demonstrated 
using two chimeric IL-3R/epoR fusion proteins, that contained either the 
extracytoplasmic and transmembrane (TM) domains of epoR (chimaera A), or just the 
extracytoplasmic domain (chimaera B). Both bind to gp55, but only chimaera A 
activates growth factor-independent growth of the Ba/F3 cell line when co-expressed 
with the gp55 gene. However, both are able to induce epo-dependent growth. This 
suggests that, although epo only requires the extracytoplasmic domain, activation of 
epoR by gp55 requires interaction via the TM domain. This has been confirmed by 
similar experiments with chimeric gp55 proteins which designated the TM region as 
crucial for its leukaemogenicity (Chung et al, 1989; Srinivas et al, 1991). 
Interestingly, different FV variants that exhibit altered host ranges and pathology
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from FV-P, have alterations in the TM portion of their gp55 protein. For example, the 
partial epo-dependence of FV-A infected cells is the result of small changes in the 
sequence of gp55 which presumably have subtle affects on its interaction with the epo 
receptor (Ruscetti and Wolff, 1985; Wolff et al, 1985). Furthermore, the ability of 
certain FV strains to infect Fv-2 resistant mice is again a consequence of gp55 
sequence alterations; in particular, a deletion near the transmembrane domain is 
invariably found in these strains (Majumdar et al, 1992). This implies that the 
negative regulatory protein, whose expression is regulated by the Fv-2 locus (see 
section 2.3.1), may in some way modify signal transduction originating from the epo 
receptor, which certain gp55 molecules are able to bypass.
The high degree of specificity in binding between gp55 and epoR accounts, at 
least in part, for the erythroid specificity of SFFV. However, the LTR of this virus 
appears to only be active in erythroid cells and may contribute to the narrow host 
range (Ruscetti and Wolff, 1984). Activation of growth factor receptors by retroviral 
env proteins may not be restricted to SFFV. D1 Andrea (1992) has proposed that 
similar interactions may be involved in the leukaemogenicity of other retroviruses. 
For example, the IL-2 receptor is activated when it is co-expressed with the env genes 
of the Friend MCF and Moloney MCF viruses, although IL-2 receptor/env protein 
complexes have not been detected (Li and Baltimore, 1991). Furthermore, mutant 
viral proteins are thought to be involved in causing immunodeficiency and neuronal 
diseases, which in some cases are dependent on interactions between the mutant viral 
protein and cell surface receptors (Aziz et al, 1989; Paquette et al, 1989)
2.3.3; F-MuLV; not just a 'helper'.
The major role of F-MuLV in FV is to act as a 'helper' virus, potentiating 
SFFV infection and mutating host genes by proviral insertion. However, infection of 
susceptible strains of newborn mice with F-MuLV alone is able to induce a variety of 
haematological neoplasms, including erythroleukaemias (Troxler and Scolnick, 1978; 
MacDonald et al, 1980; Oliff et al, 1981), the type of leukaemia induced depending
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on the genetic background of the infected mouse (Shibuya and Mak, 1982; Chesebro 
et al, 1983). Interestingly, these erythroleukaemias invariably have a constitutively 
active epo receptor. This occurs by one of two mechanisms. First, in many of these 
neoplasms, recombinant viruses are formed between the exogenous F-MuLV and 
endogenous retroviral sequences: these viruses express proteins which, like gp55, 
bind to the epo receptor and transduce a signal in the absence of epo (Figures 2.1 and 
2.2) (Ruscetti et al, 1981; Chesebro et al, 1984; Li and Baltimore, 1991). Second, a 
cell line from an F-MuLV erythroleukaemia shows constitutive epo expression as a 
result of rearrangement and amplification of the gene (McDonald et al, 1987), 
although it appears that this type of mutation is not often involved in the development 
of these malignancies.
Thus, viral activation of the epo receptor is intimately linked to the initial 
stages of Friend disease, irrespective of whether it is induced with FV or F-MuLV. 
Indeed, it seems likely that constitutive activation of the epo receptor is sufficient for 
this stage: activation of the epo receptor in vivo by other means, for example, by 
infection with a retroviral vector over-expressing the epo gene, or by constitutive epo 
production in transgenic mice, result in erythroblastosis similar to that seen in FV- 
infected mice (Hoatlin et al, 1990; Semenza et al, 1989). Furthermore, a retrovirus 
carrying a constitutively active, mutant epoR gene, is able to confer factor- 
independence on the Ba/F3 cell line and induce FV-P-like polycythaemia and 
erythroleukaemia when injected into a mouse (Yoshimura et al, 1990b; Longmore 
and Lodish, 1991), which interestingly, is often accompanied by an increase in 
granulocyte/macrophage progenitor growth (Pharr et al, 1993).
2.3.4: Leukaemic cells arise late in the Friend disease.
Early after infection with FV, or F-MuLV or SFFV alone, the vast majority of 
the infected erythroid cells have only limited self-renewal capacity and remain 
capable of terminal differentiation. In semi-solid culture these cells form small 
colonies of haemoglobinised cells. Furthermore, they will not form tumours if they
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are transplanted subcutaneously into syngeneic mice and permanent cell lines can not 
be established. Only late in the disease (3 weeks or more for FV-P; up to 6 weeks for 
FV-A; 8 weeks and above for F-MuLV alone) (Shibuya and Mak, 1982; Teich et al, 
1982) do leukaemic cells arise that exhibit the following characteristics. 1). The 
ability to form large colonies of undifferentiated cells in semi-solid media, in the 
absence of epo, that can subsequently be grown in suspension culture as permanent 
cell lines, without exogenous growth factors or stromal cells (Mager et al, 1981a, 
1981b). 2). Growth to form tumours in vivo by intra venous injection, or by
transplantation subcutaneously or into the omentum of syngeneic mice, which can 
then be cultured in vitro to form permanent cell lines (Friend and Haddad, 1960; 
Moreau-Gachelin et al, 1981; Wendling et al, 1981). 3). Colony formation in the 
spleens of irradiated normal mice, and in SHSld mice that have a defective 
microenvironment starved of SCF (Mager et al, 1980).
Established Friend cell lines are generally unable to differentiate in response 
to epo, although chemical inducers, such as DMSO (Friend et al, 1971), overcome 
this maturation arrest: this system has been extensively exploited to study erythroid 
specific gene expression in a pure population of differentiating erythroid cells 
(reviewed in Harrison, 1982). Thus, in short, in the late stages of the disease 
individual cells become immortalised, lose their ability to differentiate, and are 
autonomous of humoral and microenvironmental factors (diagrammatically 
summarised in Figure 2.2). However, several erythroleukaemia cell lines have been 
derived that do not fully express this phenotype. For example, HCD-57 cells derived 
from a NEH Swiss mouse infected at birth with F-MuLV still require epo for growth 
in culture but are unable to mature to erythrocytes (Spivak et al, 1991). The Red 5- 
1.5 cell line, which came from a Rauscher virus-infected mouse, grows in the absence 
of exogenous growth factors but will differentiate on the addition of epo (Weiss et al,
1989).
Friend erythroleukaemia is, therefore, a multistage disease with a rapid 
expansion of erythroid progenitors preceding the acquisition of a leukaemic
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phenotype (Figure 2.2). This is a common feature of tumour generation with the fully 
malignant phenotype arising after several non-neoplastic steps. This is typified by 
human colon carcinogenesis in which the invasive carcinoma is preceded by a non- 
invasive carcinoma, which itself arises from a pre-neoplastic adenoma generated in 
areas of the epithelium that are undergoing hyperproliferation. Each step correlates 
with the acquisition of a specific mutational event(s) (Fearon and Vogelstein, 1990). 
The same model is applicable to Friend erythroleukaemia (Ben-David and Bernstein,
1991). Non-neoplastic expansion of the erythroid progenitor population mediated by 
gp55 increases the probability of accumulating mutations that allow the eventual 
development of the leukaemic Friend cell, with the presence of the retroviruses 
increasing the mutation rate of the cells by acting as an insertional mutagen. By 
identifying common proviral integration sites in Friend cell lines it has been 
demonstrated that they almost always have deregulated expression of a member of the 
ets family of transcription factors. Furthermore, mutation of the p53 tumour 
suppressor gene is found in all Friend cell lines studied to date. However, the exact 
role of these mutations in generating the phenotype of the leukaemic Friend cells, and 
in the development of other tumours, is at present unclear but is discussed at greater 
length below.
2.3.5: Proviral integration and Friend erythroleukaemia.
2.3.5.1: Spi-1.
Cloning SFFV integration sites from Friend cell lines identified a locus on 
chromosome 2, named Spi-1 (Specific proviral mtegration-7), that was rearranged in a 
very high proportion (>95%) of erythroleukaemia cell lines that had been derived 
from animals infected with FV-P, FV-A, Rauscher virus or SFFV alone (Moreau- 
Gachelin et al, 1988, 1989, 1990; Paul et al, 1989, 1991). These insertions are 
clustered upstream of, and in the opposite orientation to, the Spi-1 gene. Due to the 
ability of the SFFV LTR to act as a transcriptional enhancer in erythroid cells 
(Ruscetti and Wolff, 1984), the close proximity of the LTR to the Spi-1 gene causes
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Spi-1 to become highly expressed in all these Friend cell lines. Analysis of purified 
erythroid progenitor cells has shown that Spi-1 expression is normally very low 
during erythropoiesis, and also during the initial phases of the Friend disease, 
implying that deregulated Spi-1 expression may be responsible for the leukaemic 
Friend cell phenotype (Tsai et al, 1991b; Schuetze et al, 1992; Galson et al, 1993). 
Spi-1 is identical to PU-1, a gene cloned by virtue of the ability of its product to bind 
a purine rich sequence in the promoter of a major histocompatability gene and shown 
to be a transcription activating protein when this sequence is inserted upstream of 
reporter genes (Klemsz et al, 1990; Goebl et al, 1990).
Which genes Spi-1 activates in Friend cells is not known, and equally, the 
precise effect of deregulating Spi-1 in these cells is a mystery. One would expect that 
since gp55 promotes growth factor-independent growth, Spi-1 would cooperate in 
forming the leukaemic phenotype if it were to block differentiation, analogous to v- 
erbA/v-erbB cooperation seen in AEV-ES4 (section 2.2.1). Schuetze et al (1992) 
have suggested that since Spi-1 protein levels are down-regulated during the 
chemically-induced differentiation of Friend cells, deregulated expression must 
prevent differentiation. However, this is only a correlation and no functional 
experiments have yet been reported that test this hypothesis.
2.3.5.2: Fli-L
The erythroleukaemias induced with the F-MuLV 'helper' in newborn mice, do 
not show activation of Spi-1 (Moreau-Gachelin et al, 1989), but a different proviral 
integration site has been identified that is rearranged in 75%, or more, of cell lines 
derived from these malignancies. Insertions in this locus, termed Fli-1 (Friend 
/eukaemia integration-/), have not been detected in FV erythroleukaemia cell lines, or 
in leukaemias induced in other lineages by F-MuLV (Ben-David et al, 1990a; Sels et 
al, 1992). However, integration of Cas-Br-E proviruses has also been detected in this 
locus in a subset of neoplasms classed as non-T-, non-B-cell lymphomas that are 
induced on infection of newborn NIH/Swiss mice (Bergeron et al, 1991, 1992). A
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gene has been mapped to this locus that is highly expressed in all the 
erythroleukaemia cell lines that contain the inserted retrovirus at the Fli-1 locus (Ben- 
David et al, 1991). The assumption is that Fli-1 expression is absent, or very low, in 
normal erythroid progenitors (although this has yet to be formally proven) and that 
uncontrolled expression of Fli-1, like Spi-1, is a crucial step in the progression of the 
leukaemia.
Fli-1 and Spi-1 are structurally related and both members of the ets family of 
transcription factors. Both are able to activate transcription of a reporter gene linked 
to an appropriate recognition sequence (Klemsz et al, 1990; Watson et al, 1992; 
Zhang et al, 1993). The GATA-1 promoter contains recognition sequences of this 
type, and expression of a reporter gene controlled by this promoter is up-regulated in 
vivo in the presence of Fli-1 (Watson et al, 1992). Two other cts-related proteins, c- 
ets-1 or c-ets-2, are unable to mimic this effect. This may have important 
implications as to why Fli-1 is preferentially activated in some erythroleukaemias. 
Mechanistically, it may work in a similar fashion to that proposed for the gag-myb-ets 
fusion protein of ME26: up-regulation of GATA-1 in ME26-infected cells is thought 
to result in the inappropriate expression of the epoR gene (see section 2.2.2). This 
suggests that Fli-1 may potentiate proliferative stimulation by the gp55-like proteins 
expressed in F-MuLV-transformed erythroid cells.
The restriction of Spi-1 activation to erythroleukaemias induced in adult mice 
with SFFV and Fli-1 to F-MuLV-induced tumours in newborn mice is intriguing, but 
may simply be due to differences in the availability of integration sites in the 
developmentally distinct target cells in the two types of erythroleukaemia. 
Alternatively, since the Fli-1 and Spi-1 proteins exhibit considerable sequence 
divergence, they may regulate different sets of target genes whose expression is 
required in the progression of the leukaemic cells in the two systems (Ben-David and 
Bernstein, 1991). The structure and possible function of these and other ets-related 
proteins, is discussed in depth in chapter 3.
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2.3.S.3: p53 in Friend erythroleukaemia.
Mowat and his co-workers were the first to examine p53 in Friend cell lines, 
using antibodies to look at the protein levels. They found that approximately 30% 
had either no expression, or produced antigenically-related proteins that were of a 
considerably smaller size. Southern blot analysis of genomic DNA from these 
particular cell lines detected rearrangements of the p53 gene, and complete loss of the 
normal allele (Mowat et al, 1985). These genomic abnormalities were correlated with 
insertion of proviruses, either SFFV or F-MuLV, or large deletions: all these events 
disrupted the p53 coding sequence (Rovinski et al, 1987; Munroe et al, 1988; Hicks 
and Mowat, 1988; Ben-David et al, 1988, 1990b). Furthermore, clones in which the 
p53 gene had a normal structure were found to produce proteins in which a single 
amino acid had been altered as a result of a point mutation. These clones were 
homozygous for the mutation, the wild-type allele having been lost (Munroe et al, 
1990). Mutation of p53 has been implicated in the process of establishing cell lines 
from certain cell types (Harvey and Levine, 1991). However, multiple 
erythroleukaemia cell clones independently derived from the same infected animal 
contained identical p53 mutations, proving it had occurred in vivo as a component of 
tumour progression, and not as a consequence of culture in vitro (Chow et al, 1987). 
Transgenic mice constitutively expressing a mutant p53 gene and infected with FV, 
develop erythroleukaemia much more rapidly than wild-type mice (Lavigueur and 
Bernstein, 1991). All this evidence has suggested that mutation of p53 is an 
obligatory step in Friend erythroleukaemia progression, irrespective of whether these 
tumours are induced with FV-P, FV-A or F-MuLV (Dreyfus et al, 1990; Ben-David 
and Bernstein, 1991). Reconstituting wild-type p53 gene expression in p53-negative 
Friend cells induces apoptosis, an effect reversed by erythropoietin (Ryan et al, 1993; 
Johnson et al, 1993). Differentiation was not observed, probably because other 
mutations present in these cells are preventing maturation. The role of p53 in normal 
cells, and the effect its mutation has on tumour progression, is discussed in detail 
below (Chapter 4).
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2.3.5.4: The RNA1 gene, c-myc and Pim-1.
Another integration site has recently been identified in Friend 
erythroleukaemia cells. This locus, termed Fli-2, is rearranged in two
erythroleukaemia cell lines from F-MuLV-infected animals and one from a FV-P- 
induced tumour, but remains intact in the majority of cell lines studied. These 
integrations are downstream of the heterogeneous nuclear ribonucleoprotein Al 
(RNA1) gene that is a member of a family of genes involved in RNA splicing. 
However, the integrations effect expression of this gene in separate ways. In two of 
the cell lines, RNA1 mRNA production appears unaltered compared with other cell 
lines that do not contain the rearrangement. In the other, integration in one Fli-2 
allele is accompanied by loss of the other allele and a complete absence of RNA1 gene 
expression is observed. These observations are intriguing as they are the first 
indication that splicing factors may be targeted during tumour progression. However, 
the variations that integration at Fli-2 have on RNA1 expression imply that another 
gene may be the true target oncogene of these integrations (Ben-David et al, 1992).
A single report (Dreyfus et al, 1990) contained results which showed that in a 
small proportion of primary leukaemias induced with F-MuLV, two previously 
identified genes, c-myc (a transcription factor closely linked to a cell's proliferation 
status (Evan and Littlewood, 1993)) and Pim-1 (which encodes a serine-threonine 
protein kinase (Selten et al, 1986)) had undergone rearrangement. These genes are 
more commonly associated with the progression of leukaemias from the T lymphoid 
lineage, and their involvement in erythroleukaemia is surprising. The status of the 
Fli-1 gene in these cells was not reported, and it is possible that these two genes may 
replace the requirement for ets deregulation.
2.3.5.5: Over-expression of the erythropoietin receptor.
Although the epo receptor is activated by gp55 in SFFV-infected cells, 
Lacombe et al (1991) have shown that in one particular cell line, T3C1-2, 
transcription of the epoR gene is deregulated as a consequence of insertion of the
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SFFV LTR in the first exon of the gene. The coding region is not disrupted and the 
only effect seems to be an increase in transcription. This result implies that the 
proliferative advantage generated in erythroid cells by the gp55 gene (T3C1-2 cells 
express gp55) can be potentiated by other mutational events. It is possible that the 
genes more commonly activated by proviral insertions in Friend cells, such as Spi-1 
and Fli-1, play a similar potentiating role in erythroleukaemia development.
2.4: Summary.
The identification of genes activated or mutated by retroviral insertions in 
Friend erythroleukaemia has posed several questions concerning their effect on 
normal erythropoiesis, such as whether they block differentiation, enhance self­
renewal or potentiate the growth factor-independence mediated by mutated viral 
envelope proteins. To gain an insight into their possible role in tumour progression it 
is necessary to have a full understanding of their function in normal cells and in other 
malignancies. Although Fli-1 and Spi-1 have not been extensively studied, by 
investigating the role of related ets genes it may be possible to understand why they 
are targeted in Friend erythroleukaemia. p53, on the other hand, has been the subject 
of intensive scrutiny over the last twelve years, but only now is the true role of this 
suppressor gene emerging. The following sections detail our current knowledge 
concerning p53 and the ets genes and each concludes with a discussion of its 
relevance to erythroleukaemia progression.
CHAPTER 3: The ets genes: transcription factors and oncogenes.
3.1: Structure of the ets protein family.
Since the identification of v-ets in the E26 virus, over thirty ett-related genes 
have been cloned from a number of different species, all of which show significant 
homology over the so-called ets-domain, the part of the protein involved in sequence-
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specific DNA binding (reviewed by Macleod et al, 1992, and Seth et al, 1992). The 
first cellular ets gene to be identified was c-ets-1 (Figure 3.1): this is generally viewed 
as the archetypal ets gene and will be used in this introduction to describe properties 
which may be applicable to other family members. The ets-domain, which is usually 
found in the carboxy-terminal portion of the protein, is approximately 85 amino acids 
long and has no structural homology to other known DNA binding motifs, except 
possibly c-myb (Anton and Frampton, 1988). The c-myb protein has a DNA binding 
domain consisting of a triple repeat of a region containing three a-helical structures, 
each with a conserved, essential tryptophan residue (for review, see Graf, 1992). The 
ets domain of all the ets proteins, with the exception of Spi-1 and Spi-B, is like one of 
these repeat regions and has three conserved tryptophans, implying that it may have a 
triple a-helical-type structure. The two Spi proteins, which are most diverged from c- 
ets-1, only have two tryptophans, the other being replaced by a tyrosine (Ray et al,
1992). Another region of similarity has been found towards the amino-terminus of 
several ets proteins that exhibits weak homology to the dimerisation domain of the so- 
called helix-loop-helix (HLH) proteins, like c-myc and the muscle-determining factor 
myoD, and may be involved in mediating protein-protein interactions. In particular, 
in c-ets-2 this domain shows 45% identity to part of the Id protein, an HLH family 
member that is thought to inhibit transactivation by other HLH proteins by forming 
non-functional dimers (Benezra et al, 1990; Seth and Papas, 1990). However, no 
such inhibitory function has been demonstrated for the c-ets-2 protein.
The transactivation domains of the ets proteins have not been exhaustively 
mapped, but in c-ets-1 and c-ets-2 it appears to be split either side of the putative 
HLH-like dimerisation motif in a region that is the least conserved portion of the 
protein (Schneikert et al, 1992). Between the DNA binding and transactivation 
domains a number of the ets-related proteins also have a PEST site, an area rich in 
proline, glutamine, serine and threonine residues, which is thought to be a target for 
proteases. Cleavage at this site would create a DNA binding domain free from the 
regulatory constraints of the remainder of the protein that could interfere with
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transcription mediated by the full length protein. Interestingly, ets genes have been 
cloned from Xenopus and Drosophila that simply consist of an ets domain (Pribyl et 
al, 1988; Chen et al, 1988). In Spi-1, the PEST sequence is involved in protein- 
protein interactions with other transcription factors; dimerisation could therefore 
prevent the proteolytic cleavage of the ets protein (Pongubala et al, 1992, 1993). 
Several potential kinase phosphorylation sites are apparent in the ets proteins and, as 
is discussed below, these are probably important in regulating their function in 
response to extracellular signals (Watson etal, 1988; Koizumi et al, 1990).
The ets genes have been mapped to several chromosomes, but there are two 
clusters of particular interest: Fli-1 and c-ets-1 on human chromosome 11 (mouse 9) 
and erg and c-ets-2 on human chromosome 21 (mouse 16) (Figure 3.2). The c-ets-1 
and c-ets-2 proteins are very closely related structurally and functionally, with similar 
DNA binding specificities (Watson et al, 1988a; Wasylyk et al, 1990). Similarly, the 
Fli-1 and erg proteins are highly homologous with nearly 100% identity over their 
DNA binding domains, implying functional similarities (Ben-David et al, 1991; 
Reddy and Rao, 1991; Watson et al, 1992). These properties provide clues as to the 
evolution of the ets genes: first duplication of an ancestral ets-related gene may have 
occurred giving rise to two adjacent sister genes which subsequently diverged; later 
this was followed by duplication of the entire locus to another chromosome.
3.2: DNA binding: monomers and oligomers.
The similarity exhibited by ets proteins over the DNA binding domain implies 
that their recognition sequences are also very similar. Indeed, all the ets sites 
identified to date contain a central GGAA/T core, with the sequence either side 
involved in controlling specificity (Karim et al, 1990; Macleod et al, 1992). Many of 
these sites are able to bind more than one of the ets family members in gel retardation 
assays. For example, the PE A3 site identified in the polyoma enhancer will bind c- 
ets-1, c-ets-2, elk-1 and the PEA3 protein, all of which are able to activate
30%
(68%).
c-ets-1.
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Mouse chr. 9. Mouse chr. 16.
Figure 3.2: Structural similarity between four 
clustered, and closely related, ets genes.
Overall amino acid homology shown by figure without brackets. 
Amino acid identity over ets domain indicated by figure in brackets.
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transcription through this motif in vivo when it is placed upstream of a reporter gene 
(Wasylyk et al, 1990; Rao and Reddy, 1992a; Xin et al, 1992).
DNA binding in vitro occurs in the absence of any accessory proteins. In vivo 
though the situation is likely to be very different as each putative ets binding site must 
be considered in the context of the rest of the promoter/enhancer. An emerging rule 
concerning the ets proteins, some examples of which are given below, is that their 
DNA binding specificity and transactivation properties can be modulated by 
interactions with other proteins, which form an oligomeric complex over the 
appropriate response elements. Indeed, this was a possibility that was implied when 
the first ets protein, v-ets, was discovered in the E26 retrovirus (section 2.2.2), with 
the fusion to v-myb potentially stabilising a heterodimer formed between c-myb and a 
cellular ets protein.
(1) Interactions between ets-related proteins and other transcription factors 
were first shown by Wasylyk and his co-workers (Wasylyk et al, 1989, 1990) using 
part of the polyoma enhancer, termed the oncogene responsive domain. This region 
mediates transcriptional activation by serum growth factors, phorbol esters like TPA, 
and also by numerous non-nuclear oncogenes e.g. v-src, v-raf and v-mos. They 
showed that c-ets-1 (or c-ets-2) was induced by these stimuli to bind to the PEA3 site 
in the enhancer and cooperate with AP-1 fos-jun heterodimers bound at the adjacent 
PEA1 site. Each component activates transcription to some extent on its own, but 
they exhibit extensive synergism when bound at the same time. Over-expression of 
the c-ets-1 gene in vivo results in inhibition of the transactivation of a reporter gene 
by AP-1 through PEA1, an observation which implies that cooperativity is mediated 
at the level of protein-protein interaction since the c-ets-1 protein appears to be 
competing out the binding of AP-1 to the PEA1 site. Furthermore, although 
mutations in either the PEA1 or PE A3 site diminish cooperative transactivation to 
some extent, this is significantly less than would have been expected considering the 
potent effect each mutation has on transactivation by one factor alone. In these 
mutant enhancers, binding of one component to its wild-type sequence stabilises the
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interaction of the other factor on the mutated binding site. This cooperativity is not 
restricted to viral control elements since adjacent PEA3-like and AP-1 motifs have 
been identified in the promoters of numerous oncogene-responsive cellular promoters, 
including the ECM degrading enzymes stromelysin, collagenase and urokinase, the c- 
fos gene (a component of the AP-1 complex), and the c-ets-1 and c-ets-2 genes 
(explaining the autoregulation observed for these genes) (Nerlov et al, 1991; Wasylyk 
et al, 1991; Gutman and Wasylyk, 1991; Seth and Papas, 1990; Mavrothalassitis and 
Papas, 1991). The nature of the putative AP-1 rets interaction remains unresolved: 
there has been no demonstration of AP-1 oligomer formation with c-ets-1 or c-ets-2.
(2) A similar synergistic cooperativity in transactivation has been proposed 
for c-ets-2 and c-myb in the promoter of mim-1, a myeloid-specific gene identified 
due to its activation by the v-myb protein of the avian myeloblastosis virus (Ness et 
al, 1989; Dudek et al, 1992) . Interestingly, unlike the situation with the polyoma 
enhancer discussed above, c-ets-1 will not replace c-ets-2 in the control of the mim-1 
gene. Obviously, this cooperativity may have important implications as to the 
requirement for fusion of the myb and ets components of the E26 virus, particularly if 
similar cooperation is demonstrable in the promoters of genes which may be more 
central to transformation than mim-1, like GATA-1 for instance. Thus, despite the 
inability to demonstrate heterodimerisation between c-myb and an ets-related protein, 
the E26 fusion protein may cause the constitutive expression of genes controlled 
cooperatively by c-myb and ets proteins.
(3) Ets proteins have also been implicated in complex formation over the 
serum response element (SRE). This region was first identified in the c-fos promoter 
as being essential for the rapid and transient induction of the gene by addition of 
serum to serum-starved cells (reviewed in Treisman, 1990). A dimer of the serum 
response factor (SRF) forms over this element but requires an additional factor, 
termed p62/TCF, before transcription is activated (Shaw et al, 1989). Preventing the 
formation of this oligomer on the SRE impairs the response of the c-fos gene to 
extracellular signals, in particular those mediated by a protein kinase-C-dependent
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pathway (Graham and Gilman, 1991). Using two different experimental approaches, 
two proteins have been identified, SAP-1 and elk-1, that exhibit p62/TCF activity 
(Hipskind et al, 1991; Dalton and Treisman, 1992). In both these proteins, an ets- 
domain is found at the amino-terminus which, along with a small region adjacent to it 
(termed the elk-1 SRF interaction, or ESI, domain), is required for SRFrets interaction 
(Janknecht and Nordheim, 1992; Rao and Reddy, 1992b; Dalton and Treisman, 1992). 
The elk-1 DNA binding domain alone is able to bind to the SRE, but the full length 
protein lacks this property due to intramolecular repression by the ESI domain. 
Complex formation with the SRF removes this inhibition (Rao and Reddy, 1992b). 
However, the full-length elk-1 protein is able to bind to other slightly different 
sequences, such as the PEA3 motif, without interaction with SRF (Rao and Reddy, 
1992a). Thus, the elk-1 protein can interact with DNA in two ways; either it uses its 
intrinsic properties to bind DNA autonomously, or by interacting with other proteins, 
its DNA binding specificity is altered to allow other sequences to be recognised. In 
vivo, it seems likely that elk-1 could activate transcription as a monomer on one 
promoter type, and as part of an oligomer on another, and it is possible to envisage 
that subtle post-translational alterations in the DNA binding and regulatory domains 
of the protein could alter which particular target genes are expressed.
(4) Ets binding sites have been identified in the enhancers of numerous 
viruses, such as the human immunodeficiency (Leiden et al, 1992) and T cell 
leukaemia viruses (Bosselut et al, 1990), and F-MuLV and SFFV (section 2.3), and 
many of the ets proteins have been cloned as a result of binding to these sites. The 
enhancer of herpes simplex virus binds a complex set of host and viral proteins, 
including the ets protein GABP-a, which exhibits heterodimerisation properties. 
DNA binding by this protein requires interaction (via part of the ets domain) with 
repeat structures in GABP-p that are related to those seen in the cytoskeletal protein 
ankyrin (Thompson et al, 1991; LaMarco et al, 1991). Conversely, binding of the B- 
cell-specific transcription factor NF-EM5 to the immunoglobulin kappa light chain 
enhancer requires interaction with the phosphorylated PEST sequence of Spi-1
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already bound to the enhancer (Pongubala et al, 1992, 1993). In this example, 
therefore, the ets protein is acting as a recruiting factor. Interestingly, a recent study 
(Hagemeier et al, 1993) has demonstrated that the retinoblastoma (Rb) protein is able 
to bind to the transactivation domain of Spi-1 in vitro, and probably prevents its 
interaction with general transcription factors on the promoter. Rb is thought to 
control cell cycle progression by regulating the activity of specific cellular 
transcription factors (reviewed in Hollingsworth et al, 1993): its association with Spi- 
1 tentatively implies that this ets protein may be part of this control pathway in some 
cell types.
Thus, in summary, it appears that ets proteins can bind DNA and activate 
transcription either as a monomer, or as a part of an oligomer. Interactions of the ets 
proteins with other transcription factors or accessory molecules is able to change the 
DNA binding specificity and/or transactivation properties of the ets proteins 
themselves and/or the protein(s) with which they are associating. The growing size of 
the ets gene family, and the complexity of protein iprotein and protein:DNA 
interactions being elucidated for these proteins, provides an opportunity to propose 
numerous models to explain their role in leukaemia, but the same complexity makes a 
full understanding of their function extremely difficult.
3.3: Control of ets protein activity.
The activity of the ets proteins is controlled at several levels and has been 
studied in some detail for c-ets-1 and c-ets-2 in T-cells. Expression of all the ets 
genes is tightly controlled developmentally, temporally and spatially within a given 
organism. For example, c-ets-1 is expressed at high levels in many tissues in 
newborn mice, but in adults the mRNA is only present in a subset of T-cells (Bhat et 
al, 1990), megakaryocytes (Lemarchandel et al, 1993), in endothelial cells involved in 
blood vessel formation (Wemert et al, 1992) and in the fibrocytic stroma surrounding 
invasive human carcinomas (Stehelin et al, 1992). The latter observation has 
important implications to the metastatic process, particularly in light of the known
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involvement of c-ets-1 in the production of ECM-degrading enzymes (Wasylyk et al, 
1989; Nerlov et al, 1991). It has been proposed that the invading carcinoma releases 
factors that induce c-ets-1 expression, which in turn stimulates the production of 
proteases like collagenase (Stehelin et al, 1992). c-ets-2, on the other hand, is 
expressed in all tissues and most cell types, and in particular in cells that are 
proliferating rapidly (Bhat et al, 1987). In T cells, where both c-ets-1 and c-ets-2 are 
expressed, the genes are regulated in a reciprocal fashion on stimulation of cell 
proliferation (Bhat et al, 1990). In resting T-cells, c-ets-2 mRNA is only present at 
very low levels, whilst c-ets-1 is relatively high. Stimulation of proliferation with 
phorbol esters, or with antibodies to the T-cell receptor, induces a rapid production of 
c-ets-2 mRNA accompanied by a down-regulation of the c-ets-1 gene. This switch 
between two highly homologous proteins may maintain the expression of a certain set 
of c-ets-l/c-ets-2-regulated genes, whilst switching off c-ets-1-specific genes and 
turning on a distinct set of c-ets-2-specific genes that may be involved in proliferation 
induction. Indeed, like T-cells, c-ets-2 expression is rapidly and transiently induced 
in macrophages and fibroblasts stimulated to proliferate with growth factors (Bhat et 
al, 1989; Boulukos et al, 1990). These early observations closely linked ets genes, 
and in particular c-ets-2, to the proliferative state of several cell types, an association 
that has been furthered by a number of more recent experiments discussed below 
(section 3.4).
Activation of T-cells also rapidly increases the phosphorylation state of the 
two ets proteins, an effect mediated at least in part by an as yet unidentified calcium- 
dependent kinase (Fujiwara et al, 1990; Pogonec et al, 1988). These modifications, 
mainly on serine residues, dramatically increase the stability of the c-ets-2 protein 
(Fujiwara et al, 1988), but decrease the association of c-ets-1 with chromatin and 
presumably restrict its ability to transactivate (Pogonec et al, 1989). However, 
phosphorylation, or some other form of modification, is probably a requirement for 
DNA binding by c-ets-1, since completely unphosphorylated c-ets-1 protein made in 
vitro is also unable to bind to its target sequence due to an intramolecular repression
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mechanism. Lim et al (1992) have proposed as a result of deletion analysis of the 
protein, that this is mediated by an interaction between the carboxy-terminus and a 
repressor domain within the region identified as a transactivation domain (Figure 3.1). 
Interestingly, mutations present in the v-ets gene are in these putative regulatory 
domains. The thirteen carboxy-terminal amino acids of c-ets-1 are replaced by 
sixteen foreign amino acids (the consequence of an inversion of part of the c-ets-1 
gene (Lautenberger and Papas, 1993)), and there is a point mutation in the putative 
repressor domain (Figure 3.1) (Watson et al, 1988b). It has been demonstrated that 
removal of the thirteen carboxy-terminal amino acids from c-ets-1 or -2 increases 
their DNA binding activity (Hagman and Grosschedl, 1992; Lim et al, 1992). There 
are also two point mutations in the DNA binding domain of v-ets, the function of 
which remains unclear. One report suggests that these mutations actually inhibit 
DNA binding, although these experiments were carried out using a truncated c-ets-1 
protein lacking 175 amino acids from the amino-terminus in which the true effect of 
these mutations may not be apparent (Leprince et al, 1992). In c-ets-1, this 
intramolecular inhibition could be disrupted by phosphorylating amino acid residues 
distinct from those modified on T cell activation that seem to prevent DNA binding.
To date, kinases and phosphatases that are known to directly modify ets 
proteins are few and far between. However, the activation of the oncogene responsive 
domain by non-nuclear oncogenes or phorbol esters, which is mediated by ets proteins 
(section 3.2), requires raf-1, a serine-threonine kinase (Bruder et al, 1992), although 
there is no evidence that demonstrates direct phosphorylation of ets proteins by raf-1. 
However, p62/TCF, a member of the ets family, requires phosphorylation by MAP 
kinase to allow transcriptional activation via the SRE (Gille et al, 1992), and MAP 
kinase itself is regulated by raf-1 via MAP kinase-kinase (Kryiakis et al, 1992). This 
phosphorylation is in the carboxy-terminal portion of the protein which functions as a 
regulable transcription activation domain (Marais et al, 1993). Post-translational 
modifications of p62/TCF may also alter the availability of its oligomerisation 
domain for interaction with SRF, which is masked in the in v/rro-produced protein
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(Janknecht and Nordheim, 1992). In a similar manner, phosphorylation of serine 148 
in Spi-1, possibly by casein kinase II, is a requirement for NF-EM5 interaction and 
subsequent transcriptional activation by this heterodimer (Pongubala et al, 1993). 
Likewise, post-translational modifications of c-ets-1 or c-ets-2 may permit their 
interaction with AP-1 over the oncogene responsive domain. Theoretically, these 
could occur in the regulatory domains identified by Lim and his colleagues (1992). 
Alternatively, Wasylyk et al (1992) have identified a separate portion of c-ets-1 (and 
c-ets-2) adjacent to the DNA binding domain, that also inhibits DNA binding in the 
absence of phosphorylation (Figure 3.1). It is possible that this region is involved in 
protein-protein interactions like the equivalent portion of elk-1 (see above). 
Interestingly, this region, along with the DNA binding domain, are the only parts of v- 
ets that are indispensable to retain the leukaemogenicity of the E26 retrovirus carrying 
the myb-ets fusion gene (section 2.2.2) (T. Graf, personal communication).
Numerous alternatively-spliced ets transcripts have been identified that lack 
some of these putative regulatory domains (Figure 3.1). For example, the regulatory 
region identified by Wasylyk et al (1992) is absent from an alternatively-spliced 
human c-ets-1 lacking exon VII (Koizumi et al, 1990). A similar mouse variant is 
unaffected in its ability to bind to DNA on T-cell activation unlike the full-length 
protein (Pogonec et al, 1990). Using PCR, Jorcyk et al (1991) identified c-ets-1 
transcripts that lacked exon IV and others lacking IV and VII. Exon IV contains the 
helix-loop-helix homology domain identified by Seth and Papas (1990). In chickens, 
alternative-splicing of the c-ets-1 mRNA creates proteins with different amino- 
termini, with c-ets-1 (p54) missing a transactivation domain present in c-ets-1 (p68) 
(Leprince et al, 1988). Interestingly, these two variants are expressed in different cell 
types with p54 preferentially expressed in lymphoid cells in the thymus and spleen, 
whilst p68 appears to be present in non-lymphoid cells, probably endothelial cells, in 
the spleen only (Leprince et al, 1988, 1990). The exact role of these different proteins 
is unknown, but it seems likely that their transactivation properties will vary, and that 
they will be subject to distinct regulatory processes.
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Thus, activity of ets proteins is regulated at the level of gene transcription, by 
alternative splicing and intramolecular repression, and also by post-translational 
modifications. Much more work is still required to determine how these regulatory 
steps are controlled by extracellular signals, and also if these mechanisms are 
common to all ets proteins. This seems likely as many of the other ets-related 
proteins are highly tissue specific which can be produced from alternatively spliced 
transcripts and are phosphorylation substrates for cellular kinases (Ben-David et al, 
1991; Ray et al, 1992; Watson et al, 1992; Xin et al, 1992; Reddy et al, 1987; Gille et 
al, 1992; Galson etal, 1993).
3.4: Intracellular signalling and the ets proteins.
Control of cell proliferation and maturation is mediated by extracellular 
molecules binding to receptors on the target cell to elicit a complex intracellular 
response that eventually culminates in alterations in the genes being expressed in that 
cell. Most cellular proto-oncogenes are components of these signalling pathways, and 
the genetic alterations found in transforming oncogenes result in signalling 
proceeding in the absence of the appropriate stimulus. The involvement of ets 
proteins in the oncogene responsive domains of cellular and viral promoters, and in 
the serum response process, is a strong indication that they are a nuclear component 
of mitogenic pathways. Many other genes that contain ets binding sites are rapidly 
induced with extracellular signals: for example, a large number of cytokine genes 
contain ets binding sites (Klemsz et al, 1990; Seth et al, 1992; Thompson et al, 1992). 
The rapid changes in the phosphorylation state of the ets proteins on cell stimulation, 
some of which is mediated by kinases known to be crucial in mitogenic cell signalling 
like MAP kinase, and the in vitro interaction of Spi-1 with the Rb protein, is further 
evidence that these proteins play a role in mediating a cell's response to proliferation- 
inducing stimuli.
There is now emerging some direct functional evidence for a role in 
proliferation induction. First, infection of chicken erythroid cells with v-ets results in
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growth factor-independent growth of cells still able to differentiate, and will 
cooperate with v-erbA, a differentiation-blocking oncogene (section 2.2.1), to 
generate erythroleukaemias (Metz and Graf, 1991b, 1992). Thus, v-ets mimics the in 
vitro transformation and cooperative leukaemogenic effects observed with the 
mutated EGF receptor, v-erbB, and other kinase-type oncogenes e.g. v-raf, v-src 
(Klinken, 1988). Second, over-expression of c-ets-1 or c-ets-2 in fibroblasts causes 
transformation, as defined by increased proliferation and an induction of 
tumorigenicity (Seth et al, 1989; Seth and Papas, 1990). Third, Langer et al (1992) 
have recently shown that over-expressing a dominant-negative c-ets-2 mutant 
containing only the DNA binding domain of the protein, prevents mitogenic 
stimulation of cells by colony-stimulating factor-1 (CSF-1). Induction of c-ets-2, c- 
jurt and c-fos by CSF-1, which is seen in the absence of the c-ets-2 mutant, still 
occurred, but c-myc expression was severely reduced. Furthermore, CSF-1 signalling 
was restored in NIH 3T3 cells expressing a mutant CSF-1 receptor if a full-length c- 
ets-2 gene was artificially over-expressed. These same cells can be rescued for CSF- 
1-responsiveness if c-myc is over-expressed (Roussel et al, 1991): a similar 
phenomenon is observed with c-myc expression constructs introduced into cells 
containing the wild-type receptor and the dominant-negative c-ets-2 mutant. In short, 
these results suggest that c-ets-2 plays a mediating role in the transduction of CSF-1 
signals to c-myc expression. Indeed, preliminary evidence quoted by Langer and his 
colleagues (1992), reports the identification of a number of ets-binding sites in the 
promoter of the c-myc gene. These observations, in conjunction with the work on the 
serum response element, demonstrate that ets proteins are involved in regulating the 
expression of several immediate-early genes that are rapidly induced by proliferative 
signals, and thought to facilitate a cell's progression through the cell cycle (for 
reviews see Gillespie, 1991 (fos/jun) and Evan and Littlewood, 1993 (myc)).
It is possible that proliferation could also be induced indirectly by autocrine 
production of growth factors, since several cytokine promoters contain putative ets- 
binding sites (Seth et al, 1992; Klemsz et al, 1990). For example, mitogenic
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activation of T-cells is potentiated by the autocrine production of interleukin-2 and its 
receptor (reviewed in Smith, 1988). IL-2 gene expression requires binding elf-1, an 
ets-related protein, to a site within its promoter (Thompson et al, 1992). 
Alternatively, growth factor receptor expression may be controlled by ets-related 
proteins. For example, as discussed in section 2.2.2, in cells transformed by the 
ME26 virus (the mouse homologue of E26), the myb-ets fusion protein induces 
GATA-1 expression which in turn results in the inappropriate expression of the epo 
receptor in cells not usually epo-responsive. Similarly, the Fli-1 protein, unlike c-ets- 
1 and -2, can induce the expression of a reporter gene linked to the GATA-1 promoter 
which may explain the selective activation of Fli-1 in F-MuLV-induced 
erythroleukaemias (Watson et al, 1992). However, it has yet to be demonstrated 
whether GATA-1 or epoR expression is increased in F-MuLV-transformed erythroid 
cells, and what implications this result has, if any, on their proliferation. Finally, in 
vivo, the production of ECM-degrading enzymes, which appear to be regulated by ets 
proteins, may also play a role in the proliferative response by destroying restrictive 
signals present in the microenvironment. The microenvironment of the haemopoietic 
organs is crucial to the regulation of blood cell production (chapter 1), and any 
disruption may affect the progression of developing leukaemic cells.
There is also some suggestive evidence that ets proteins may be involved in 
the control of differentiation. It has been proposed that activation of Spi-1 in FV- 
induced erythroleukaemia cells, already in a highly proliferative state due to the gp55- 
epo-R interaction, is involved in blocking differentiation (Schuetze et al, 1992). No 
functional evidence was presented in this report, and the conclusion was based on the 
observation that Spi-1 protein levels dropped significantly when Friend cells were 
forced to differentiate in response to chemical inducers. More compelling evidence 
comes from the observation that the multipotent cells transformed with a mutant E26 
virus containing a temperature-sensitive mutation in the v-ets component of the fusion 
protein, undergo terminal erythroid differentiation at the non-permissive temperature 
(Golay et al, 1988). However, it is a distinct possibility that differentiation may be a
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result of decreased cell division, and indeed, it is feasible that an oncogene which 
increases the proliferative potential or life-span of a progenitor cell may block 
differentiation simply as a consequence of that increased viability. Moreover, many 
of the chemicals used to artificially induce the differentiation of leukaemic cells in 
vitro, act by blocking DNA replication (Terada et al, 1977), presenting differentiation 
as a default pathway when a cell's proliferative potential is exhausted or inhibited. If 
this is true, then ets proteins do have the potential to play a dual role in controlling 
proliferation and maturation of erythroid cells, simply by increasing proliferation.
With respect to a more direct effect on differentiation, it is worth remembering 
that many of the genes known to be regulated by members of the ets family, code for 
lineage-restricted proteins; for example certain cytokines, like IL-2, the 
immunoglobulin kappa light chain, mim-1, the ECM-degrading enzymes and several 
cell adhesion molecules (Pahl et al, 1993; Lemarchandel et al, 1993). One could 
envisage a mechanism whereby deregulated expression of an ets gene could disrupt 
the expression of these proteins, and thus prevent normal maturation, perhaps by a 
dominant-negative mechanism akin to v-erbA in AEY (section 2.2.1). The 
observation that the Fli-1 protein can induce the expression of a reporter gene linked 
to the GATA-1 promoter, also has possible implications in the differentiation block 
observed in F-MuLV-induced erythroleukaemias (Watson et al, 1992), bearing in 
mind that GATA-1 is central to the expression of many erythroid-specific genes. 
Furthermore, several recent reports have identified cooperative transactivation effects 
between GATA-1 and ets-related transcription factors in the regulation of certain 
lineage-restricted haemopoietic genes. For example, Spi-1 is able to bind to a 
sequence, adjacent to a GATA-1 site, in the regulatory regions of the (3-globin gene 
(Galson et al, 1993), whilst erythroid expression of glutathione peroxidase seems to 
require GATA-1 and ets proteins binding to an enhancer 3' to the gene (O'Prey et al,
1993). Similarly, in megakaryocytes, GATA-1 and ets-related proteins regulate the 
expression of a lineage-restricted integrin (Lemarchandel et al, 1993).
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3.5: ets genes and human tumours.
The activation of Spi-1 and Fli-1 in Friend erythroleukaemias in mice, and the 
role v-ets plays in the leukaemogenicity of the avian E26 virus, is very strong 
evidence that these genes are involved in tumour progression. Furthermore, in rare rat 
thymic lymphomas induced by the Moloney MuLV, c-ets-1 is activated as a result of 
viral insertion (Bear et al, 1989; Seth et al, 1992). Erythroleukaemias are relatively 
rare in humans, representing as few as 5% of leukaemias, and have not been 
extensively analysed cytogenetically or at a molecular level to identify genes involved 
in their evolution, although Klemsz et al (1993) have reported that a subset of these 
malignancies express the Fli-1 gene.
Translocation breakpoints in other leukaemias are often closely associated 
with regions of chromosomes where ets genes are located (reviewed in Papas et al, 
1990). For example, the c-ets-1/Fli-1 region on chromosome llq23 is a constitutive 
and heritable fragile site (Yunis and Soreng, 1984), and a frequent breakpoint in 
leukaemias and lymphomas (Diaz et al, 1986; Rovigatti et al, 1986), whilst the c-ets- 
2/erg site on chromosome 21q22 is involved in a translocation with chromosome 8 in 
acute myelogenous leukaemia (Sacchi et al, 1986; Rao et al, 1988). Interestingly, erg 
and c-ets-2 are located in the minimal trisomic region in Down's syndrome sufferers: 
coincidentally, these individuals have an increased susceptibility to developing 
leukaemias, in which erg and/or c-ets-2 gene dosage may play a part (Papas et alt
1990). However, in all these examples, the role of the ets genes has yet to be directly 
proven. Indeed, recent work cloning breakpoints from these sites, has identified novel 
genes at llq23 and 21q22 that are disrupted by the translocations present in these 
leukaemias (Tkachuk et al, 1992; Gu et al, 1992; Djabali et al> 1992; Ziemin van der 
Poel et al, 1992; Miyoshi et al, 1991; Chen et al, 1993; McCabe et al, 1993). In both 
cases, there is no homology to the ets gene family, yet this does not necessarily 
exclude a role for the closely-linked ets genes in tumour progression. For example, in 
chronic myeloid leukaemia there is no correlation between a (3;21) translocation and 
c-ets-2 expression in chronic-phase patients, but all acute-phase patients tested
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express c-ets-2 (Lafage-Pochitaloff et al, 1992): it is possible that translocations have 
secondary effects on adjacent genes that are selected for during tumour development.
Only one example exists that unequivocally shows ets gene involvement in 
human tumorigenesis. Cytogenetic analysis of Ewing's sarcoma and related 
neoplasms derived from primitive neuroectodermal tissue has demonstrated that these 
tumours always have translocations between specific parts of chromosomes 11 and 
22, a property that has been used for diagnostic purposes (reviewed in Granowetter,
1992). This abnormality fuses Fli-1 to a putative RNA binding protein termed EWS 
(Delattre et al, 1992). The expressed fusion protein contains the DNA binding 
domain of Fli-1 linked to the amino-terminal portion of EWS, a region that contains 
considerable homology to a subunit of the RNA polymerase II complex. The effects 
of this protein are two-fold. First, it results in the ectopic expression of the Fli-1 
DNA binding region that may disrupt DNA binding and transactivation by other ets 
genes and activate other specific target genes itself. Second, the EWS component 
may mimic or interfere with the normal action of RNA polymerase II, the Fli-1 
portion bringing it in close proximity to gene promoters and enhancers.
3.6: Summary.
The ets family is an ever-increasing group of closely-related transcription 
factors which bind to similar recognition sequences, either as monomers or as part of 
an oligomeric complex. Several studies have demonstrated that the DNA binding 
activity and sequence specificity of many of these proteins is dependent on post- 
translational modifications and/or oligomer formation, but the role of these proteins in 
vivo remains largely unresolved. However, an emerging theme is that they are 
involved in controlling the expression of other genes known to be induced during 
proliferation induction, or during the process of lineage-specific differentiation. In 
each case, these genes are controllable by extracellular stimuli which presumably alter 
the activity of a specific ets protein, via a signal transduction cascade. Considering 
these observations, it is not surprising that a number of the ets genes have oncogenic
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potential and are involved in the progression of certain malignancies, such as the 
deregulated expression of Fli-1 and Spi-1 in Friend erythroleukaemias. These genetic 
alterations could permit the constitutive activation of certain signal transduction 
pathways in the absence of the appropriate stimuli, or interfere with the action of 
other closely-related ets proteins. The development of an erythroid cell system which 
shows variation with respect to differentiation and growth factor or stromal cell 
signalling, should allow a detailed appraisal of these possibilities, first by looking for 
correlations between expression and phenotype, and then by testing the significance 
of these correlations by ectopic ets gene expression.
CHAPTER 4: p53.
4.1: Historical perspective.
p53, a nuclear phosphoprotein, was originally identified by its ability to form a 
high affinity complex with the large T antigen of simian virus 40 (SV40) (Lane and 
Crawford, 1979; Linzer and Levine, 1979). Tumour-derived or transformed cells 
were shown to produce abnormally large amounts of the p53 protein, which was 
barely detectable in normal cells. Furthermore, cDNA and genomic clones were 
isolated from libraries made from normal and malignant cell DNA, that could 
immortalise cells in culture and cooperate with activated ras to transform primary rat 
embryo fibroblasts (REFs) (Eliyahu et al, 1984; Jenkins et al, 1984; Parada et al, 
1984). These results implied that p53 was a classical dominant oncogene, activated 
by over-expression. However, this was challenged by several observations. First, 
Jenkins and his colleagues demonstrated that the inability of a particular p53 construct 
to transform cells could be overcome by introducing small deletions into the p53 
coding sequence (Jenkins et al, 1985). Second, there was accumulating evidence 
from Friend erythroleukaemia cell lines that gross disruptions and deletions in the p53 
gene appeared to be associated with tumour progression (section 2.3.5.3). Third,
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Rovinski and Benchimol (1988) showed that a presumed wild-type (wt) p53 genomic 
clone, controlled by its own promoter, was as efficient at transforming REFs as 
grossly mutant clones isolated from the Friend cell lines. At the time, this suggested 
that wtp53 could be oncogenic as a result of very subtle changes in expression and/or 
gene dosage. Finally, it was observed that there were small sequence differences 
between cDNA clones that were transforming and those that were not (Finlay et al, 
1988). Furthermore, comparison of p53 sequences from different species had 
identified five evolutionarily conserved domains (reviewed in Soussi, 1990) into 
which these differences mapped, implying that they may alter the function of the 
protein. Subsequently, it was shown that all the p53 clones capable of cooperating 
! with activated ras in transformation, including the 'wt' gene used by Rovinski and
| Benchimol (1988), were in fact mutants (Eliyahu et al, 1988; Hinds et al, 1989). In
| view of the gross alterations seen in the Friend cell lines, it was assumed that
j  mutation of p53 was a loss-of-function alteration and that their ability to transform
| was a consequence of a dominant-negative effect over the wt protein in these cells
|
| (discussed in length in section 4.4 below). This was supported by a crucial set of
| experiments performed by Finlay and her co-workers (Finlay et al, 1989), in which it
i
| was demonstrated that co-transfection of wtp53 significantly reduced REF
|
| transformation by mutant p53 and activated ras. Furthermore, wtp53 had a similar
i
j effect on transformation induced by a combination of activated ras and the adenovirus
! Ela gene; any transformed clones that did develop lacked wtp53 expression. Thus,
! p53 was finally classified as a tumour suppressor gene.
4.2: Mutation of p53 during tumorigenesis: loss of growth suppression.
Mutation in one copy of the p53 gene, usually accompanied by loss of the 
other wt allele, is the commonest genetic alteration detected to date in human 
tumours, and is involved in tumour progression in numerous animal model systems. 
This indicates the importance of this gene in controlling normal cell growth and 
justifies the extensive studies that have been performed concerning its properties. As
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discussed above, p53 mutation appears to be an obligate step in the generation of 
leukaemic cells in Friend disease, but it has also been shown to be involved in other 
animal model systems. For example, formation of chemically-induced carcinomas in 
mouse skin often requires mutation of the p53 gene (Bums et al, 1991). In humans, it 
was demonstrated that allelic deletions of the short arm of chromosome 17, in 
particular region 17ql2 to 17ql3.3, are associated with tumours derived from various 
cell types (Baker et al, 1989). This region contains the p53 gene, and subsequent 
sequencing of the remaining allele, first from colorectal carcinomas, but later from a 
wide variety of tumour types, revealed that it had become mutated (Baker et al, 1989; 
Nigro et al, 1989; reviewed in Hollstein et al, 1991). These alterations usually take 
the form of a base change, either transition or transversion, that changes a single 
amino acid in the mature protein. Occasionally, small deletions or insertions are 
found that usually shift the reading frame resulting in production of a truncated 
protein. Also, a number of splicing mutants have been characterised that generate 
transcripts that lack exons and/or contain intronic sequences with the result that the 
encoded proteins are truncated by the introduction of a stop codon. A comprehensive 
review of p53 mutations has been made by Hollstein et al, 1991, and Caron de 
Fromentel and Soussi, 1992.
Unlike the activating mutations found in ras which are targeted to a few 
codons (reviewed in Bos, 1988), p53 mutations are widely spread throughout the 
gene. However, approximately 98% of the base substitutions are found in the central 
portion of the gene coded by exons 5 to 8, clustered in the evolutionarily conserved 
domains (labelled 'HOT in Figure 4.1) (Soussi, 1990). Nearly 90% of these alter an 
amino acid that is invariant between species as widely diverged as trout and man, 
implying a functional importance to these changes. Interestingly, the type of mutation 
and its position varies between tumours of different origin. This has implied the 
direct involvement of environmental carcinogens in mutations found in lung, liver and 
skin tumours. For example, individuals exposed to aflatoxin B1 and the hepatitis B 
virus have mainly G to T transversions clustered in codon 249 (Bressac et al, 1991;
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Hsu et al, 1991); G to T mutations are also induced with benzo[a]pyrene, a major 
constituent of tobacco smoke (Ruggeri et al, 1993). Similarly, CC to TT double base 
changes are most common in skin cancer; these types of alterations are induced by 
UV light (Brash et al, 1991; Zeigler et al, 1993). However, mutations in other tumour 
types, especially in colorectal carcinoma, are often G:C to A:T transitions occurring at 
CpG dinucleotides. These sites become methylated on the cytosine residue: as a 
consequence, they can undergo spontaneous or enzymatic deamination to a thymidine 
residue generating a transition mutation (Sved and Bird, 1990; Shen et al, 1992). 
Thus, CpGs act as endogenous mutagens, and indeed, it is thought that approximately 
35% of human genetic disorders are the result of mutations at these sites, despite 
being under-represented by a factor of five in the genome (Rideout et al, 1990).
Germ-line mutations in the p53 gene, half of which involve CpG 
dinucleotides, appear to be responsible for the Li-Fraumeni syndrome (LFS), 
characterised by the early development of tumours (median age of presentation is 
approximately 30 years of age) at different sites within the body. Breast cancer, soft 
tissue sarcomas and brain tumours are particularly common (Malkin et al, 1990; 
Srivastava et al, 1990, 1992). LFS individuals are heterozygous for these mutations 
still retaining a copy of the wt gene, although losing this allele during tumour 
formation. Thus, development of LFS-associated tumours requires only one 
mutational event to remove the suppressive effect of the p53 protein, whilst two 
mutations are necessary in sporadic tumour progression. This disease has now been 
mimicked to some extent in genetically-engineered mice that only contain one copy 
of the p53 gene, the other being deleted by homologous recombination (Donehower et 
al, 1992). These animals have an increased susceptibility to tumour formation, which 
can be increased dramatically by deleting the other allele to create a p53-null animal 
These null mice appear to be developmentally normal but tumours form within three 
months of birth, usually in the lymphoid tissues. Prior to these results, p53 mutation 
had been implicated as a late event in tumour progression, for example in the 
adenoma to carcinoma step in colon cancer (Baker et al, 1990a) and in the blast crisis
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of chronic myelogenous leukaemia (Ahuja et al, 1989; Feinstein et al, 1991). LFS 
and the p53-null mice suggest that it is the accumulation of mutations, not necessarily 
the order in which they occur, that is important in tumorigenesis. Indeed, as discussed 
in detail below, there is increasing evidence to suggest that mutation of p53 may 
actually facilitate the accumulation of these mutations.
By transfection of wtp53 under the control of a viral LTR, it has been 
demonstrated that the growth and tumorigenicity of several tumour cell types is 
inhibited by the re-expression of the wt protein (Baker et al, 1990b; Chen et al, 1990; 
Diller et al, 1990; Casey et al, 1991). The identification of a temperature-sensitive 
(ts) p53 mutant allowed Michalovitz and his colleagues (1990) to confirm these 
results elegantly by simply altering the incubation temperature of tumour cells 
transfected with the mutant. At 37.5°C, the cells grow normally, whereas on shifting 
to 32.5°C causes the protein to act as a suppressor and inhibit cell growth. Inhibition 
appears to be the result of a block in the cell cycle in late Gl, just prior to DNA 
replication (Lin et al, 1992). In two cell lines tested, derived from a myeloid 
leukaemia and a colon carcinoma, wtp53 induced apoptosis, implying that in some 
cell lines at least, p53 has more than a cytostatic role (Yonish-Rouach et al, 1991; 
Shaw et al, 1992). Furthermore, in a separate experiment, Feinstein and her co- 
workers (1992) reported that wtp53 could induce the differentiation of K562 along the 
erythroid lineage, whilst Shaulsky et al (1991a) detected mature B-cell formation on 
transfection of the normal gene into a B-lymphoma cell line. This may simply be 
because arrest in the cell cycle causes differentiation, rather than cell death, in certain 
cell types. Alternatively, it is possible that these results actually reflect an induction 
of apoptosis but that cytokines present in the cultures encourage maturation rather 
than cell death once cells stop proliferating. Indeed, Yonish-Rouach and colleagues
(1991) could inhibit /?53-induced apoptosis by treatment with interieukin-6 which 
induced the cells to differentiate along the monocytic lineage instead. An important 
aspect of haemopoietic cytokine biology is their ability to suppress apoptosis (see 
Erythropoietin section in chapter 1 and Williams et al, 1990b). Furthermore, as
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discussed in section 23.53, reconstitution of wtp53 in Friend erythroleukaemia cells 
lacking any p53 proteins induces apoptosis, an effect that can be reversed to some 
extent by the addition of erythropoietin (Ryan et al, 1993; Johnson et al, 1993). 
Differentiation is not induced in this case, probably because of other mutations 
present in the cells that can not be overridden by the wtp53 protein or the epo.
4.3: p53 and viral oncoproteins.
SV40, some adenoviruses and human papilloma virus (HPV) type 16 and 18 
are capable of initiating tumours in animals and transforming cells in vitro. Certain 
viral oncoproteins are known to be both necessary and sufficient for this: these are the 
SV40 large T and small t antigens, Ela, Elb-55kDa and Elb-19kDa from the 
adenoviruses and HPV E6 and E7. These proteins exhibit a wide variety of effects 
within a host cell, such as altering transcription or affecting mRNA stability and 
processing; however, probably the most important functions a number of these 
proteins perform is to inactivate the p53 and Rb tumour suppressor proteins (reviewed 
in Lane, 1989). The SV40 large T antigen, adenovirus Elb-55kDa and HPV E6 are 
all able to bind to p53 (Lane and Crawford, 1979; Linzer and Levine, 1979; Samow et 
al, 1982; Wemess et al, 1990); more recently the x antigen of the hepatitis B virus has 
been added to this list (Feitelson et al, 1993). Tumours generated in transgenic mice 
expressing the large T antigen, and human cervical cancers which show HPV 
involvement, do not have mutations in their p53 genes (Moore et al, 1992; Crook et 
al, 1992), presumably because these viral proteins inactivate wt function. On the 
other hand, non-HPV-associated cervical tumours often do have mutant p53 genes.
The E6 protein prevents tumour suppression by p53 by increasing its rate of 
degradation, virtually removing it all from HPV-infected cells (Scheffner et al, 1990). 
However, large T and Elb-55kDa stabilise p53 and probably inhibit its function by 
sequestration into inactive complexes, similar to the way mutant p53 is thought to 
exert its dominant-negative effect (section 4.4). Indeed, large T mutants that are 
unable to bind p53 are transformation-incompetent (Peden et al, 1989) although other
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work has implied that SV40 can overcome the antiproliferative effects of wtp53 in the 
absence of detectable large T-p53 complex formation (Michalovitz et al, 1991). 
Furthermore, free p53 in SV40-transformed cells is as stable as p53 bound to the large 
T antigen, results that have led to the proposal that p53 inactivation may involve a 
covalent modification that is either prevented or induced by large T (Deppert and 
Haug, 1986). Nevertheless, the targeting of p53 by these viruses reiterates the 
importance of p53 in preventing tumour formation, and shows that mutation of the 
gene is not the sole mechanism of p53 inactivation.
4.4: Properties of mutant p53: protein structure, and dominance over wild-type.
Early in the study of p53 it was noticed that mutant protein present in tumour 
cells is highly stable, possibly a consequence of interaction with heat shock proteins 
mediated by a domain between amino acids 13 and 29 at the very amino-terminal end 
of the p53 protein (Oren et al, 1981; Finlay et al, 1988; Lam and Calderwood, 1992). 
This association may result from the inability of the mutant to fold into the wt 
conformation, thus revealing the amino-terminus. Indeed, Gannon and his co-workers
(1990) generated an antibody (PAb240) that specifically recognises many of the 
mutant p53 proteins, but will not bind to the wt form. These p53 mutations have, 
therefore, altered not just the sequence of the protein but also its conformation 
Irrespective of the position of the mutation, the epitope for this antibody, which is 
located in the centre of the protein between conserved regions 3 and 4 (Stephen and 
Lane, 1992; Figure 4.1), becomes exposed.
Unlike the retinoblastoma protein that becomes non-functional on mutation, 
the ability of mutant p53 genes to transform primary REFs in combination with 
activated ras (section 4.1), suggests that it has obtained a new function in addition to 
losing its ability to act as tumour suppressor. Also, transgenic mice that contain a 
mutant allele and two normal alleles have an increased susceptibility to tumour 
formation compared to normal mice, despite still requiring two mutational events to 
remove all wtp53 (Lavigueur et al, 1989). In fact, these animals get tumours at about
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the same age as heterozygous /?53-null mice that only have one wt allele (Donehower 
et al, 1992). These results suggest that some p53 mutations act as dominant-negative 
inhibitors of wtp53 function.
However, other mutations, including LFS mutations, do not confer this 
property; whilst these genes are unable to inhibit REF transformation, they are also 
only weakly transforming, in effect behaving like recessive-negative mutants (Halevy 
et al, 1990; Hinds et al, 1990; Malkin et al, 1990). The p53 truncation mutants seen 
in LFS and in sporadic tumours (see section 4.2 and Sameshima et al, 1992), are also 
thought to be of this type. It is possible that this is necessary to permit the survival of 
LFS individuals to adulthood, to allow the subsequent transmission of the mutant
I allele. Interestingly, Prosser et al (1992) have reported a p53 mutation in a family
j
I prone to developing tumours much later than LFS family members, suggesting that
|
; this mutation may be an even 'weaker' dominant-negative allele than LFS mutations. 
However, it can not be excluded that the genetic background and lifestyle of this 
family may also prevent the early appearance of tumours.
p53 dominant-negative mutant proteins are believed to work by a process of 
sequestration of the wt protein into non-functional mutant-wt oligomers.
! Oligomerisation of wtp53, and in particular tetramer formation, has been
demonstrated in vivo and is known to be mediated by two contiguous motifs in the
carboxy-terminus (Figure 4.1) (Kraiss et al, 1988; Milner and Medcalf, 1991; Stengerf
I et al, 1992; Sturzbecher et al, 1992; Friedman et al, 1993). However, the formation
[ of mutant-wt complexes has been difficult to mimic in vitro. Using the ts p53
| dominant-negative mutant (section 4.2), it has been possible to show that, when in the 
mutant conformation, mixed complexes of mutant and endogenous wtp53 protein
!
i form in the cytoplasm; however, these are lost when the ts mutant acquires its wt 
properties (Martinez et al, 1991). Interestingly, protein synthesis is necessary for this 
sequestration (Gannon and Lane, 1991), and recent work has indicated that it may be 
synthesis of p53 itself that is required, since only when mutant and wtp53 are co­
translated can they form oligomers in vitro in which the wtp53 is driven into the
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mutant PAb 240-positive conformation (Milner and Medcalf, 1991; Milner et al,
1991). Truncated p53 proteins lacking the carboxy-terminal oligomerisation domain 
are unable to complex with, and alter the conformation of, the wtp53 protein, and are 
thus, unable to exert a dominant-negative effect. Intriguingly, p53 miniproteins, 
essentially containing only the oligomerisation domain, are highly effective 
dominant-negative transforming proteins, presumably by a mechanism of 
sequestration (Shaulian etal, 1992).
However, it seems unlikely that any of the mutant p53 proteins are totally 
dominant over the wt protein, since tumour cells expressing a mutant p53 gene 
invariably lose the wt allele by another mutational event. It is possible that in a 
developing tumour cell containing both wtp53 and dominant-negative mutant p53, 
some wt protein is not sequestered and mutant dominance is only partial, but 
nevertheless sufficient to give the cell a growth advantage over its neighbours. 
Complete loss of the wt by a second mutation could then also be seen as a progressive 
step to tumour formation, explaining the reduction to homo- or hemizygousity that is 
seen in most tumours.
There is also evidence suggesting that mutant p53 may gain an additional 
oncogenic function since the tumorigenicity and plating efficiency in semi-solid 
media of p5i-negative cell lines is increased by expressing a mutant p53 gene (Wolf 
etal, 1984; Shaulsky etal, 1991b; Dittmer etal, 1993).
4.5: Properties of wtp53, a transcription factor.
Until very recently the role played by p53 in normal cells remained somewhat 
mysterious. However, there is now accumulating evidence that wtp53 is a 
transcription factor (reviewed in Vogelstein and Kinzler, 1992). First, it was noted 
that a fusion protein containing p53 linked by its carboxy- or amino-terminus to the 
GAL4 DNA binding domain could activate transcription from the GAM operon 
(Fields and Jang, 1990; Raycroft et al, 1990; O'Rourke et al, 1990). More detailed 
work has narrowed this effect down to the region between amino acids 20 and 42,
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many of which are acidic, which is now considered to be the minimal transactivation 
domain (Figure 4.1) (Unger et al, 1992; Miller et al, 1992). Second, by screening 
genomic DNA fragments, several groups have identified DNA sequences that 
specifically bind to wtp53 in vitro: these have a consensus that requires two copies of 
the lObp motif 5'-PuPuPuC(A/T)(A/T)GPyPyPy-3’ separated by up to 13bp of 
random sequence (Kern et al, 1991b; El-Deiry et al, 1992; Funk et al, 1992; Foord et 
al, 1993). The requirement for two copies of a symmetrical sequence for the binding 
of wtp53 to a specific DNA sequence in vitro, implies that wtp53 protein may bind as 
a tetramer. However, in vivo it is possible that one copy of the motif is sufficient for 
p53 binding, if adjacent factors cooperate to stabilise the p53-DNA complex.
This evidence alone does not prove that p53 is a transcription factor. 
However, it is supported by transient co-transfection experiments in which 
transfection of p53-negative cell lines with a reporter gene linked to a p53 binding 
site, along with a p53 expression vector, causes up-regulation of reporter gene 
transcription (Kern et al, 1992; Funk et al, 1992). Although this could be mediated 
by other cellular proteins controlled by p53, Vogelstein and Kinzler (1992) have 
argued that p53 is having a direct effect on the promoter for the following reasons. 
First, the experiments are repeatable in yeast (Scharer and Iggo, 1992; Kern et al,
1992): if other cellular proteins mediated the transcription there would have to be 
remarkable conservation in evolution between yeast and mammals, even though there 
is no known p53 homologue in yeast. Second, Farmer et al (1992) have been able to 
show transcriptional activation by p53 in vitro using purified wtp53 and similar 
reporter constructs. Third, by using a number of different reporter plasmids, Kern and 
his colleagues (1992) were able to correlate the strength of p53 binding to its 
recognition site to the extent of transactivation.
4.6: Target genes and DNA replication.
Co-transfection experiments have been used to identify p53-responsive 
domains in the promoters of many cellular proteins. Of particular relevance to the
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antiproliferative effects of wtp53 has been the demonstration that retinoblastoma gene 
expression is down-regulated by wtp53, and that the promoter of the gene encoding 
the so-called proliferating-cell nuclear antigen (an auxiliary factor of DNA 
polymerase 8) is also inhibited (Shiio et al, 1992; Deb et al, 1992). Both of these 
proteins probably play an important role in DNA replication, and their regulation by 
wtp53 may be partly responsible for the cell cycle block induced by the protein. 
However, in both these examples, direct binding of wtp53 to the promoter was not 
demonstrated: it is therefore possible that regulation of these and other promoters by 
wtp53 is, in fact, mediated by the binding of other cellular proteins whose activity has 
been affected, directly or indirectly, by the general change in the cycling state of the 
cell (Ginsberg et al, 1991).
Furthermore, it could be argued that p53 binding sites in genomic DNA are 
being used to control a process distinct from transcription, such as replication. Taken 
out of context in an artificial reporter gene expression vector, transcription may be 
affected as a result of a conformational change in the DNA, such as local unwinding 
of the helix, that is involved in a different process in vivo. Indeed, there is some 
evidence that implicates wtp53 directly in the process of DNA replication. First, 
immunostaining with anti-p53 antibodies has localised the protein to sites of viral 
replication in herpes virus-infected cells (Wilcock and Lane, 1991). Second, it has 
been demonstrated that wt, but not mutant, p53 can inhibit DNA replication from the 
SV40 origin of replication (Braithwaite et al, 1987; Sturzbecher et al, 1988; Wang et 
al, 1989; Friedman et al, 1990). This appears to be achieved by the combination of a 
number of different mechanisms, all involving inhibition of the normal function of the 
large T antigen. During initiation of viral replication, the large T antigen binds to the 
origin and unwinds the DNA. wtp53 binds to a sequence adjacent to the origin as a 
large oligomeric complex, where it prevents the binding of large T (Bargonetti et al, 
1991). This region is similar to the p53-binding consensus, shown above, that acts as 
an transcription enhancer element. Large T is able to displace the wtp53 molecules 
from the DNA, but, once complexed, the wtp53 inhibits the DNA helicase activity of
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large T and prevent it from binding to DNA polymerase a , properties required for 
large T to initiate normal viral replication (Sturzbecher et al, 1988; Gannon and Lane, 
1987). To overcome these problems large T inactivates wtp53, thus removing 
inhibition at the viral, and also possibly at cellular, origins of replication.
More recently however, Zambetti et al (1992), identified a p53 binding site in 
the promoter of muscle creatine kinase which mediates up-regulation of the gene. 
This directly correlated p53-DNA interaction with transactivation, and since this 
discovery numerous other genes have been identified that are repressed or activated 
by wtp53 (Kastan et al, 1992; Chin et al, 1992; Agoff et al, 1993): one of these, 
GADD45, is discussed below (section 4.9). Moreover, a number of reports have 
proposed that wt, but not mutant, p53 may exert a general repressive effect on genes 
regulated by TATA boxes, by interacting directly with the basal transcription 
machinery (Seto et al, 1992; Mack et al, 1993; Ragimov et al, 1993). Thus, wtp53 
has been accepted as a transcription factor, but this evidence does not exclude the 
possibility of a separate direct interactive role for wtp53 in the replication machinery.
4.7: Control of wtp53 function.
Interestingly, in vtfro-translated p53 protein is unable to bind to its recognition 
sequence unless it is mixed with nuclear extract, a result which implied that post- 
translational modification, or possibly hetero-oligomer formation is required to 
activate DNA binding (Funk et al, 1992). Many potential phosphorylation sites have 
been identified in the amino- and carboxy-termini of the protein where the 
transactivation and oligomerisation domains are found (Figure 4.1), and thus, 
phosphorylation may modulate their activity. Serine 389 of mouse p53 (serine 391 in 
human p53), the penultimate amino acid of the protein, is phosphorylated by casein 
kinase II, a heterodimeric protein that is thought to mediate signal transduction of 
extracellular mitogenic stimuli (Meek et al, 1992). Mutation of this residue to an 
alanine removes the antiproliferative properties of wtp53 (Milne et al, 1992a), and 
phosphorylation of this serine appears to be required to permit wtp53 to bind to its
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recognition site (Hupp et al, 1992). Similarly, deletion of the last thirty amino acids 
from the carboxy-terminus of the unphosphorylated protein allows DNA binding in 
vitro, identifying this region as a negative regulator of wtp53 function that can be 
controlled by phosphorylation (Hupp et al, 1992): larger deletions of this region 
abrogate DNA binding (Foord et al, 1991). The oligomerisation domain, thought to 
be essential for wtp53 function, is located in the negative regulatory domain identified 
by Hupp et al (1992).
These results have collectively given rise to the following hypothesis 
concerning the role of the carboxy-terminus in regulating p53 function. This proposes 
that the 02  domain (residues 341-355; Figure 4.1) mediates wtp53 dimerisation, and
I is therefore probably essential for DNA binding, whilst the Ol region (residues 365-
i
| 386) is involved in sequestering wtp53 into large inactive oligomers which can be
| disrupted by Ol removal or phosphorylation by casein kinase II at the penultimate
serine. However, removal of 02 prevents DNA binding irreversibly, explaining the 
selection for truncation mutants in developing tumour cells (Hupp et al, 1992). 
Intriguingly, serine 389 is also the target for addition of a small 5.8S rRNA moiety, 
the function of which remains a mystery (Fontoura et al, 1991; Samad and Carroll, 
1991).
Serine 309 in mouse p53 (315 in human) is a target for the p34cdc2 kinase, a 
protein that controls cell cycle progression. Interestingly, this residue lies in one of 
the nuclear localisation domains, and thus, may control subcellular localisation of p53 
in a cell cycle-dependent fashion (Milner et al, 1990; Bischoff et al, 1990a; Addison 
et al, 1990). At the amino-terminal are several serines, adjacent to and within the 
minimal transactivation domain, that are phosphorylated by a casein kinase I-like 
protein, and can be dephosphorylated in vitro by protein phosphatase 2A (Wang and 
Eckhart, 1992; Milne et al, 1992b). The exact role of these modifications is 
unknown, but interestingly, a double-strand DNA-dependent kinase also 
phosphorylates these sites and, as discussed below, may modify p53 activity in 
response to DNA damage.
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4.8: Mutant p53 proteins fail to bind to DNA.
Defining wtp53 as a regulable transcription factor made it important to 
determine the effect mutation of the gene has on its properties. First, in carboxy- 
terminal truncation mutants, the lack of the oligomerisation domain means these 
proteins are unable to form a tetrameric complex with DNA. Second, in many of the 
reports showing transactivation by wtp53, it was also demonstrated that a variety of 
mutant p53 proteins carrying a single amino acid change had lost this ability 
(Raycroft et al, 1990; Deb et al, 1992; Kern et al, 1992; Zambetti et al, 1992; Unger 
et al, 1992; Farmer et al, 1992). Furthermore, Yew and Berk (1992) showed that 
transactivation by the wtp53-GAL4 fusion protein was dominantly inhibited in vivo 
by p53 mutants or by the Elb-55kDa protein, presumably by the formation of inactive 
oligomers. Invariably the mutant proteins have lost their ability to bind to DNA 
(Kern et al, 1991a, 1991b; El-Deiry et al, 1992), but Raycroft and her colleagues 
(1990, 1991) showed that even if a full-length tumour-derived point-mutated p53 
cDNA is linked to the DNA binding domain of GAL4, it is still unable to activate 
transcription from a GAL4 operon. When the ts p53 mutant is used in these fusion 
experiments, transcription only occurs at 37.5°C, when the mutant has the 
transformation-suppressing ability of the wt (Raycroft et al, 1991). Thus, point- 
mutated tumour-derived p53 genes code for proteins that are unable to bind to DNA 
and/or activate transcription. Interestingly, a mutant protein from an LFS family 
exhibited transactivation to the same extent as wt in the GAL4 assay system, although 
the DNA binding ability of this protein was not assessed (Raycroft et al, 1991).
The viral oncoproteins produce the same effect on p53 DNA binding 
properties as seen with point mutation: E6 by degrading the protein and large T and 
Elb-55kDa by disrupting the interaction (Farmer et al, 1992; Lechner et al, 1992; 
Yew and Berk, 1992; Mietz et al, 1992; Segawa et al, 1993). It was proposed that 
there may be a functional cellular homologue of the viral oncoproteins that could be 
regulated to prevent DNA binding in response to specific signals (Levine etal, 1991). 
One such candidate has recently been identified, termed mdm2, that forms a complex
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with p53, inhibits its DNA binding and masks the amino-terminal transactivation 
domain of the protein (Momand et al, 1992; Oliner et al, 1993). This gene was 
originally identified by virtue of its amplification in a transformed mouse fibroblast 
cell line (Cahilly-Snyder et al, 1987), and has been shown to increase the 
tumorigenicity of cells in which it is over-expressed artificially (Fakharzadeh et al,
1991), presumably because it interferes with wtp53 function. Indeed, Finlay (1993) 
has shown that mdm2 can prevent wtp53-mediated suppression of rat embryo 
fibroblast transformation. Furthermore, Oliner et al (1992) detected amplification of 
the gene in a third of human sarcomas tested. These tumour types often do not have 
p53 mutations: it is probably not required if mdm2 is over-expressed.
Thus, whether by mutation of the gene itself, infection with viruses containing 
wtp53~inactivating proteins or by mdm.2 amplification, wtp53 appears to be removed 
from a large variety of developing tumour cells. Until recently, this was thought to 
result in uncontrolled proliferation, by mimicking the effect of mitogenic stimuli. 
However, there are now indications that wtp53 only prevents cell division at certain 
times, in particular when cells have sustained damage to their DNA.
4.9: p53 and DNA damage.
Although wtp53 can block cell cycling when expressed at high levels, it does 
not seem to play a role in normal cell cycle control. Thus, in mice lacking both p53 
genes, and in humans with germ-line mutations of p53 (LFS), development is normal 
although there is an increased susceptibility to developing tumours (Donehower et al, 
1992; Malkin et al, 1990; Srivistava et al, 1990). It seems unlikely that this normal 
development is due to functional redundancy. This would imply that cells containing 
a p53 mutation would have to acquire a second mutation in the gene responsible for 
the redundancy to allow the p53 mutation to be favourable for tumour progression. In 
fact, evidence is now emerging that the wtp53 protein prevents the division of cells 
that have sustained DNA damage.
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In 1984, Maltzman and Czyzyk found that treatment of fibroblasts with UV or 
UV-mimetic drugs induced an increase in the levels of p53 protein as a consequence 
of a post-translational event (Maltzman and Czyzyk, 1984), a result repeatable in 
normal human skin (Hall et al, 1993). More recently, Kastan and his colleagues
(1991) showed the same effect with y-radiation and correlated it to a Gl-S block in 
the cell cycle. They were unable to produce the same results in cells harbouring 
mutant p53 proteins unless wtp53 expression was artificially restored (Kuerbitz et al,
1992).
These alterations in the wtp53 levels at times of stress probably alters the 
transactivating properties of the protein: indeed, it has been demonstrated that 
expression of the GADD45 gene at this time is dependent on wtp53 binding to an 
element within one of its introns, which presumably does not occur without the 
radiation treatment (Kastan et al, 1992). GADD45 was originally identified as being 
specifically up-regulated in response to DNA damage induced by ionising radiation 
(Fomace et al, 1988; Papathanasiou et al, 1991). Its function is unclear, but it is 
thought to be involved in DNA repair and shows slight homology to a yeast DNA 
repair gene, radl (Papathanasiou et al, 1991). In cells that have lost wtp53, GADD45 
is not induced and gene amplification potential is increased; this can be reversed by 
restoring the wtp53 by introducing expression constructs containing the gene (Kastan 
et al, 1992; Yin et al, 1992; Livingstone et al, 1992). Interestingly, Kastan et al
(1992) have also shown that p53 stabilisation and GADD45 expression are not 
induced following irradiation of cells from ataxia-telangiectasia individuals. This 
inherited genetic disorder is characterised by an increased instability of the genome, 
with homozygotes often developing cancer early in life (Swift et al, 1991). This is 
not surprising if the p53 Gl-S checkpoint is abrogated. This result has also led to the 
suggestion that the product of the ataxia-telangectasia gene(s) is an upstream 
regulator of wtp53 function. Further support for a role for wtp53 in reducing DNA 
damage comes from observation that the large T antigen of S V40 or HPV E6 converts 
cells to a state that permits gene amplification (Perry et al, 1992; Kessis et al, 1993).
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Furthermore, fibroblasts from LFS individuals exhibit an increased genomic 
instability and are more likely to become tumorigenic than their normal counterparts 
(Bischoff etal, 1990b, 1991).
From these results the following working model was proposed and is depicted 
diagrammatically in Figure 4.2 (Lane, 1992). DNA damage induces an increase in 
wtp53 protein levels, and also possible alterations in its transactivating properties, 
which prevents the transition into the S phase of the cell cycle. This gives time for 
the damage to be repaired; wtp53 may also induce the expression of the appropriate 
genes to do this. Should the DNA fail to be repaired, then apoptosis may be induced 
to prevent the division of a damaged cell (Figure 4.2A) (Yonish-Rouach et al, 1991; 
Shaw et al, 1992; Ryan et al, 1993; Johnson et al, 1993). Mutating p53 during 
tumour progression removes this Gl-S checkpoint, thus permitting the accumulation 
of other mutations that contrive to prevent maturation and enhance proliferation 
(Figure 4.2B).
Exactly how the DNA damage is detected, how it is converted into a wtp53 
stabilisation message and which kind of damage (e.g. DNA breaks or point mutation 
etc.) induces the effect is currently unknown, but is presumably the subject of intense 
investigation. However, the model has received support in studies of T cell apoptosis 
in normal mice compared to p53-null animals. In the absence of p53, the cells were 
unable to die in response to radiation treatment, unlike their normal counterparts, but 
were still responsive to agents which mimicked T cell receptor-mediated death (Lowe 
et al, 1993; Clarke et al, 1993). With reference to the mechanism of p53-mediated 
damage-induced apoptosis, it is interesting to note that two groups have identified a 
protein kinase, termed DNA-PK, that is active only in the presence of double-stranded 
DNA and which phosphorylates serines 15 and 37 in the amino-terminal 
transactivation domain of the p53 protein (Lees-Miller et al, 1990, 1992; Carter et al, 
1990). It seems possible that such a kinase may be regulated by damaged DNA, 
although a great deal more work is needed to evaluate this signalling pathway and its 
affect on wtp53. Another possibility is that the mdm2 gene product acts as a p53
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regulator that may be targeted by modifying enzymes, like protein kinases, to alter its 
affinity for p53.
4.10: Summary.
During the last three years, we have witnessed major advances in the 
understanding of the p53 tumour suppressor with the identification of its role as a 
transcription factor, the alterations in this property as a result of mutation, and the 
generation of a new working model for p53 as a DNA damage-regulated proliferation 
inhibitor. At the outset of this thesis, the effect of p53 mutation on the progression of 
leukaemia was uncertain. Recent reconstitution experiments have attempted to link 
p53 mutation with a loss of differentiation and/or a block in apoptosis. However, like 
other tumour cells, the genome of these cells is probably highly unstable, and these 
effects may be a consequence of damage detection, rather than a true representation of 
the role of wtp53 in normal erythroid progenitors. One problem with the Friend 
erythroleukaemia model is that only the most advanced leukaemic cells are available 
for study, which have lost most of the characteristics of normal erythroid progenitors. 
A cell system which shows a stepwise acquisition of particular phenotypes would 
facilitate attempts to correlate p53 mutation with abrogation of a particular aspect of 
erythropoiesis. If, however, it is insufficient to affect these processes, cells should 
still be capable of differentiation and death in the absence of wtp53, a hypothesis 
supported by the normal development of p53-null mice.
CHAPTER 5: The ELM erythroleukaemia system.
5.1: Erythroleukaemia induced with X-ray irradiation.
A disease with the characteristics of an erythroblastic leukaemia, termed the 
ELM erythroleukaemia, was induced in a female C3H mouse by X-ray irradiation of 
300 Rads when the animal was 10 weeks old (Figure 5.1) (Itoh et al, 1988a).
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Hepatomegaly, splenomegaly and anaemia were noticed after a ten month latency. 
Like Friend erythroleukaemia cells, intra venous injection of leukaemic ELM spleen 
cells induced the same disease in a syngeneic host although with a latency of two 
months. Subsequent passage in vivo generated erythroleukaemia within two weeks of 
injection, implying selection for more leukaemogenic cell clones during these early 
passages. Cytological analysis of peripheral blood from animals with a well- 
developed leukaemia showed that it consisted almost entirely of erythroid cells at 
different stages of differentiation.
It is unusual for irradiation to induce erythroid malignancies in mice; usually 
cells from the lymphoid and other myeloid lineages are affected, with the genetic 
background of the irradiated host determining, to some extent, the nature of the
| haematological malignancies formed (Janowski and Boniver, 1986; Mole, 1986). In
[
some cases, these involve the production of recombinant endogenous retroviruses that
[
| are leukaemogenic in other non-irradiated host animals. Itoh et al (1988a) performed
a number of experiments that appeared to exclude any endogenous or exogenous 
retroviral involvement in the ELM tumour. First, cell-free medium from short-term 
ELM spleen cell cultures, and ultrasonicated ELM cells, both failed to induce 
erythroleukaemia in 8-10 week-old C3H mice, demonstrating that no leukaemogenicI
j retroviruses are being produced by the cells. Second, reverse transcriptase (RT)
| activity, which is present in retrovirus-producing cells, was not detected in the spleen|
j  and liver of mice with advanced ELM erythroleukaemia: the same assay had been
used effectively to detect RT activity in Friend virus-infected cells (Ono et al, 1984). 
These results distinguished ELM from Friend and Rauscher virus-induced 
erythroleukaemias, and implied that the X-ray irradiation was the sole factor involved 
in initiating this malignancy, presumably by generating mutations in cellular genes. 
Autocrine growth factor production has been recorded in a number of haemopoietic 
malignancies (Miyanomae et al, 1985; Sawada et al, 1986; McDonald et al, 1987; 
Meeker et al, 1990). However, conditioned medium from short-term ELM leukaemic 
spleen cell cultures failed to increase erythroid 'burst' formation from normal bone
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marrow cells, demonstrating that erythroid stimulatory factors, such as epo, were 
probably not being produced by the leukaemic cells as a result of these putative 
mutations (Itoh et al, 1988a).
5.2: Long-term growth in vitro supported by stromal cells.
Attempts to culture spleen cells from the ELM tumour in vitro proved difficult 
and even with IL-3, GM-CSF or epo supplements no cell lines could be established. 
This is quite distinct from Friend erythroleukaemias from which cell lines are readily 
generated, even in the absence of growth factors (section 2.3.4). However, after an 
initial decrease in viability, ELM cells grew well on stromal cells, initially on primary 
bone marrow-derived stromal cells, then later, on a bone marrow-derived stromal cell 
line, MS-5 (Figure 5.1) (Itoh et al, 1988b). This gave rise to the ELM-D cell line, the 
'D' representing the stromal cell-dependence of the erythroleukaemia cells. The MS-5 
cells are fibroblastic-like cells established after 900 Rads X-ray irradiation of a 
LTBMC; they are capable of supporting the adhesion-dependent growth of 
haemopoietic stem cells and their progeny for greater than two months in LTBMC 
(Itoh et al, 1989). The ELM cells adhere tightly to the stromal cells, with regions of 
extremely close contact (-10 Angstroms), and are physically separable only by 
trypsinisation (Itoh et al, 1993). Dependence on specific growth factors for the 
survival and proliferation of leukaemic cells in vitro has been demonstrated in 
malignancies affecting several other blood cell lineages (Poiesz et al, 1980; Lange et 
al, 1987; Spivak et al, 1990), but the use of stromal cells to support growth has rarely 
been recorded. However, Hiai et al (1981) showed that the proliferation of murine 
lymphoid leukaemia cells in vitro could be supported by stromal cells, an effect that 
was dependent upon intimate association between the two cell types. Likewise, 
Manabe et al (1992) and Gluck and his colleagues (Gluck et al, 1989) reported that 
human acute lymphoblastic leukaemia cells survived in the presence of stromal cells, 
but underwent apoptotic cell death when separated. Furthermore, recent unpublished 
work performed in Dr. Ostertag's laboratory suggests that coculture of murine
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retrovirus-induced myeloid leukaemia cells with stromal cells dramatically increases 
the survival rate of the leukaemic cells in vitro (Ostertag, personal communication). 
Paradoxically, in 50% of acute myeloid or lymphoblastic leukaemias in humans, 
maintenance in LTBMCs has been used to select for normal cells and purge their 
leukaemic counterparts (reviewed in Dexter et al, 1990). This suggests that rather 
than supporting growth, stromal cells actually compromise leukaemic cell growth. 
The reasons for this phenomenon are unknown, but it demonstrates that during the 
progression of some leukaemias, but not others, cells develop altered survival 
requirements which are unavailable from normal LTBMC stromal cells.
The ELM-D/MS-5 cell line provides a unique opportunity to examine the 
interaction between stromal cells and erythroid progenitors. However, use of this 
system may not accurately reflect the situation in vivo. For instance, the ELM-D cells 
are capable of proliferation on the MS-5 stromal cells: one function of haemopoietic 
stroma may be to keep progenitor cells dormant and provide long-term survival, but 
not proliferation, until demand for a specific cell type arises. Furthermore, the ability 
of the ELM cells to generate leukaemias in vivo obviously indicates a loss of certain 
normal progenitor characteristics. However, the coculture may give an insight into 
cell-cell interactions involved in haemopoiesis. Thus, a collaborative study was 
initiated with Dr. Ostertag's group in Hamburg to study the coculture to attempt to 
define the cell biological characteristics of the interaction, and to identify stromal 
cell-derived signals that act to permit ELM-D cell survival and proliferation. The 
results of this study (Itoh et al, 1993) are described in part in sections 5.3 and 5.4 of 
this introduction, and also in the Discussion section, whilst my contribution is shown 
in the Results (Chapter 9).
53: Dependence on stromal cell contact for the long-term growth of ELM-D#6 
cells.
The ELM-D cell line is a fairly heterogeneous population of ELM cells, 
containing a small proportion that will grow without stromal cells (Ostertag, personal
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communication). In order to study the interaction between the stromal cells and the 
erythroleukaemia cells, several stromal cell-dependent ELM clones were generated 
from the original ELM-D cell line onto MS-5 cells, and termed ELM-D clone 2,3 and 
6, and referred to hereafter as D#2, D#3 and D#6 (Figure 5.1). The majority of the 
work described in this thesis used the D#6 cell line, although the other clones were 
used to confirm certain conclusions.
Clonal growth of D#6 cells in the presence of stromal cells was very efficient, 
but could be reduced by a factor of 103 when a stromal cell layer was omitted from 
the cloning assay dish. Furthermore, analysis of 200 D#6 colonies formed in this 
second experiment showed that they all contained contaminating stromal cells earned 
over from the coculture from which the D#6 cells were harvested. To get a true 
estimate of the cloning efficiency of D#6 cells in the absence of stromal cells, they 
were established on a lethally-irradiated stromal cell layer that supports D#6 growth 
for up to two weeks, but then disintegrates. When the cloning experiment was 
repeated, the survival rate of the D#6 cells was extremely low, with stromal cell- 
independent clones arising at a frequency of <2x1 O'5 (section 5.4). However, during 
the first couple of weeks many large colonies were generated that later disintegrated. 
This was not due to stromal cell contamination which was undetectable, or due to the 
cells reaching saturation density since serial recloning of small colonies every two 
weeks resulted in clonal extinction after the second or third recloning stage. From 
these experiments, it was concluded that D#6 cells showed a exquisite dependence on 
stromal cells for long-term growth and survival, but were capable of proliferative cell 
expansion in the short-term (2-3 weeks). Furthermore, using an elegant two-layered 
agar culture system, it was shown that only when direct contact was established 
between D#6 cells and stromal cells adhered to a solid surface, was the full long-term 
viability of the leukaemic cells achieved. Moreover, MS-5 and MS-5/D#6 
conditioned media were unable to replace the MS-5 cells in these assays.
The process by which the D#6 cells lose their viability once they are removed 
from the stroma remains uncertain. Differentiation is not observed and late erythroid
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markers are not expressed; nor are the cells undergoing senescence, the process of 
irreversible proliferation arrest (reviewed in Goldstein, 1990), since cell number 
decreases dramatically once proliferation has ceased. However, it has proven difficult 
to demonstrate certain characteristics of apoptosis or programmed cell death, such as 
DNA fragmentation (Ostertag, personal communication), but this does not necessarily 
exclude this process for a number of reasons. First, it seems unlikely that all the D#6 
cells die at the same time, which may make it difficult to detect apoptosis due to 
contamination by a large number of cells that have not yet initiated the process. 
Second, a recent report suggests that programmed cell death can occur using 
mechanisms quite distinct from the classically defined apoptotic pathway involving 
membrane blebbing, chromatin condensation and DNA fragmentation (Schwartz et al,
1993). A tentative conclusion is that D#6 cells undergo some form of programmed 
cell death once separated from the MS-5 cells, although possibly not via a classical 
apoptotic pathway (Itoh et al, 1993).
Several growth factors (DL-3, GM-CSF and soluble SCF; reviewed in Chapter 
1) were tested to see if they could replace the stromal cells and support growth of D#6 
cells. Whether alone, or in combination, long-term growth was never achieved, 
although the cells exhibited an increased life-span and a more extensive proliferative 
expansion than that seen in the complete absence of these growth factors and stromal 
cells. Thus, these ligands delayed, but did not prevent, the death of D#6 cells. 
Intriguingly, cells maintained initially in growth factors, then transferred back to 
stromal cells rapidly regained the full growth potential of cells maintained 
permanently on stromal cells. For example, GM-CSF permits D#6 proliferation for 
approximately eight weeks. If, after six weeks in GM-CSF, the cells are replated on 
MS-5 cells for as little as 48 hours (Ostertag, personal communication), they are then 
able to grow in GM-CSF without stromal cells for a further eight weeks before dying. 
This effect can be repeated time and time again, provided the cells are replated on 
stromal cells before the end of the crucial eight week period. It appears, therefore, 
that the MS-5 stromal cells are able to 'prime' the D#6 cells for growth factor-
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dependent growth. Interestingly, GM-CSF and IL-3 are able to over-ride the survival 
signal from the stromal cells: treating a D#6/MS-5 coculture with these growth factors 
induces clonal extinction within the same time frame as D#6 cells in growth factor but 
in the absence of stromal cells (Itoh et al, 1993). In vivo, normal erythroid progenitor 
cells, lacking the increased proliferative capacity of the D#6 cells, may be subjected 
to a similar effect by erythropoietic growth factors to initiate maturation away from 
the survival signals emanating from the stroma, which manifests as apoptosis if the 
appropriate differentiation signals are absent.
The D#6/MS-5 coculture is perhaps analogous to the way in which antigen- 
dependent T-cells primed by antigen-presenting cells, can be maintained only 
temporarily in the presence of interleukin-2 after which they undergo apoptosis, and 
require renewed contact with the antigen-presenting cell for long-term growth and 
viability (Smith, 1988; Ramsdell and Fowlkes, 1990; Lenardo, 1991). Moreover, the 
observations discussed here using the D#6/MS-5 may be a general phenomenon in 
haemopoietic/stromal cell interactions. Human erythroid TF-1 cells, growing on 
stromal cells, exhibit similar properties as D#6 cells: retrovirus-induced leukaemic 
precursor cells from other myeloid lineages can also be 'primed' for growth factor- 
dependent proliferation by MS-5 stromal cells (Ostertag, personal communication).
5.4: Loss of stromal cell-dependence.
During the course of investigations by Dr. Ostertag's group, it was calculated 
that stromal cell-independent cells arise from the coculture at a frequency of <2xl0"5, 
a rate consistent with a requirement for a stable genetic, rather than epigenetic, 
alteration. Fifteen cell lines have been established from ELM-D and D#6 as a result 
of this phenomenon (Figure 5.1). ELM-I-1 was derived from the non-adherent cell 
population from a dense culture of ELM-D cells grown on feeders for seven weeks; 
the 'I' denotes that growth of these cells is independent of stromal cells and growth 
factors (Itoh et al, 1988b). ELM-I-2 arose after culturing ELM tumour cells (that had 
been passaged in vivo), directly in vitro in the absence of stromal cells. The
80
remaining ELM-I cell lines were independently derived from D#6 by selection for 
growth in suspension in the presence (eleven cell lines), or absence (1-5 and 1-6), of 
GM-CSF. However, continued growth of all these cell lines proved not to be 
dependent on GM-CSF once feeder-dependence was lost (Ostertag et al, 1992). In 
this thesis, the cell lines 1-1, 1-2, 1-5 and 1-6 were routinely used, but the other cell 
lines were occasionally used to check the validity of certain conclusions.
5.5: Aims and objectives.
The ELM system is distinct from previously described murine 
erythroleukaemia systems in that a stromal cell-dependent cell line is available from 
which Friend cell-like cells arise with further mutation. This provides an excellent 
system in which to attempt to define (a) stromal factors required for the growth of 
erythroid progenitor cells and the nature of stroma/progenitor interaction, and (b) the 
genetic alterations necessary to generate distinct leukaemic cell phenotypes.
The first aim of this thesis was to further characterise the ELM system by 
examining the tumorigenicity and differentiation properties of the various cell lines. 
It seemed possible that this may demonstrate other phenotypic variations within the 
system. The second point of interest concerned the nature of the stromal cell-derived 
signal which allows the long-term growth of the ELM cells in vitro. This was 
undertaken as a collaborative project with Dr. Ostertag’s laboratory, and aimed to first 
identify growth factors present in MS-5 cells, to verify the expression of the relevant 
receptors on the ELM cells, and then to examine the effect of abrogating the 
interaction between ligand and receptor on ELM cell survival. There were a large 
number of potential candidates, discussed in Chapter 1, but one particularly attractive 
possibility was SCF. This factor has a potent effect on erythroid progenitor cell 
growth, and, although soluble SCF does not permit D#6 cell survival, when it is 
presented as a transmembrane (TM) form it may act as a more permanent stimulus, a 
point raised and discussed in section 1.3.6. Alternatively, a TM SCF/c-kit interaction 
may mediate cell-cell adhesion (Flanagan et al, 1991) allowing the establishment of
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close cell contact and other advantageous receptorrligand interactions. In this 
scenario, SCF would be necessary, but not sufficient for ELM cell survival.
The third objective, and the main thrust of this thesis, was to identify genetic 
alterations involved in (a) generating the initial erythroleukaemia, and (b) changing 
the phenotype of the leukaemic cells throughout the system. The first genes to be 
examined were p53 and the ets genes, Spi-1 and Fli-1, known to be central to Friend 
virus-induced erythroleukaemia development (section 2.3.5). It was of interest to see 
if the same genes were involved when X-rays are used to induce leukaemia, rather 
than retroviral infection. With relation to the phenotypic differences between ELM 
cells, it is worth considering that the wtp53 gene has been implicated in the induction 
of cell death in a number of cell lines, including Friend cells (section 4.2), and so its 
mutation may correlate with stromal cell-independent growth. Similarly, ets genes 
are thought to be nuclear components of mitogenic signal transduction pathways, and 
it is possible to envisage a situation where deregulated expression of an ets gene in a 
stromal cell-dependent cell could allow it to lose its requirement for the stromal cell- 
derived survival signal.
PART 2: METHODS AND MATERIALS.
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CHAPTER 6: Methods.
6.1: Cell culture and differentiation induction.
6.1.1: Cell culture.
All the ELM cell lines (Itoh et al, 1988a), and the MS-5 stromal feeder cells 
(Itoh et al, 1989), were maintained in Minimal Essential Medium (a-MEM), 
containing deoxyribonucleosides and ribonucleosides, and supplemented with 20% 
(v/v) donor horse serum, 4mM glutamine, 100 |ig/ml streptomycin and 37.5 |ig/ml 
penicillin in 5% (v/v) CO2 at 37°C. This medium will be referred to as ELM growth 
medium hereafter. F4-12 cells, which were derived from an SFFV-induced 
erythroleukaemia (Ostertag et al, 1972), were grown in Special Liquid Medium 
containing 10% (v/v) foetal calf serum, plus the same concentrations of glutamine and 
antibiotics used above, in 5% CO2 (v/v) at 37°C. This cell line, and all the stromal 
cell-independent cell lines of the ELM system, grow to some extent adhered to the 
surface of the tissue culture flask, and were passaged as follows. Cells growing in 
suspension were harvested by centrifugation at 1,200 rpm for 5min in a MSE Centaur 
benchtop centrifuge. The remaining adherent cells were washed with PE, then 
removed from the flask by treating with a 0.25% trypsin solution in CT buffer, after 
which an equal volume of ELM growth medium was added to inhibit the trypsin. 
These cells were then harvested by a similar centrifugation step, and then combined 
with the suspension cells in 15ml of medium. l-2ml was then used to seed a flask 
containing fresh medium.
ELM-D, D#2, D#3 and D#6 cells growing on live MS-5 cells, and the MS-5 
cells themselves, were passaged in a similar way, except any suspension cells were 
aspirated from the flask and discarded. Reseeding the coculture at low cell number 
increased the ratio of leukaemic to stromal cells, and was employed to reduce stromal 
cell contamination in DNA, RNA and nuclear protein samples prepared from these 
cells (section 6.6). D#6 cells were also established on MS-5 cells irradiated with 
17,000 Rads of y-rays from an Alcyon II Teletherapy Unit containing a 60Co source
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(Ostertag et al, 1993). On passage, 10% of the cells from a freshly-irradiated 
confluent culture of MS-5 cells were added to 10% of the cells from a confluent 
ELM-D#6/MS-5 (irradiated) culture.
6.1.2: Cell storage.
Stocks of cells used in this work were stored in liquid nitrogen. Cells were 
harvested as above, resuspended to a final concentration of 107 cells/ml in ELM 
growth medium containing 10% (v/v) DMSO, then dispensed into l-2ml Nunc 
cryotubes and stored at -70°C for 24hrs in a well insulated container. Tubes were 
then transferred to liquid nitrogen for long-term storage.
Cells were placed in a 37°C water bath to thaw, then diluted in 20ml of ELM 
growth medium and harvested by centrifugation for 5min at 1,200 rpm in a MSE 
Centaur benchtop centrifuge. Cells were then seeded into a tissue culture flask 
containing fresh medium.
6.1.3: Differentiation induction.
Cells were grown to 90% confluence, harvested, washed in phosphate- 
buffered saline (PBS) and then seeded at 2.5xl05 cells/ml in Ham's F12 medium 
(supplemented with the same components added to the ELM growth medium above), 
plus either no additional growth factors or 2U/ml of recombinant human epo and/or 
lOU/ml of murine IL-3. Cultures were incubated for 3, 5 or 7 days and the RNA 
extracted (section 6.6).
6.2: Animal experimentation.
6.2.1: Passage of ELM tumour cells and tumorigenicity assay.
Cells from a homogenised spleen, enlarged with ELM leukaemic cells, were 
provided by Dr. Ostertag. These cells, termed IVP ELM (late), had already been 
passaged several times through syngeneic C3H mice (see Figure 5.1 in the 
Introduction). These could be grown in vivo by resuspending 5xl06 cells in 0.2ml of
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PBS and injecting them, via the tail vein, into recipient C3H mice immunosuppressed 
by irradiation with 300 Rads of y-rays from a ^C o source. After 14 days, the mice 
were sacrificed and the enlarged spleen removed and homogenised. Cells were then 
either passaged again in vivo, stored in liquid nitrogen in 10% (v/v) DMSO, or used to 
prepare RNA or DNA. Dr Ostertag also provided cells from an earlier passage of the 
ELM leukaemia, termed IVP ELM (early) (see Figure 5.1). RNA was extracted 
directly from these cells (section 6.6) to test for Fli-1 and erg expression (see 
Results).
To test the tumorigenicity of the ELM cell lines, cells harvested from tissue 
culture were injected at the appropriate concentration into groups of female C3H 
mice, as above. After a specified latency period, by which time some animals 
appeared unhealthy, the mice were sacrificed, and the spleen and liver isolated and 
weighed, after first removing any visible connective tissue from the organ. A group 
of five control mice of similar age, which had not been injected with cells, were also 
sacrificed and their spleens and livers weighed.
6.2.2: Anaemia induction.
To generate erythropoietically-active spleens, anaemia was transiently induced 
in two C3H mice, by two consecutive injections of phenylhydrazine (60 mg/kg of 
body weight) separated by a 24hr period. 72hrs from the second injection, the 
animals were sacrificed, the spleens isolated and RNA extracted (section 6.6).
6.3: Recombinant DNA techniques.
6.3.1: Host cells.
Throughout this thesis, four separate strains of E. coli were used. In general, 
plasmids were propagated in JM83 cells (Genotype: ara A(lac-proAB) rpsL 
<j>80/acZAM15). Occasionally, when high transformation was required, library- 
efficient competent DH5a cells, purchased from GIBCO, were used (Genotype: 
supEAA A/acU169 (<J)80/flcZAM15) hsdRYl recAl endAl gyrA96 thi-l relAl).
86
Propagation of erg-containing plasmids used the INVclF' cells (Genotype: endAX 
recAX hsdRXl ( rK,m+K) X,' supE44 gyrA96 thi-1 relAl (J)80/flcZAM15 A(/acZYA- 
argF)U 169 deoR) that were provided with the TA cloning kit (see Materials). 
Preparation of the genomic library used the P2 lysogen bacterial strain, P2392 
(Genotype: supEAA supF5& hsdR5\4 galK2 galTll metBX trpR55 lacYl P2), which 
will only permit the growth of recombinant bacteriophages lacking the red and gam 
genes from the stuffer fragment.
JM83, DH5a, INVclF' and their derivatives were grown at 37*C shaking at 
250rpm in a New Brunswick G25 shaker at 37°C in Terrific broth or L-broth liquid 
medium, or on inverted 1.5% (w/v) agar L-broth plates also at 37°C, in both cases 
supplemented with the appropriate antibiotics. Ampicillin and kanamycin were used 
at a final concentration of 50|ig/ml. P2392 cells were grown under similar conditions 
in NZCYM liquid medium or on 1.5% (w/v) agar NZM plates. A description of how 
these cells were used is included in section 6.16 concerning preparation and screening 
of the genomic library.
6.3.2: Preparation of competent cells.
DH5a and INVclF ' cells were purchased in a transformation-competent state. 
To prepare competent JM83 cells, 2ml of an overnight culture was used to inoculate 
200ml of L-broth (plus the necessary antibiotics), which was then incubated at 37*C 
shaking at 250rpm until the absorbance at 650nm was 0.5 units above an L-broth 
blank. These log. phase cells were harvested by centrifugation at 2,000rpm for lOmin 
at 4°C in an IEC Centra-8R centrifuge. The pelleted cells were resuspended in 80ml 
of RF1 solution (lOOmM RbCl, 50mM MnCl2, 30mM KAc, lOmM CaCl2, 15% (v/v) 
glycerol, pH5.8), incubated on ice for 2hrs, then pelleted with an identical 
centrifugation step and resuspended in 16ml of RF2 solution (lOmM MOPS, lOmM 
RbCl, 75mM CaCl2, 15% (v/v) glycerol). After a 15min on ice, 0.8ml aliquots were 
transferred into 2ml Nunc cryotubes, frozen in a dry ice/ethanol bath, then transferred 
to -70°C for storage.
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6.3.3: Transformation of bacterial hosts.
Competent cells were thawed slowly at 4°C, and lOOpl aliquots put into 
precooled 15ml 2059 Falcon tubes. An appropriate amount of plasmid DNA or 
ligation mix (<10ng) was pipetted into the cells, mixed by gently tapping the tube, 
and incubated on ice for 30min. The cells were then heat-shocked at 37’C for 45sec, 
cooled on ice for 2min and then 0.9ml of L-broth added. This was incubated for lhr 
at 37#C, shaking at 225rpm in a New Brunswick G25 shaker, to allow time for the 
expression of the antibiotic resistance gene. 100-200|il was spread onto 1.5% (w/v) 
agar L-broth plates supplemented with the appropriate antibiotic. The plates were 
allowed to dry for 5min, then inverted and incubated overnight to allow colony 
formation. To identify colonies containing recombinant plasmids in which the lacZ 
gene of the vector had been disrupted, blue/white colour selection on X-gal was often 
employed. Prior to spreading the cells, 40fil of a 20jag/ml solution of X-gal, mixed 
with 160(0.1 of L-broth, was spread onto the plate and left for lhr to permit full 
absorption into the agar. White colonies will contain a non-functional lacZ gene.
6.3.4: Bacterial glycerol stocks.
Host strains, and their derivatives containing useful plasmids, were stored as 
glycerol stocks for future retrieval. Stationary cultures in liquid medium were mixed 
with an equal volume of a 30% (v/v) glycerol/L-broth solution, cooled on ice, then 
frozen at -70°C. Cells were retrieved using a sterilised tungsten loop.
6.4: Isolation of plasmid DNA.
6.4.1: Purification and precipitation of nucleic acid samples.
Unless otherwise stated, these procedures were performed as follows. To 
remove protein contaminants, a combination of phenol-only (<J>OH), 
phenol/chloroform (<{>OH/CHCl3) (50:50 (v/v) mix) and chloroform (CHCI3) 
extractions were used. Phenol was prepared according to Sambrook et al (1989). 
CHCI3 was saturated with distilled water. To extract proteins, an equal volume of
88
these solutions was added to nucleic acid samples, vortexed, and the layers separated 
by centrifugation either for lOmin at 3,000rpm at RTemp in an IEC Centra-8R rotor 
(large samples), or for 5min at 13,000 at RTemp in a MSE Micro Centaur (small 
samples), hereafter referred to as a microfuge. The upper layer was invariably the 
nucleic acid-containing fraction.
Nucleic acid was precipitated by the addition of 2.5 volumes of ethanol and 
then NaAc (pH5.2) to a final concentration of 0.1M. This was mixed by vortexing, 
cooled to -70°C for lhr, and the nucleic acid pelleted by centrifugation for 25min at 
3,000rpm at 4°C in an IEC Centra-8R rotor (for large samples), or for 15min at 4°C in 
a microfuge.
6.4.2: Minipreparations of plasmid DNA.
Colonies were picked from an agar plate with a sterile toothpick and used to 
inoculate 10ml of Terrific broth (containing appropriate antibiotics), which was 
incubated overnight at 37°C shaking at 250rpm. Cells from 1.5ml of this culture were 
pelleted by spinning for lmin in a microfuge, resuspended in 100|il of solution A 
(50mM glucose, 25mM Tris.Cl (pH8), lOmM EDTA, 4mg/ml lysozyme) and stored 
on ice for lOmin. 200|il of alkaline lysis buffer (1% SDS, 0.2M NaOH) was added, 
mixed gently, and incubated on ice for 15min to allow the bacteria to lyse. 150|il of 
3M NaAc (pH5.2) was mixed into the preparation by vortexing, and placed on ice for 
a further 5min. Cell debris was removed by a 5min spin in a microfuge and the 
supernatant (JjOH/CHC^ extracted to remove residual protein. Plasmid DNA was 
precipitated by the addition of 1ml of ethanol and incubation at RTemp for 5min, then 
pelleted by a lOmin centrifugation in a microfuge. DNA was resuspended in 40|il of 
lxTE (lOmM Tris.Cl (pH7.5), ImM EDTA), and 10|il used in restriction digests.
6.4.3: Large scale preparations of plasmid DNA.
The alkaline lysis protocol, employing the same solutions, was also used to 
purify large amounts of plasmid DNA. All centrifugation steps in this protocol were
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performed in 50ml 2098 Falcon tubes spun at 3,000rpm in an IEC Centra-8R rotor 
cooled to 4°C. 200ml of Terrific broth (containing the necessary antibiotics) was 
inoculated with 5ml of an overnight cell culture and incubated for 16hrs at 37*C. 
Cells were harvested with a 20min spin, 2ml of solution A added to each tube and the 
cells resuspended and left on ice for lOmin. 4ml of alkaline lysis buffer was mixed 
gently into the cell suspension, left on ice for a further 20min to permit cell lysis, and 
3ml of 3M NaAc (pH5.2) added. After another 5min on ice, cell debris was removed 
by spinning for 20min and passing the supernatant through a gauze swab. A two- 
thirds volume of isopropanol precipitated the DNA after 15min at RTemp, which was 
pelleted with a 40min spin. This was resuspended in 5ml of lx TE, 0.5mg of DNAse- 
free RNAse was added and the mixture incubated at 37°C for 30min. After a 
<|)OH/CHCl3 extraction, and an ethanol precipitation step, the plasmid DNA was 
loaded onto a Bio-Rad Bio Gel A-50M column in 1ml of lx TE containing a one 
tenth volume of gel loading buffer (see section 6.5.1) and 2ml fractions eluted with lx 
TE. 5fil aliquots from these fractions were run on a 1% (w/v) agarose gel (as 
described in section 6.5.2) to assess for the presence of DNA. Positive fractions were 
pooled, the plasmid precipitated with ethanol and resuspended in 0.5ml of lx TE. 
The DNA was further purified by two <j)OH/CHCl3 extractions, a CHCI3 extraction 
and an ethanol precipitation, and finally resuspended in 0.2-0.5ml of TE.
6.4.4: Quantitation of DNA and RNA.
Nucleic acid concentrations were determined spectrophotometrically. 5pl of 
the sample was added to 495jil of distilled water and absorbance (A) readings taken at 
260 and 280nm in a quartz cuvette compared to a distilled water blank. An A250 
value of 1 was taken to be equivalent to 50|ig/ml of plasmid or genomic DNA, 
40fig/ml of RNA and 20|ig/ml of oligonucleotide. The A250/A280 rati° was used as a 
measure of purity: samples giving a ratio less than 1.75 were further purified by 
<j)OH/CHCl3 extraction and ethanol precipitation, and the A260/A28O rat^° reassessed.
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6.5: Restriction digests and agarose gel electrophoresis of plasmid DNA.
6.5.1: Restriction digests.
Restriction digests were carried out in small volumes buffered using 
concentrated solutions available with the enzyme from the supplier. Small quantities 
of plasmid DNA (<2|ig) were digested in a total volume of 20|il using 1-10 units of 
enzyme per |ig of DNA, depending on the enzyme used and the number of sites 
present. Larger, preparative digests were carried out in proportionately larger 
volumes. For double digests, suppliers' information was consulted and the 
appropriate buffer used. DNAse-free RNAse, at a final concentration of 0.5pg/jil, 
was added to digests of minipreparations of plasmid DNA. Reactions were incubated 
for 2-3hrs at the recommended temperature (usually 37°C), then terminated by the 
addition of one tenth volume gel loading buffer (0.25% (w/v) bromophenol blue, 
0.25% (w/v) xylene cyanol, 25% (v/v) Ficoll in water).
6.5.2: Agarose gel electrophoresis.
DNA fragments were resolved on non-denaturing agarose gels and visualised 
by ethidium bromide staining. In general, 1% (w/v) agarose gels were used, but 
smaller fragments (100-400bp) were separated on 2-4% gels. Preparative gels used 
low melting-point agarose at a concentration of 1% (w/v). Gel mixes containing the 
appropriate amount of agarose in lxTAE buffer (50xTAE is 2M Tris, 50mM EDTA, 
57.1 ml/1 glacial acetic acid) were heated in a microwave to dissolve the agarose, 
cooled to approximately 60°C, ethidium bromide added to 5fig/ml then poured into an 
appropriate gel former. Gels were allowed to set at room temperature, cooled for 
lOmin at 4°C, and installed into the electrophoresis tank in lxTAE buffer. Samples, 
containing one tenth volume of gel loading buffer (section 6.5.1), were loaded and 
separated at various currents. Molecular weight standards used include bacteriophage 
X {Hind Ill-digested), bacteriophage <|>xl74 (Hae IE-digested) and the lkb ladder. A 
photograph was taken of the gel with a Polaroid camera, using a UV source to 
illuminate the DNA bands.
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6.5.3: Purification of DNA fragments from agarose gels.
Three different procedures were used depending on the size and quantity of 
the fragment of interest. In all cases, DNA was electrophoresed in low melting-point 
agarose and excised after visualising with ethidium bromide and a UV source. For 
fragments >500bp but <4kb in length, which were present in large quantities, 
’Genecleaning' was used in accordance with the suppliers instructions. For fragments 
<500bp or >4kb, or when a higher recovery of the fragment was required, pre-packed 
NACS columns were employed. The columns were equilibrated and run at 37°C 
according to the manufacturers instructions, and the resulting purified fragment 
precipitated with ethanol in a solution containing 10|ig of tRNA to act as a carrier. 
The pelleted DNA was resuspended in a small volume of lx TE (<30pl).
Electroelution of DNA from a gel slice was used only in the preparation of 1-1 
genomic DNA partially-digested with Sau 3AI during the construction of a genomic 
library (see section 6.16.3), due to the large size of the agarose fragment. The gel 
slice was enclosed in a piece of dialysis tubing containing 5ml of 0.5xTAE, and 
placed in a tank of 0.5xTAE. The DNA was electrophoresed from the agarose by 
applying 100V across the tank for 3hrs. The polarity was then reversed for 30sec, to 
remove the DNA from the tubing walls, after which the buffer was removed and spun 
at 3,000rpm in an IEC Centra-8R rotor for 5min to remove any agarose fragments. 
After a <}>OH/CHCl3 and a CHCI3 extraction, the DNA was precipitated from the 
supernatant using ethanol, and the pellet resuspended and further purified on a NACS 
column.
Prior to further manipulation, the quality and quantity of the purified 
fragment(s) was assessed by electrophoresing a small aliquot of the DNA on an 
agarose gel.
6.5.4: Ligation of DNA fragments into plasmids.
Both plasmid and potential insert were digested and purified as described 
above. The plasmid was dephosphorylated at its termini to prevent religation, by
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including two units of calf intestinal alkaline phosphatase in the restriction enzyme 
digestion reaction. The DNA was then included in the following reaction mix in a 
final volume of 10|il:
~20ng of dephosphorylated plasmid
2-5-fold molar excess of the potential DNA insert
2|il of 5x ligation buffer (0.25M Tris.Cl (pH7.6), 50mM MgC^, 5mM dATP, 
5mM dithiothreitol, 25% (w/v) polyethylene glycol-8000)
1^ 1 of T4 DNA ligase (1 U/ i^l)
This was incubated at 16°C overnight and l-3|il used to transform competent cells 
(see section 6.5.3).
6.6: Preparation of RNA and genomic DNA.
6.6.1: Preparation of cells and use of the elutriating centrifuge.
For the preparation of genomic DNA and cellular RNA, single cell 
suspensions of the sample were prepared. Cells in culture were harvested according 
to section 6.1.1. For the stromal cell-dependent cell lines, attempts were made to 
reduce MS-5 contamination by (i) only selecting cultures with a high leukaemic cell: 
stromal cell ratio, and (ii) harvesting cells by partial trypsinisation to release fewer 
MS-5 cells from the surface of the flask.
A more efficient protocol to separate stromal cell-dependent cells from MS-5 
feeders was developed late in the preparation of this thesis, and was used to generate a 
nearly 100% pure population of leukaemic cells. This employed an elutriating 
centrifuge (Beckman Elutriator Rotor system), operated according to the 
manufacturers instructions and with the help of Dr. J. Lanfear. This separates cells 
with respect to their size by applying a flow-through of media against a centrifugal 
force. By adjusting the flow rate through the machine, cells of different sizes can be 
collected. The centrifuge was calibrated using pure populations of MS-5 or ELM-I-2 
cells. D#6 cells were then collected from a coculture at a flow rate of 0.33ml/sec and 
0.4ml/sec, rates at which 1-2, but not MS-5, cells could be collected. 5xl05 cells were
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seeded into 10ml of fresh medium and the proportion of leukaemic to stromal cells 
assessed visually: both preparations had a very low number of stromal cells. These 
cells were passaged in vitro, in the absence or presence of MS-5 cells, for several 
weeks to ensure their stromal cell-dependence. Other samples taken from the 
elutriating centrifuge at 0.33ml/sec were grown in ELM growth medium for 2-3hrs 
and RNA and nuclear proteins extracted. Tissue samples were homogenised in PBS 
in a Dounce homogeniser. All cell suspensions were harvested by centrifugation at 
l,200rpm for 5min in a MSE Centaur benchtop rotor, washed with PBS, repelleted by 
a second spin and the supernatant removed: DNA and RNA was then extracted.
6.6.2: Preparation of mammalian genomic DNA.
'Cells were resuspended in lx TE to a final concentration of 5xl07 cells/ml, 
and 10ml of extraction buffer added per ml of cells (Extraction buffer: lOmM Tris.Cl 
(pH8), 0.1M EDTA, 0.5% (w/v) SDS, 20|ig/ml DNAse-free RNAse). After a 60min 
incubation at 37°C mixing gently on a Stuart TR-2 tube rotator, proteinase K was 
added to a final concentration of 0.1 mg/ml. This was gently mixed and placed in a 
50#C water bath for 3hrs, swirling periodically. After cooling to RTemp, the protein 
fragments were removed by two phenol-only extractions. DNA was ethanol 
precipitated and collected by spooling it onto a clean Pasteur pipette moulded into a 
hook shape over a Bunsen. The DNA was allowed to air-dry for 15min then slowly 
resuspended at 4°C for three days, in a volume of lx TE such that 1ml was included 
for every 2xl07 cells in the original sample. This solution was then dialysed in lx TE 
for 18hrs at 4°C to remove any remaining salt and ethanol. The final solution was 
stored at 4°C: the DNA concentration was determined spectrophotometrically just 
prior to its use.
6.6.3: Preparation of mammalian RNA.
Total cellular RNA was prepared using the RNAzol B method, following the 
manufacturers instructions. However, once the RNA had been isolated, additional
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<{>OH/CHCl3 and CHCI3 extraction steps were performed to further purify the sample, 
after which the RNA was precipitated with ethanol, washed in 70% (v/v) ethanol, 
resuspended in a small volume (<200pl) of RNAse-free water and stored at -20°C.
To avoid degradation by contaminating RNAses, a number a precautionary 
steps were taken. First, all tubes and solutions were precooled on ice, and all 
manipulations and centrifugations were carried out at 4°C. Second, all the tubes used 
were pretreated with diethylpyrocarbonate (DEPC), an irreversible inhibitor of 
RNAses. The tubes were immersed in a 0.1% (v/v) solution of DEPC overnight in a 
fume hood: the solution was then decanted off the tubes which were autoclaved, then 
dried in an 80°C oven. These were subsequently stored in a sealed DEPC-treated 
container. DEPC-treated water was also prepared by incubating a 0.1% (v/v) DEPC 
solution in a fume hood overnight then autoclaving. This was used in all the solutions 
employed in the protocol.
6.7: Preparation of oligonucleotides.
Oligonucleotides used in this thesis were synthesised on an Applied 
Biosystems model 381A DNA synthesiser according to the manufacturers 
instructions. 5' trityl groups were removed by the machine, and the DNA 
immobilised on a column. The DNA was eluted in 29% (v/v) ammonia by passing 
the solution through the column -20 times every lOmin for 1.5hrs. This solution was 
sealed in a glass vial and incubated at 55°C overnight. DNA was precipitated at - 
20°C for 2hrs in 2.5 volumes of ethanol in a final concentration of 0.1M NH4Ac, then 
pelleted by centrifugation at 13,000rpm in a microfuge. The oligonucleotides were 
resuspended in 0.4ml of water, ethanol precipitated in the conventional manner 
(section 6.4.1), washed in 70% (v/v) ethanol, dried, and resuspended in 0.2-0.5ml of 
water. The concentration of the oligonucleotide solution was determined 
spectrophotometrically (section 6.4.4) and the sample stored at -20°C until required. 
The sequences of the oligonucleotides used in this thesis are shown in Tables 6.2, 6.3 
and 6.4.
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6.8: Northern blot analysis.
20|ig of RNA was freeze-dried then resuspended and denatured at 65°C for 
lOmin in 25|il of RNA loading buffer (lxMOPS/EDTA buffer [20mM MOPS, 5mM 
sodium acetate, ImM EDTA (pH7)], 10% (w/v) formaldehyde, 50% (v/v) formamide, 
0.5% (w/v) bromophenol blue). The samples were then cooled on ice, ethidium 
bromide added to a final concentration of 10|ig/ml, then separated on a 1% (w/v) 
denaturing agarose gel containing 6.5% (w/v) formaldehyde in a lxMOPS/EDTA 
buffer. A photograph was taken of the gel illuminated by a UV source. Gels were 
washed twice in sterile water for 20min then for 15min in 20xSSC (lxSSC is 150mM 
NaCl, 15mM sodium citrate) prior to vacuum blotting onto Hybond-N membrane, 
using 20xSSC as the transfer buffer. Filters were fixed by baking for 2hrs at 80°C. 
Prehybridisation was performed at 42°C for between 6-18hrs in 5xSSPE (lxSSPE is 
180mM NaCl, lOmM NaHjPO^ ImM EDTA), 5xDenhardt's (0.1% (w/v) bovine 
serum albumin, 0.1% (w/v) Ficoll, 0.1% (w/v) polyvinyl pyrollidone), 0.5% (w/v) 
SDS, 50% (v/v) formamide and 50|ig/ml heat-denatured herring testis DNA. 
Hybridisation was performed for 18-24hrs in the same solution containing probes 
radiolabelled with 32P-labelled phosphate (described in section 6.10). Filters were 
washed twice at room temperature in 2x SSPE, 0.1% (w/v) SDS for lOmin, then for 
15min at 65°C in lx SSPE, 0.1% (w/v) SDS and finally for lOmin at 65°C in O.lx 
SSPE, 0.1% (w/v) SDS. Filters were exposed to Kodak X-OMAT AR imaging film 
at -70°C. Some autoradiographs were scanned using a Molecular Dynamics 
ImageQuant version 2.0 computing densitometer. For each band the value of the OD 
multiplied by area of the band was calculated and used for comparative analysis of 
gene expression between RNA samples. Filters were stripped in boiling 0.1% (w/v) 
SDS prior to reprobing. Sizes of RNA species were determined by comparison with a 
RNA ladder run next to the samples, that was blotted and fixed as above, then cut off 
the blot and treated for 15min in 5% (v/v) acetic acid, lOmin in RNA stain (0.5M 
NaAc, 0.04% (w/v) methylene blue), then washed in water to visualise the bands.
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6.9: Southern blot analysis.
For most Southern blots, 20|ig of DNA was digested for 16hrs, in the 
appropriate buffer and at the recommended temperature, with 50U of enzyme in a 
final volume of 90|il, then for another 6hrs after the addition of a further 20U of the 
enzyme. Digestion was stopped by the addition of 10|J.l of gel loading buffer (section
6.5.1). Digestions using large amounts of the Dra III restriction endonuclease were 
performed in a final volume of 250|il. After incubation at 37#C for 16hrs, Dra III- 
cleaved DNA fragments were ethanol precipitated and resuspended in 80|il of lx TE 
plus 8ml of gel loading buffer (section 6.5.1).
Samples were then separated on a 0.9% (w/v) agarose lx TAE gel run at 40mA 
overnight in lx TAE buffer. The gel was then depurinated with a 15min treatment 
with 0.2M HC1, denatured in 1.5M NaCl, 0.5M NaOH for two spells of 15min, then 
neutralised for lhr in 3M NaCl, 0.5M Tris.HCl (pH 7.5), changing the solution twice. 
Blotting, hybridisation, washing, autoradiography and densitometric scanning was 
carried out as for the Northern blots, except formamide was omitted from the 
prehybridisation and hybridisation stages which were, therefore, performed at 65°C. 
Probes were labelled with 32P-labelled phosphate as described in section 6.10.
6.10: Random-primed radiolabelling of DNA probes.
All DNA probes used for hybridisation to Northern and Southern blots were 
labelled with [a-32P] dCTP using a random-priming kit supplied by Boehringer 
Mannheim, in accordance with the manufacturers instructions. Unincorporated 
nucleotides were removed by gel filtration on a Sephadex G-50 column run in O.lx 
SSPE, 0.1% (w/v) SDS. Radiolabelled probes were denatured by boiling for 5min 
prior to addition to the hybridisation mix.
Probes used in this study were either donated or generated during the course of 
the thesis. Table 6.1 gives the details, and appropriate reference, for all the probes 
generously given by other workers.
TABLE 6.1.
DNA Probes.
The following probes were obtained from other workers and are listed along with the 
appropriate reference. The figures adjacent to the restriction enzyme denote the position of 
the cleavage site, with numbering taken from the reference cited.
Gene. Probe. Source. Reference.
Human c-ets-2
Human c-ets-1
Murine p53
Murine SU-9
Murine skeletal 
Ac tin
Murine GAPDH.
F-MuLV ENV
F-MCF ENV
SFFV gp55
499bp Sst Ii 152/4va I i65i cDNA fragment A.Begue
spanning most of the ets domain.
Hybridises to murine c-ets-2.
435bp Pst I394/Pst 1829 cDNA fragment A.Begue
N-terminal to the ets domain.
Hybridises to murine c-ets-1.
Full-length cDNA fragment (Xho I/Bgl II) J.Jenkins
excised from p4JJKan.
~800bp Hinc ll/ECo RI genomic fragment E.Rassart 
from the Fli-1 locus.
1177bp Pst I-2/Pst Ii 175 cDNA fragment 
cleaved from the pAM91 plasmid.
720bp cDNA probe isolated by the 
RT-PCR protocol (section 6.11) by 
M. Walker.
830bp Bam HI5718/Bam HI6548 fragment 
spanning the envelope gene of F-MuLV.
486bp ECo RbM/Kpn I1120 fragment 
isolated from the pMCF-54B plasmid. 
Spans the envelope gene of F-MCF.
620bp Bam H Ii65/ECo Rhss portion 
of SFFVp envelope gene, gp55.
F.Fee
Watson et al, 1988
Watson et al, 1988
Jenkins et al, 1984 
Bergeron etal, 1991 
Minty et al, 1982 
M.Walker Tso e ta l ,  1985
W.Ostertag Perryman e ta l, 1991
W.Ostertag Koch et al, 1984 
Oliff et al, 1983
W.Ostertag Wolff et al, 1983
Murine alpha 377bp Pst 1358/Pst 1735 genomic fragment P.R.Harrison Nishioka and
Globin spanning the first exon, and half of the Leder, 1979
second exon.
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6.11: Reverse transcription-polymerase chain reaction (RT-PCR).
The reverse transcription (RT) reaction was performed as previously described 
(Bartek et al, 1990), using 10|ig of total cellular RNA. The gene-specific 
oligonucleotides used to prime the reaction are shown in Table 6.2A: erg RT reaction 
was primed with oligo-dT. 5fil from the reverse transcription reaction was amplified 
by PCR using the primers shown in Table 6.2B. The reactions contained lOfil of lOx 
reaction buffer (500mM KC1, 15mM MgC^, lOOmM Tris.Cl (pH9), 1% (v/v) Triton 
X-100), 8|il of 2.5|iM dNTPs, 500ng of each primer and 10U of Taq polymerase in a 
total volume of 100|il, overlaid with 100p.l of paraffin oil. The reactions were 
incubated for 30 cycles at 93°C for lmin, 55-60°C for lmin and 72°C for l-2min 
(depending on the length of the fragment being amplified). The products were 
electrophoresed on an agarose gel and the appropriate sized fragments purified on 
NACS columns, as previously described (section 6.5.3).
The p53 PCR products were further purified by phenol/chloroform extraction 
and ethanol precipitation prior to direct sequencing (section 6.13). The Fli-1 product 
was cloned, to create the pFli vector, by cleavage of the Hind III and Sal I sites 
incorporated into the primers, ligation into Hind III/Sal I cut, alkaline phosphatase- 
treated pBluescriptll KS+, and selection on ampicillin/X-gal plates (section 6.5.4). 
The Spi-1 cDNA fragment was cloned using Xho I and Hind III restriction sites in the 
primers. Likewise, the SCF, c-kit and epoR PCR fragments were inserted into the 
pBluescriptll KS+ vector by virtue of restriction sites Xba I/Bam HI, Pst 1/Hind HI 
and Pst I, respectively, included in the oligonucleotide primers. The erg PCR product 
was cloned using the TA cloning kit, according to the manufacturers instructions.
6.12: PCR from genomic DNA.
Amplification of p53 genomic fragments used 0.5|ig of DNA as a template 
and the primers shown in Table 6.3A. The oligonucleotides p53 U2, p53 125' and p53 
123’ will not prime the p53 pseudogene on account of their 3’ end terminating in intron 
sequences, thus allowing preferential amplification of the correct genomic fragment.
TABLE 6.2.
A . O ligon u cleotide p rim ers for  rev erse  tra n scr ip tion .
N am e. S eq u en ce. P osition .
p53  RT 5' CAGCAGAAGGGACCGGGAGGATTG 3' 1247-1270
Fli-1 RT 5’ TCCAGTTTTCTTATCTCTTC 3’ 1687-1706
SCF RT 5' TTAGGATCCACATGAACTGTTACCAGCC 3’ 1042-1062
c-kit RT 5' GAGAGAAAGCTTGGGGTCGGAGACAGCAGCAAA 3’ 2980-3000
Spi-1 RT 5’ GAGAGAGAATTCCTGGCGGTCTCTGCGGGCG 3' 953-972
EpoR RT 5’ GG CC AG AT CTT CTGCTG C AG AGT C 3' 853-875
B . O ligon u cleotide p rim ers for P C R  from  rev erse -tra n scr ib ed  m R N A .
N am e. S eq u en ce (p lus restr iction  en zym e site). P osition .
p53 D1 5' CAGCAGAAGGGACCGGGAGGATTG 3’ 1247-1270
p53  U1 5’ ACCTCACTGCATGGACGATCTGTTGCT 3’ 111-137
p53  D2 5' CTATTACACATGTACTTGTAGTGGATG 3’ 684-710
p53  U2 5' TTCCACCTGGGCTTCCTGCAGTCT 3’ 
Sal I
316-339
Fli-1 D1 5' GAGAGAGTCGACAGAGTATCCAGTAAAGTGAGA 3’ 
Hind III
1641-1662
Fli-1 U1 5' GAGAGAAGCTTCGGGTCAATGTGTGGAATATTG 3’ 
Bam HI
197-218
SCF D1 5' TTAGG ATCCACATGA ACTGTT ACCAGCC 3’ 
Xba I
1042-1060
SCF U1 5' CCGT CT AG ACT CTT CT GG AC A AGTT CTC A A 3' 
Hind IB
432-452
c-kit D1 5' GAGAGAAAGCTTGGGGTCGGAGACAGCAGCAAA 3’ 
Hind III
2980-3000
c-kit D2 5' GAGAGAAAGCTTCCAACCAGGAAAAGTTTGGCA 3’ 
Pst I
373-393
c-kit U1 5' GAGAGACTGCAGCTCAGAGTCTAGCGCAGCCAC 3' 
Pst I
4-24
c-kit U2 5' GAGAGACTGCAGTATTTGCAGAAACCCATGTAT 3' 
ECo RI
1664-1684
Spi-1 D1 5' GAGAGAGAATTCCTGGCGGTCTCTGCGGGCG 3' 
Sal I
953-972
Spi-1 U1 5’ GAGAGGTCGACCAACCTGGAGCTCAGCTGG 3' 132-151
Erg D l 5' CTTGGTCATGATGTTCTTGTC 3' 1331-1351
Erg U1 5’ TCTCCACGGTTAATGCATGC 3’
Pst I
927-946
EpoR Dl 5’ GGCC AG AT CTT CTG CTG C AG AGT C 3’
P st I
853-875
EpoR U1 5’ GTTTTGTGCCGCTGGAGCTGCAGG 3’ 375-398
Numbering taken from the following references: p53 (Bienz et al, 1984); Fli-1 (Ben-David et al,
1991); SCF (Anderson et al, 1990); c-kit (Qiu et al, 1988); Spi-1 (Klemsz et al, 1990); Erg 
(Rao et al, 1987); epoR (D'Andrea et al, 1989a).
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For amplification of the non-coding region of Fli-1, ljig of spleen DNA was 
used and the two primers shown in Table 6.3B.
All PCR reactions from genomic DNA were carried out under the same 
conditions used in the RT-PCR protocol (section 6.11). Products were purified on 
NACS columns prior to subsequent experimental manipulation.
6.13: Sequencing.
All sequencing was performed using the Sequenase Version 2.0 kit supplied 
by USB, according to the recommended protocol, incorporating [a-3^S] dATP as the 
radioactive label. However, to anneal the primer a slightly different approach from 
that recommended was found to give better results. 2fig of the template was boiled 
for 5min with lOng of primer in lx reaction buffer from the kit (40mM Tris.Cl 
(pH7.5), 20mM MgC^, 50mM NaCl), frozen on dry ice then slowly thawed to room 
temperature. The erg, Fli-1, c-kit, SCF and Spi-1 plasmids were sequenced using 
either the primers used for the PCR, or the following two primers, available from 
USB, which anneal to region adjacent to the multiple cloning site of vectors used in 
this thesis:
M13 Reverse (-24): 5? AACAGCTATGACCATG 3’
M l3 Universal: 5' TAAAACGACGGCCAGT 3’
For direct sequencing of p53 PCR products, the same protocol was used with 
0.5-1.5fig of the NACS column-purified DNA as a template. The following 
oligonucleotide, which hybridises to bases 557 to 577 of the p53 cDNA (Bienz et al, 
1984), was used to prime the sequence reaction in which the ELM deletion 
discovered: p53 U3 S’-CTCCTCCCCAGCATCTTATCC-T.
6.14: Electrophoretic mobility shift assays (EMSAs).
6.14.1: Preparation of probes.
Blunt-end 5’-end-labelled double-stranded oligonucleotides were prepared 
essentially as previously described (Plumb et al, 1989). 5|ig of two complementary
TABLE 6.3.
Oligonucleotide primers for PCR from genomic DNA.
Name. Sequence.
A. p53.
For PCR across the ELM deletion:
P53  U2 5’ TCAGGCTTATGGAAACTGTGAGTGGAT 3*
p53  D2 5' CTTCCAGTGTG ATGATGGTAAGG AT AG 3’
Position.
67-83 (plus 10 
nucleotides from 
intron 2) 
740-766
To generate a p53  intron 7 probe:
p53  175’ 5' ATCATCACACTGGAAGACTCCAG 3’
p53  173' 5’ TGTCCCGTCCCAGAAGGTTCCCA 3’
751-773
774-796
To generate a p53  intron 2 probe:
p53  125’ 5’ TCAGGCTTATGGAAACTGTGAGTGGAT 3'
p53  123’ 5* ATCTTCTGGAGGAAGTCTGGAAAACA 3’
B. Fli-1.
To generate a probe for the non-coding region of the Fli-1 gene: 
Fli-1 U2 5’ TGAAGTCACTTCCCAAAATTAG 3’
Fli-1 D2 5’ ACCCGGTTACAGCCTGACCTCG 3'
67-83 (plus 10 
nucleotides from 
intron 2)
84-99 (plus 10 
nucleotides from 
intron 2)
5-26
180-202
Numbering according to Bienz et al, 1984 (p53) and Ben-David e t al, 1991 (Fli-1)
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single-stranded oligonucleotides were annealed in 100fJ.l of a lx TE, 0.1M NaCl 
solution, by boiling for lOmin in a water bath and then allowing to cool slowly to 
RTemp. 2|il from this solution was end-labelled with ^2P in the following reaction: 
2pl of double-stranded oligonucleotide (100ng/|il)
0.5fil of 0.1M dithiothrietol 
2p.l of [y-32P] dATP
ljil of lOx kinase buffer (0.5M Tris.Cl (pH8), 0.1M MgC^, 5mM spermidine, 
O.lmMEDTA, lmMZnS04)
3.5pl of distilled water 
l|il T4 polynucleotide kinase (10U/|nl) 
which was incubated at 37°C for 30min, heated to 70°C for 5min, incubated for a 
further lOmin at 37°C, then cooled to RTemp. The ragged ends of the oligonucleotide 
were filled in by adding to the end-label reaction mix, 2pl of a 5mM dNTPs solution, 
6p.l of water, lpl of lOx TA (0.33M Tris.Ac (pH7.9), 0.66M KAc, 0.1M MgAc2» 
5mM dithiothrietol, lmg/ml BSA) and lpl of Klenow enzyme (lU/|il), and 
incubating on ice for lhr. The oligonucleotide was then precipitated by adding 8|il of 
1M NaCl, 15|ig tRNA, 300|il of ethanol, cooling at -20°C for 2hrs, and then spinning 
for 15min in a microfuge. The pellet was resuspended in a 20% (v/v) glycerol 
solution and electrophoresed on a lx TBE (90mM Tris, 90mM boric acid, 2mM 
EDTA), 8% (w/v) polyacrylamide gel at 100V for 90min in lx TBE running buffer. 
The gel was exposed to Kodak X-OMAT AR imaging film for lOsecs, the film 
developed, and the radiolabelled oligonucleotides excised from the gel by aligning the 
autoradiograph with the gel. A second exposure was then taken to ensure the 
oligonucleotide had been removed. The gel slice was then incubated at 37°C 
overnight in 1ml of lxTE. To estimate the amount of unlabelled sequence used in 
competition experiments it was assumed that 50% of the oligonucleotide was lost 
during the procedure, giving a concentration of labelled oligonucleotide of lOOng/ml.
The sequence of the oligonucleotides used in EMSA experiments in this thesis 
are shown in Table 6.4.
TABLE 6.4.
Oligonucleotides for electrophoretic mobility shift assays.
Name. Sequence (GGAA motif boxed). Reference.
E74 G ATCTCTAGCTG AAT AACClGGAAlGTAACTCATCCTAGGATC Reddy and Rao, 1991.
E74(mut) G ATCTCTAGCTG AAT AACdCAAbTAACTCATCCT AGGATC Reddy and Rao, 1991.
PEA3 GATCCTCGAGCAGGAAQTTCGAGATC Wasylyk et al, 1990.
PU-1 GATCCATAACCTCTGAAAGA|GGAA|CTTGGTTAGGTGATC Klemsz etal, 1990.
a-P3a GATCCAAACCAGCCAATGAGAACTGCTCCAGATC Plumb et al, 1989.
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6.14.2: Preparation of nuclear proteins from mammalian cell lines.
Nuclear proteins were extracted using a rapid extraction protocol as follows. 
5xl07 cells were homogenised in hypotonic buffer (lOmM Tris.HCl pH 7.4, lOmM 
NaCl, 1.6mM MgCl2, ImM CaCl2) then spun at 2,000rpm in an IEC Centra-8R 
centrifuge at 4°C for lOmin. The nuclear pellet was washed with 10ml of TMS 
(0.25M sucrose, 5mM MgCl2, lOmM Tris.HCl pH 7.4) then resuspended gently in 
100(il of storage buffer (50mM NaCl, 20mM Hepes pH 7.9, 5mM MgCl2, O.lmM 
EDTA, ImM DTT and 20% glycerol). One tenth volume of 4M NaCl was added, 
mixed and incubated on ice for 20min, then spun at 55,OOOrpm at 4#C for 1 hr in a 
Beckman Benchtop Ultra-Centrifuge and the supernatant stored at -70°C.
The relative concentration of proteins in the samples was assessed by 
comparing aP3a binding activity in 2 and 5|il aliquots. This sequence contains the 
CCAAT box of the mouse a-globin promoter which is thought to bind to a ubiquitous 
protein present at similar amounts in many cell types (Plumb et al, 1989; Cohen et al, 
1986). It seemed unlikely that their would be any gross differences in the expression 
of this protein between the various cell lines of the ELM system. In subsequent 
EMSAs, the volume of nuclear protein used was adjusted to compensate for 
differences in the aP3a activity.
6.14.3: DNA:protein binding reaction and gel electrophoresis.
The appropriate volume of protein extract (1 to 5(0.1) was incubated for lOmin 
on ice with 6|ig of poly (dl-dC) and 5 to 500ng of any appropriate unlabelled 
competitor oligonucleotides, made up to a final volume of 15(0.1 with storage buffer. 
~500pg of labelled oligonucleotide was added to each sample, made up to 20(0.1 with 
storage buffer, and incubated for 20min at room temperature. Samples were 
electrophoresed in a 0.25x TBE, 5% (w/v) polyacrylamide gel in 0.25x TBE running 
buffer (pre-run for lhr at 150V) for 2hrs at 150V at 4°C; the gel was then dried for 
autoradiography.
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6.15: In vitro transcription-translation.
lfig of the ipFli vector was linearised with Sal I then incubated in lx 
transcription buffer (40mM Tris.Cl (pH7.5), 6mM MgClj, 2mM spermidine, lOmM 
NaCl) with 2.5mM dNTPs, lOmM dithiothreitol, 40U of RNasin and 30U of T7 RNA 
polymerase in a final volume of 20|il for 90min at 37°C. 2fil from this transcription 
reaction was then used in the translation reaction, performed in a nuclease-treated 
rabbit reticulocyte lysate (purchased from Promega) according to the manufacturers 
instructions. Aliquots from this reaction were then used in EMSAs as described 
above. A control reaction was performed in which the pFli vector was omitted.
6.16: Isolation of lambda 'phage clones.
6.16.1: Preparation of plating cells.
E. coli strain P2392 were used throughout the preparation and screening of the 
genomic library (section 6.3.1). To make the cells competent for 'phage infection, 
50ml of NZCYM medium containing 0.2% (w/v) maltose was inoculated with a 
single colony of P2392 cells from an NZCYM agar plate and grown at 37°C 
overnight. This induces expression of the maltose receptor which also acts as a 
receptor for bacteriophages. The cells were pelleted by centrifugation at 3,000 rpm 
for 25min in an IEC Centra-8R centrifuge, resuspended in 20ml of SM (0.1M NaCl, 
5mM MgSC>4, 50mM Tris.Cl (pH7.5), 0.1% (w/v) gelatine) and stored at 4"C until 
required. Cells were prepared fresh for each infection.
6.16.2: Plating 'phage.
To titre and amplify 'phage stocks, 400|il of plating cells were incubated with 
10|il of various dilutions of the 'phage stock in a Falcon 2059 tube at 37°C for 20min. 
6.5ml of molten 0.6% (w/v) agarose NZM (45 °C) was added to the tube and the mix 
poured onto a 150mm diameter plate containing 1.5% (w/v) agar NZM. This was 
allowed to solidify for 15min and then incubated inverted overnight at 37*C. To plate
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'phage for screening, large 200mm^ plates were employed with the incubation mixes 
scaled up appropriately.
6.16.3: Preparation of a genomic library from ELM-I-1 DNA.
10|ig aliquots of 1-1 genomic DNA were digested with a range of Sau 3AI 
concentrations to optimise reaction conditions such that the majority of the 
subsequent DNA fragments were between 12 and 20kb. The reaction was then scaled 
up to generate 12-20kb fragments from 300|ig of DNA: these fragments were isolated 
by electrophoresis on a 0.4% (w/v) low melting point agarose gel followed by 
electroelution and NACS column purification (section 6.5.3), and finally resuspended 
to an approximate concentration of 0.5mg/ml. The vector used in forming the library 
was XGEM11, digested with Bam HI and ECo RI, purified on a NACS column and 
resuspended to a final concentration of 0.5mg/ml. 0.125-l|ig of the Sau 3AI partially- 
digested DNA was ligated into 0.5p.g of Bam HIJECo RI A.GEM11 using T4 DNA 
ligase (section 6.5.4). One fifth of this reaction was packaged using Gigapack Plus 
packaging extracts, according to the manufacturers instructions, and suspended to a 
final volume of 100|il with SM. lOp.1 of chloroform was added, the mixture vortexed, 
the two layers were allowed to separate and the stock stored at 4°C. The chloroform 
prevents bacterial contamination of the 'phage solution. l|xl was plated to assess the 
number of plaque-forming units (pfu) present in the stock. If the titre was greater 
than 250,000 pfu/ml, then the remainder of the ligation mixes were packaged.
6.16.4: Amplification of the library.
Fifteen 150mm diameter dishes, each containing 100,000 pfu of the library, 
were covered with 12ml of SM and incubated overnight at 4#C. The SM was then 
spun at 3,000rpm for 15min in an IEC Centra-8R rotor to remove agarose fragments, 
and the supernatant then transferred to sterile 20ml glass tubes, 200|il of chloroform 
added, vortexed and stored at 4°C. The amplified library was titred as described 
above.
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6.16.5: Screening the library with radiolabelled DNA probes.
-150,000 pfu of the amplified or unamplified library were plated onto 200mm2 
NZM plates as described above (section 6.16.2) and incubated overnight at 37°C. The 
plates were then cooled at 4°C for 2hrs. Duplicate lifts were taken off each plate onto 
nitrocellulose Hybond-C membranes purchased from Amersham, and subsequently 
denatured and neutralised according to their instructions. DNA was fixed to the filter 
by baking in an 80°C vacuum oven for 2hrs. The filters were prehybridised, 
hybridised to radiolabelled DNA probes, washed and exposed in an identical fashion 
to the Southern blots (section 6.9). A Southern blot of DNA from mouse spleen was 
included in these procedures to verify the quality of the probe being used. Putative 
positive plaques were cut from the original plate, incubated in 1ml of SM, plus 50(il 
of chloroform, at 4°C overnight, titred, then rescreened with the same probe. Single 
positive plaques from this secondary screen were screened for a third time to verify 
their identity. Single plaques from the tertiary screen were used to prepare DNA for 
further analysis.
Three probes from the Fli-1 locus were used to screen the library: SU-9 (see 
table 6.1), the full-length Fli-1 cDNA, and a PCR product generated from the 51 non­
coding region of the Fli-1 gene (section 6.12). The latter probe proved to be difficult 
to use due to its short length (<200bp) reducing hybridisation efficiency, and the two 
clones described in detail in this thesis were isolated using the SU-9 probe.
6.16.6: Preparation of 'phage DNA.
lml of fresh P2392 plating cells were incubated in a Falcon 2059 tube with 107 
pfu from a stock of the positive recombinant ’phage, incubated for 20min at 37*C and 
then used to inoculate 500ml of NZCYM. After incubation for between 12-16hrs the 
cells lyse, apparent from the accumulation of cell debris in the culture. 10ml of 
chloroform was then added and the mixture shaken at 225rpm for 15min in a New 
Brunswick G25 shaker. The lysate was then cleared by centrifugation at 3,000rpm for 
15min in an DEC Centra-8R rotor. The DNA was isolated using the glycerol step
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gradient method, after first precipitating the 'phage particles using polyethylene glycol 
(8000) (described in detail in Sambrook et al, 1989).
6.16.7: Restriction mapping and characterisation of 'phage clones.
The approximate length of the genomic DNA insert present in positive ’phage 
clones was determined by cleavage with Sfi I and subsequent electrophoresis on a 
0.8% (w/v) low melting point agarose gel. ~10pg of the insert was then isolated by 
Sfi I digestion, electrophoresis, and NACS purification (section 6.5.3). A series of 
Southern blots were then prepared (section 6.9) in which 0.5(ig of this Sfi I fragment 
had been cleaved with a second enzyme. The probes hybridised to these blots were 
prepared by transcription labelling from the T7 and SP6 promoters in the A.GEM11 
vector, performed as follows. lOfig of the clone DNA was cleaved with Hae III, 
^OH/CHClj extracted, ethanol precipitated and resuspended in lOfil of DEPC-treated 
water, lfil of this DNA preparation was then incubated in lx transcription buffer 
(section 6.15) with lpl of rATP, rGTP and rCTP (all lOmM), l|il 0.5M dithiothrietol, 
20U RNasin, 5fil [a-32P] rUTP and 10U of T7 or SP6 RNA polymerase in a final 
volume of 25p.l. The reaction was incubated at 37°C for 30min and the labelled 
fragments separated from unincorporated nucleotides by gel filtration on a Sephadex 
G-50 column (section 6.10). The probe was hybridised to the filters after heating to 
65°C for 5min using the same procedure used for Northern blot analysis (section 6.8).
Filters were stripped and hybridised with probes from the Fli-1 locus, such as 
SU-9 and the 5' non-coding region of the cDNA, to further map restriction sites. 
Once a comprehensive map had been generated, fragments of interest were cloned 
into pBluescriptll KS+ and sequenced, as described above. Comparisons were made 
with known sequences using the VAX (Devereux et al, 1984).
6.17: Immunostaining ELM-D cells.
ELM-D cells growing on MS-5 stromal cells were seeded at 10% confluence in 
a sterile 100mm diameter Petri dish containing 10ml of ELM growth medium (section
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6.1.1) and a number of glass coverslips. Cells were grown for three days until ~75% 
confluence; the medium was then removed and the cells washed three times with 
PBS. After a brief rinse in fixing solution (50:50 (v/v) mix of methanol and acetic 
acid) cooled to -20°C, cells were left in fresh fixing solution for lOmin at -20°C. 
After a brief rinse with cold PBS, individual coverslips were then used in the 
immunostaining protocol, which used the Vectastain ABC-AP kit (mouse IgG) and 
the anti-p53 antibody PAb 246 as the primary antibody (gift from Dr. D. Lane; 
Yewdell et al, 1986). The fixed cells were treated according to the method 
recommended by the manufacturers of the kit with the help of M. Clarke. The 
protocol employed a biotinylated horse anti-mouse IgG antibody to detect PAb 
246:p53 complexes, which is then itself bound to an. avidin molecule linked to 
horseradish peroxidase. Then, by incubating with a peroxidase substrate (diamino 
benzidine), a brown stain is formed coincident with the position of the PAb246:p53 
complexes. The stained cells were dehydrated by washing with increasing 
concentrations of ethanol, up to 100%, air dried, mounted, and photographed with a 
Leitz microscope set at a range of magnifications.
As a control, an identical procedure was followed using a separate coverslip of 
cells, except that the PAb 246 binding step was omitted.
CHAPTER 7: Materials.
7.1: Murine cell lines, media and tissue culture supplies.
The MS-5 stromal feeder cell line, and all the ELM cell lines and tumour cells, were 
obtained from Dr. W. Ostertag. F4-12 cells were taken from laboratory stocks. 
Supplier: Beatson Institute Central Services.
Penicillin (7.5mg/ml).
Streptomycin (lOmg/ml).
Sterile CT buffer.
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Sterile PE.
Sterile PBS.
Sterile glassware and pipettes.
Supplier: Fisons Scientific Equipment, Loughborough, Liecs., England.
DMSO.
Supplier: Gibco Europe Life Technologies Ltd., Paisley, Scotland.
a-Minimal Essential Medium, plus deoxyribonucleosides and ribonucleosides. 
Ham's F12 Medium.
Special Liquid Medium.
Foetal Calf Serum.
2.5% (w/v) Trypsin.
200mM Glutamine.
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Donor Horse Serum.
Supplier: A/S Nunc, Roskilde, Denmark.
Tissue culture flasks.
Nunc tubes.
Supplier: Becton Dickinson Labware, Plymouth, England.
100mm diameter tissue culture dish.
Recombinant human erythropoietin was the generous gift of Dr. T. Holyoake, whilst 
IL-3 was purified from WEHI-3 conditioned-medium by Dr. J. Ihle. These were used 
in differentiation induction experiments at 2U/ml and lOU/ml, respectively.
7.2: Bacterial hosts and media.
E. coli host strain JM83 was obtained from laboratory stocks held by M. Walker. 
DH5a competent cells were purchased from Gibco Europe Life Technologies Ltd., 
Paisley, Scotland. INVclF' cells came with the TA cloning kit (section 7.6), whilst 
P2392 cells used for 'phage propagation were the generous gift of Dr. C. 
Bartholomew.
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Terrific broth, NZCYM and NZM were prepared according to Sambrook et al (1989). 
Components of the media were purchased from BDH Chemicals Ltd., Poole, Dorset, 
England, unless they are included in the following list:
Supplier: Beatson Institute Central Services.
L-broth (prepared according to Sambrook et al (1989)).
Kanamycin (lOmg/ml)
Sterile glassware.
Supplier: Difco, Detroit, Michigan, USA.
Agar.
Bacto-tryptone.
Casamino Acids.
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Ampicillin.
X-gal.
Supplier: Gibco Europe Life Technologies Ltd., Paisley, Scotland.
NZ broth.
Supplier: Beta Laboratories, East Molesey, Surrey, England.
Yeast extract.
7.3: Plasticware.
Supplier: Becton Dickinson Lab ware, Plymouth, England.
Falcon tubes.
Supplier: Bibby-Sterilin Ltd., Stone, Staffs., England.
All bacteriological dishes.
30ml Universal tubes.
7.4: Mice.
Female C3H mice were purchased from Harlem-Olac and housed by S. Bell.
Injection, sacrifice and dissection were performed with the help of T. Hamilton.
108
Phenylhydrazine, used to induce anaemia, was purchased from Sigma Chemical Co. 
Ltd., Poole, Dorset, England.
The Beatson Institute's Alycon II Teletherapy Unit was used for all irradiation 
procedures.
7.5: Plasmids and bacteriophages.
pBluescriptll KS+ was supplied by Stratagene Ltd., Cambridge, England, and pUC19 
by Gibco Europe Life Technologies Ltd., Paisley, Scotland, and used to propagate a 
number of DNA fragments generated during this thesis. Recombinant plasmids 
supplied by other workers are shown in Table 6.1. The XGEM11 'phage vector was 
the generous gift of Dr. C. Bartholomew.
7.6: Kits.
Supplier: Invitrogen Corporation, San Diego, California, USA.
TA Cloning kit.
Supplier: Bio 101 Inc., Stratatech Scientific, Luton, England.
Geneclean kit.
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England.
Random-Primed DNA Labelling kit.
Supplier: United States Biochemical, Cleveland, Ohio, USA.
Sequenase Version 2.0 kit.
Supplier: Promega, Madison, Wisconsin, USA.
Nuclease-treated rabbit reticulocyte lysate in vitro translation system.
Supplier: Stratagene Ltd., Cambridge, England.
Gigapack Plus bacteriophage packaging extracts.
Supplier: Vector Laboratories, Burlingame, California, USA.
Vectastain ABC-AP kit (mouse IgG).
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7.7: Membranes, paper and X-ray film.
Supplier: Amersham International pic, Amersham, Bucks., England.
Hybond N nylon membranes.
Hybond C nitrocellulose membranes.
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland.
Dialysis tubing.
Supplier: Vemon-Carus Ltd., Preston, Lancs., England.
Gauze swabs.
Supplier: Whatman International Ltd., Maidstone, Kent, England.
3MM filter paper.
Supplier: Eastman Kodak Co., Rochester, New York, USA.
X-ray film (X-OMAT AR).
Duplicating film (DUP-1).
Supplier: Presentation Technology Ltd., Clydebank, Scotland.
AGFA Rapitone paper (PI-2 and P I-4).
7.8: Nucleotides, polynucleotides, RNA and DNA.
The following nucleotides, used to radiolabel DNA or RNA fragments, were 
purchased from Amersham International pic, Amersham, Bucks., England:
[a-32P] dCTP -3,000 Ci/mmol.
[a-35S] dATP -1,000 Ci/mmol.
[a-32P] rUTP -800 Ci/mmol.
[y-32P] dATP -5,000 Ci/mmol.
Unlabelled nucleotides were also supplied by Amersham.
Supplier: Pharmacia Ltd., Milton Keynes, Bucks, England.
Poly (dl-dC).
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
E. coli tRNA.
Herring testis DNA.
1 1 0
Supplier: Promega, Madison, Wisconsin, USA.
Oligo-dT 15mer.
Total cellular RNA from the Jurkat T cell line was the generous gift of Dr. R. Fulton. 
Murine kidney RNA was the generous gift of Dr. C. Bartholomew.
7.9: Gels and columns.
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland.
Agarose and low melting-point agarose (Ultrapure grade).
NACS Prepac columns.
DNA markers (lmg/ml): lkb ladder, bacteriophage <|)xl74 DNA (Hae Ill-cut) 
and bacteriophage X DNA (Hind Ill-cut).
0.24-9.5kb RNA ladder (lmg/ml).
Supplier: Severn Biotech Ltd., Kidderminster, England.
Design-a-Gel 40% (w/v) acrylamide: 2% (w/v) bis-acrylamide solution. 
Supplier: Pharmacia Ltd., Milton Keynes, Bucks, England.
Sephadex G-50.
Supplier: Bio-Rad Laboratories, Richmond, California, USA.
Bio-Rad Bio Gel A-50M.
7.10: Enzymes and enzyme inhibitors.
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland.
All restriction endonucleases with buffer concentrates, with the exception of 
Dra HI.
T4 DNA ligase (lU/pl) and 5x ligation buffer.
Proteinase K.
Taq DNA polymerase (10U/fil) and lOx PCR reaction buffer.
SP6 (15U/|il) and T7 (50U/|il) RNA polymerases and lOx transcription buffer. 
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England.
Dra in  (lOU/pl) and lOx buffer.
I l l
Calf intestinal alkaline phosphatase (lU/p.1).
DNAse-free RNAse.
RNAse A.
Supplier: Northumbria Biologicals Ltd., Cramlington, Northumberland, England.
T4 polynucleotide kinase (10U/|il).
Klenow DNA polymerase (lU/|il).
Supplier: Promega, Madison, Wisconsin, USA.
M-MLV Reverse transcriptase (200U/fil) and 5x H-RT buffer.
RNAsin (20U/jil).
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Diethylpyrocarbonate (DEPC).
Lysozyme.
Protease inhibitors, used to prepare nuclear protein extracts, were the generous gift 
from J. O'Prey.
7.11: Chemicals.
All other chemicals not listed above, were obtained (AnalaR grade) from BDH 
Chemicals Ltd., Poole, Dorset, England, with the following exceptions:
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Bromophenol Blue. RbCl.
Dithiothreitol. Spermidine.
Methylene Blue. TEMED.
MOPS. Triton X-100.
PIPES. Xylene Cyanol.
Polyvinylpyrollidone. ZnS04.
Supplier: James Burrough Ltd., Witham, Essex, England.
Ethanol.
Supplier: Rathbum Chemicals Ltd., Walkerbum, Scotland.
Water-saturated phenol.
1 1 2
Supplier: Pharmacia Ltd., Milton Keynes, Bucks, England.
Ficoll 400.
Supplier: Cinna/Biotecx Laboratories Inc., Houston, Texas, USA.
RNAzol B.
Supplier: Northumbria Biologicals Ltd., Cramlington, Northumberland, England.
Bovine Serum Albumin (20% w/v).
Supplier: Fisons Scientific Equipment, Loughborough, England.
Formaldehyde (38% w/v).
Supplier: Fluka Chemika-Biochemika AG, Buchs, Switzerland.
Formamide.
7.12: Water.
Distilled water for buffers and general solutions was obtained from a Millipore 
MilliRO 15 system. Water for protein/enzyme work or recombinant DNA protocols 
was further purified on a Millipore MilliQ system to 18MQcm.
PART 3: RESULTS.
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CHAPTER 8: Tumorigenicity and Differentiation differences within 
the ELM system.
8.1: Relative tumorigenicity.
The original tumour can be passaged in vivo, and it has been shown that both 
ELM-D and 1-1 are tumorigenic (Itoh et al, 1988). To compare tumorigenicity within 
the system, cells were injected via the tail vein into syngeneic C3H mice that had 
been immunosuppressed by irradiation with 300 Rads of y-rays. Initially, four of the 
stroma-independent cell lines (1-1, 1-2, 1-5, 1-6) were tested. For each cell line, 107 
cells were injected into five mice which were sacrificed 15 days post-injection, at 
which time their spleens were weighed as a measure of leukaemogenicity (Figure 8.1, 
graph A). Those injected with 1-1 and 1-5 showed a significant splenomegaly, up to 
eight times that of a normal spleen, often accompanied by enlargement of the liver 
(indicated by the letter 'L'), whilst 1-2 and 1-6 showed only a moderate increase in 
spleen weight with the liver remaining normal. Although 1-5 induces a more rapid 
splenomegaly than 1-1, mice injected with 1-1 cells appeared much less healthy prior 
to sacrifice. This is probably a consequence of severe anaemia since the 1-1 spleens 
were significantly paler than those taken from other animals.
The stromal cell-independent cell lines were then compared with D#6 cells, 
which were grown on lethally-irradiated MS-5 feeders to remove any influence they 
may have on tumorigenicity. The same procedure was used except that fewer cells 
had to be used as the D#6 cells tended to clump with the feeders at high 
concentrations and resulted in several mice dying shortly after injection, probably as a 
result of blood vessel blockage. Prior to harvesting the cells from tissue culture 
flasks, it was estimated visually that the D#6 to MS-5 cell ratio was 6 to 1: the 
appropriate adjustment was made so that equal numbers of D#6 and stromal cell- 
independent cells were used in subsequent experiments. Two groups of 
immunosuppressed mice received 2xl06 or 6xl06 cells and were sacrificed after 20 
days and 15 days respectively. The spleen weights confirmed the differences between
Figure 8.1: Relative tumorigenicity within the ELM system.
Cells were harvested and the specified number injected into immunosuppressed C3H 
mice as described in the Methods and Materials. After an appropriate incubation 
period when the animals began to appear unhealthy, the mice were sacrificed and 
their spleens weighed. Each bar is the average spleen weight from five injected mice, 
with the standard deviation shown by the error bar. The letter 'L' represents groups in 
which all the animals also exhibited significant hepatomegaly.
Graph A: 107 cells injected; incubation period of 15 days.
Graph B: 2x10^ cells injected; incubation period of 15 or 20 days as indicated. 
Graph C: 6xl06 cells injected; incubation period of 15 days.
Cells tested were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones I-1,1-2,1-5 and 1-6.
D#6:- ELM-D#6 cells growing on lethally-irradiated MS-5 cells (6 D#6 cells per MS- 
5).
IVP ELM:- In vivo passaged ELM tumour cells.
M:- Lethally-irradiated MS-5 cells (NB: Only one seventh the number of cells 
indicated were injected to control for MS-5 cells included in the D#6 injection).
'N' shows the average weight of the spleen from an untreated C3H mouse of the same 
age and sex as those used in the experiment.
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the stroma-independent cell lines, whereas the mice injected with D#6 showed a 
weight increase similar to that seen with 1-2 (Figure 8.1, graphs B and C). As a 
control, other mice received irradiated MS-5 cells only. Six-fold fewer cells were 
used to give an amount roughly equivalent to the number of MS-5 cells injected along 
with D#6. These animals showed no significant splenomegaly after the specified 
incubation period.
In a parallel experiment, 2xl06 spleen cells that had been passaged in vivo 
from the original erythroleukaemia were similarly injected into irradiated recipient 
mice. Again a group of 5 mice was used which had to be sacrificed only 15 days 
post-injection due to their unhealthy appearance. The mice were not anaemic, but 
their spleens were enormous, on average sixteen times larger than normal mice 
(Figure 8.1, graph B). All contained a liver at least twice the normal size. The rapid 
enlargement of these organs engorged with differentiating leukaemic cells may arise 
for a number of reasons. First, it may simply reflect a technical problem: it is more 
difficult to accurately estimate the number of leukaemic cells in a homogenised 
spleen preparation, than cells harvested from a tissue culture flask, a problem that 
could have resulted in the injection of the inappropriate number of cells. 
Nevertheless, it seems unlikely that this fully explains the rapid splenomegaly 
observed in mice receiving in vivo passaged tumour cells. A second possibility is that 
normal haemopoietic and stromal cells, injected in combination with the 
erythroleukaemic cells, enhance their proliferative capacity or viability. 
Alternatively, continuous passage may have selected for clones with a greater 
proliferative capacity than the cells that gave rise to the ELM cell lines. This does not 
necessarily have to be due to a genetic change, but may simply reflect epigenetic 
conditioning for growth in vivo, which is absent from the cells cultured in vitro that 
will not have been subjected to the same selective pressures. Re-injection of 
leukaemic spleen cells arising in mice injected with the cell lines, may induce 
tumours more rapidly than when freshly-harvested cells from tissue culture are used, 
but this has yet to be tested. However, despite this possible selection, the in vivo
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passaged tumour cells seem not to have lost their stromal cell-dependence as they still 
appear to require stromal cells for long-term viability in vitro: seeding cells from a 
homogenised ELM spleen in ELM growth medium (see Methods) results in a rapid 
reduction in cell numbers which is followed by the formation of small colonies of 
ELM cells on stromal cells present in the spleen cell homogenate. Inclusion of 
additional stromal cells, in the form of a MS-5 cell layer, reduces the initial loss of 
cell viability (data not shown). Whatever the explanation, this result does not detract 
from the obvious differences that exist between the ELM cell lines with respect to 
both growth and differentiation in vivo.
8.2: Differentiation induction in vitro in response to epo and IL-3.
Since mice injected with 1-1 appeared more anaemic than mice injected with 
other ELM cell lines, their differentiation capacity was tested in vitro in response to 
erythropoietin (epo) and interleukin-3 (IL-3), physiological inducers of 
erythropoiesis. Cells were grown to near confluence, harvested and reseeded at 
2.5xl05 cells/ml in assay medium containing 2U/ml of epo and/or lOU/ml of IL-3 
(see Methods and Materials). After 72 hours, the cells were harvested and, as 
expected from the in vivo observations, all the ELM cell lines examined, with the 
exception of 1-1, had developed a red colour. To quantify this effect, RNA was 
extracted and analysed by Northern blotting (Figure 8.2). Probing with a mouse a- 
globin genomic fragment (spanning exons 1 and 2 of the gene) demonstrated that 1-1 
differentiated only slightly in response to epo and undetectably in IL-3, whilst the 
other independent cell lines exhibited extensive a -globin mRNA induction with epo, 
an effect slightly enhanced by the presence of IL-3. F4 erythroleukaemic cells, which 
arose from SFFV infection (Ostertag et al, 1972), show the same insensitivity to epo 
and IL-3 as that seen in the 1-1 line. The blot was stripped of the radiolabelled a- 
globin probe and hybridised to a cDNA fragment from the GAPDH gene to quantitate 
the amounts of RNA loaded in each of the lanes. The D#6 loading appears 
significantly higher than the other samples, but this is simply because it is a longer
Figure 8.2: Differentiation capability of erythroleukaemia cell lines in response 
to erythropoietin and/or interleukin-3.
Freshly-harvested cells were incubated for three days in assay medium (see Methods 
and Materials) containing either no additional growth factors or erythropoietin 
(2U/ml) and/or interleukin-3 (lOU/ml), indicated by the V  andsymbols .  RNA was 
extracted and 20pg used to prepare a Northern blot which was hybridised to a ^2P- 
radiolabelled a -globin probe as a marker of erythroid differentiation. Exposure time: 
3 hours. The blot was stripped of the a -globin probe and hybridised to a GAPDH 
cDNA fragment to assess RNA loading. Exposure time: 12 hours.
Cell lines tested were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones I-1,1-2,1-5 and 1-6.
D#6:- ELM-D#6 cells growing on live MS-5 cells (6 D#6 cells per MS-5).
F4:- Friend virus-induced erythroleukaemia cell line, F4-12.
Cell line. 1-6 1-6 1-6 1-6 1-2 1-2 1-2 1-2 F4 F4 F4 F4
2U/ml epo. - + - + - +  - + - + - +
lOU/ml IL-3. - - + + - - + + - - + +
Globin.
GAPDH.
Cell line.  
2U/m l epo.  
lOU/ml IL-3.
1-5 1-5 1-5 1-5 1-1 1-1 1-1 1-1 I)#6  D # 6  I)#6  1)#6
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+
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exposure of a separate blot: when this is taken into account, the extent of a -globin 
expression is only slightly lower in the D#6 cells, probably the result of 
contaminating stromal cells (data not shown). Identical results to those presented 
here were seen after 5 and 7 day inductions with epo and/or IL-3 (data not shown).
Surprisingly, a -globin gene expression and haemoglobin production were 
enhanced by treatment with IL-3 alone. Inspection of the pellet of harvested cells 
suggested that this was confined to a small population of differentiating cells, 
coloured red by haemoglobin production. One possible explanation for this result is 
that IL-3, conventionally viewed as an enhancer of erythroid progenitor 
growth/survival not differentiation, synergises with low concentrations of epo in the 
serum allowing more cells to become committed to differentiation.
The insensitivity of 1-1 cells to epo, appears not to be due to the level of epo 
receptor (epoR) gene expression (Figure 8.3). Northern blot analysis, using an epoR- 
specific cDNA probe generated by RT-PCR, has shown that, once the relative loading 
of the RNA samples has been taken into account, epoR gene expression is at a similar 
level in all the ELM cell lines, although possibly slightly lower in 1-1 cells (Figure 
8.3B). Furthermore, Shiozaki et al (1990b) have demonstrated that 1-1 cells possess 
epo binding sites on their cell surface. They also showed that on exposure to epo, 1-1 
cells exhibited an increased proliferation, and a slight differentiation induction 
(similar to that shown in Figure 8.2). Thus, 1-1 cells are probably able to generate 
intracellular signals through epoR as a result of ligand binding, but their ability to 
respond by differentiating is more efficiently blocked than other ELM cell lines. One 
possibility which this experiment does not address, is that different forms of the epo 
receptor, like the truncated receptor created by alternative-splicing of nascent mRNA 
(Nakamura et al, 1992), may be present on the various cell lines which may alter the 
cellular effect exerted by ligand binding.
One interesting, though surprising, observation is the detection of epoR 
expression in the MS-5 stromal cells (Figure 8.3), a result confirmed by Ostertag and 
his colleagues (personal communication). The significance of this is unclear, but it is
Figure 8.3: Expression of the erythropoietin receptor (epoR) gene in the ELM 
system.
A: Position of PCR primers (epoR U1 and epoR Dl) used to generate a cDNA probe 
for epoR by RT-PCR (see Methods and Materials). The identity of the product was 
confirmed by cloning the fragment into pBluescriptll KS+ followed bj partial 
sequencing of the termini of the insert. Primer sequences are shown in Table 6.2 in 
the Methods and Materials section. The structure of the cDNA is from D'Andrea et 
aU 1989a. The position of the region encoding the putative membrane spanning 
region of the protein is indicated by 'TM'.
B: Northern blot of 20|ig samples of total cellular RNA hybridised to the epoR 
cDNA fragment labelled with 32P (Exposure time: 3 days), stripped aid then 
hybridised to a similarly labelled actin cDNA to assess RNA loading (Exposure time: 
12 hours). Molecular weight markers are given in kb to the right of the blot.
Cell lines and tissues tested were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
MS-5:- Stromal cell line, MS-5.
ELM-D:- Uncloned ELM-D cells growing on live MS-5 cells (7 ELM-D cells per 
MS-5).
IVP ELM:- In vivo passaged ELM tumour cells.
Spleen and kidney samples from a C3H mouse.
F4-12:- Friend virus-induced erythroleukaemia cell line, F4-12.
A .  i i
lOObp
Figure 8.3.
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possible that in vivo it may allow stromal cells to respond to increases in the levels of 
circulating erythropoietin and change the nature of the haemopoietic 
microenvironment to favour erythropoiesis. However, no experiments have been 
performed to determine whether a functional epo receptor is expressed on the surface 
of these cells.
8.3: Summary of phenotypic differences in the ELM system.
Thus, in summary, the ELM system consists of a number of cell lines derived 
from the same tumour which show marked differences in (a) their stromal cell- 
dependence, (b) their tumorigenic growth and differentiation properties in vivo and (c) 
their ability to differentiate in vitro in response to physiological inducers of 
erythropoiesis, such as epo. In the case of the 1-1 cell line, the differentiation block 
may be responsible for its increased tumorigenicity and the severe anaemia induced in 
the host animals. However, 1-5, which is also highly tumorigenic, still retains the 
ability to differentiate, like 1-2 and 1-6. Interestingly, the 1-1 cell line is 
phenotypically very similar to many of the Friend cell lines generated from mice 
infected with FV or F-MuLV (see Introduction, section 2.3).
CHAPTER 9: The role of SCF in the stromal cell-dependence of 
ELM-D#6 cells.
9.1: Expression of SCF in MS-5 cells.
A collaborative study was initiated with Dr. Ostertag's group in an attempt to 
(a) identify erythropoietic growth factors expressed in the MS-5 cells and (b) 
determine what effect these factors have on the growth of the leukaemic cells by 
blocking the interaction between the growth factor and its receptor with specific anti- 
sera. Obvious candidates are IL-3, GM-CSF and SCF, which are unable to support 
the long-term growth of D#6 cells when presented in a soluble form, either alone or in
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combination (Itoh et al, 1993), but may represent part of the inductive 
microenvironment established by the stromal cells. However, using both Northern 
blot analysis and PCR, IL-3 mRNA is undetectable in MS-5 cells (Itoh et al, 1993): 
GM-CSF mRNA has been detected in this cell line (Suzuki et al, 1992), but is absent 
from other MS-5 cultures that are equally capable at supporting D#6 survival (Itoh et 
al, 1993). The interleukin-6 and colony-stimulating factor-1 genes are expressed, but 
both these factors have no reported direct influence on the survival/growth of 
erythroid cells, and furthermore, the known receptors for these ligands are not present 
on D#6 cells (Suzuki et al, 1992; Itoh et al, 1993).
Examination of MS-5 and ELM cells for SCF gene expression was performed 
using RT-PCR and Northern analysis of RNA samples (Figure 9.1). Using an 
antisense SCF-specific oligonucleotide (SCF Dl), a reverse transcription reaction was 
performed, followed by PCR amplification using the SCF Dl primer, and a sense 
oligonucleotide, SCF Ul. These primers are located either side of a region that is 
known to be alternatively spliced during SCF expression, the inclusion of which 
allows the proteolytic cleavage of the mature membrane-spanning protein to release 
soluble SCF (Flanagan et al, 1991; Huang et al, 1990, 1992). PCR from normal 
spleen mRNA produced two fragments of the expected size which represent the two 
SCF transcript variants (Figure 9.IB). SCF mRNA was readily detectable in the MS- 
5 feeder cells, but the smaller product was absent. It is likely, therefore, that these 
cells are able to produce both transmembrane and soluble forms of SCF through the 
production of a cleavable precursor. Indeed, Ostertag and his colleagues have 
detected SCF activity in MS-5-conditioned medium that can be blocked with anti- 
SCF antibodies (Itoh et al, 1993). All the other cells tested were SCF-negative, 
although small quantities of PCR product X were generated from ELM-D, D#6 and in 
vivo passaged ELM cells: this was probably a consequence of contaminating stromal 
cells in these samples.
The PCR product generated from MS-5 RNA was purified and cloned into the 
pBluescriptll KS+ vector, using the restriction sites incorporated into the PCR
Figure 9.1: Expression of SCF in the ELM system.
A: Position of PCR primers (SCF U1 and SCF Dl) used to assess SCF expression by 
RT-PCR (see Methods and Materials). Primer sequences are shown in Table 6.2 in 
the Methods and Materials section. The structure of the cDNA is from Flanagan et al, 
1991. The position of the proteolytic cleavage site, which is alternatively spliced 
during SCF expression, and the putative membrane spanning domain (TM), are 
shown.
B: RT-PCR analysis of SCF gene expression in RNA samples from ELM cell lines, 
MS-5 cells and C3H spleen. RT-PCR reactions were performed as described in the 
Methods and Materials, the products electrophoresed on a 1% (w/v) agarose gel and 
visualised using ethidium bromide staining. Molecular weight DNA markers are 
shown to the right of the gel photograph. X represents the 629bp product derived 
from the transcript containing the proteolytic cleavage site: Y is probably from the 
alternatively-spliced product lacking the exon coding for the cleavage site. The X 
product generated from MS-5 cell RNA was cloned into pBluescriptll KS+ and 
partially sequenced.
C: Northern blot of 20|ig of RNA samples probed with 32P-radiolabelled SCF cDNA 
fragment X. The position of the 28S and 18S rRNA bands, as determined by 
ethidium bromide staining, is indicated to the right of the blot. The filter was stripped 
of the SCF probe and hybridised to 32P-radiolabelled actin cDNA to assess RNA 
loading.
Cells tested in the above two experiments were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
MS-5:- Stromal cell line, MS-5.
D#6:- ELM-D#6 cells growing on live MS-5 cells (6 ELM-D#6 cells per MS-5).
IVP ELM:- In vivo passaged ELM tumour cells.
Spleen RNA from a C3H mouse.
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primers. It was partially sequenced which verified its identity and also confirmed the 
presence of the region encoding the proteolytic cleavage site (data not shown). The 
SCF cDNA was then radiolabelled and used to probe a Northern blot of various RNA 
samples. As expected, SCF mRNA was only detected in spleen and MS-5 cells, with 
a faint smear in the in vivo passaged ELM tumour cells (Figure 9.1C). The level of 
RNA loading was demonstrated by reprobing the blot with an actin cDNA fragment.
9.2: Expression of c-kit in ELM cells.
The RT-PCR procedure was used to generate two cDNA probes for c-kit, the 
gene encoding the SCF receptor, using spleen RNA and the c-kit-specific 
oligonucleotides shown in Figure 9.2A. The RT reaction was primed with c-kit Dl: 
the Ekit probe from the extracellular domain was amplified by PCR using primers c- 
kit U1 and c-kit D2, whilst to produce the cytoplasmic domain-encoding Veit probe, c- 
kit U2 and c-kit Dl were used. These two products were cloned and partially 
sequenced (data not shown). The Ekit fragment was initially used to probe the same 
Northern blot previously hybridised to the SCF probe, once it had been stripped of 
radiolabelled SCF probe. ELM-D#6 cells were found to express high levels of the c- 
kit mRNA, as did all the other ELM cells tested, whilst it was absent from MS-5 cells 
(Figure 9.2B). The low expression of c-kit in both normal spleen and 
erythropoietically-active spleens from anaemic mice, but its relatively high expression 
in in vivo passaged ELM tumour cells, indicates that the ELM erythroleukaemia 
probably arose from a small population of c-kit-expressing haemopoietic cells. 
Alternatively, the c-kit gene may have become deregulated during tumour progression 
as a consequence of mutation. Uncontrolled expression of growth factor receptors has 
been associated with other leukaemias, usually as a result of retroviral insertion (Fung 
et al, 1983 (EGF receptor); Lacombe et al, 1986 (epo receptor); Gisselbrecht et al, 
1987 (CSF-1 receptor)). Although Southern blot analysis of ELM cell DNA probed 
with Veit and Ekit has demonstrated that c-kit is not amplified or grossly rearranged
Figure 9.2: Expression of the c-kit gene in the ELM system.
A: Position of PCR primers {c-kit Ul, U2, D l and D2) used to generate two cDNA 
probes for c-kit by RT-PCR (see Methods and Materials). Primer sequences are 
shown in Table 6.2 in the Methods and Materials section. The structure of the cDNA 
is from Qiu et al, 1988. The portions of the gene encoding the putative membrane 
spanning domain (TM), and the cytoplasmic and extracellular domains of the 
protein, are shown. Both the Ikit and the Ekit PCR products were cloned into 
pBluescriptll KS+ and partially sequenced to verify their identity.
B: Northern blot of 20|ig of RNA samples probed with 32P-radiolabelled Ekit cDNA 
fragment. The position of the 28S and 18S rRNA bands, as determined by ethidium 
bromide staining, is indicated to the right of the blot. The filter was stripped of the 
Ekit probe and hybridised to 32P-radiolabelled actin cDNA to assess RNA loading.
Cells tested were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
MS-5: Stromal cell line, MS-5.
D#6:- ELM-D#6 cells growing on live MS-5 cells (6 ELM-D#6 cells per MS-5).
IVP ELM:- In vivo passaged ELM tumour cells.
Spleen:- Normal C3H mouse spleen.
Anaemic spleen:- Erythropoietically-active spleen from a C3H mouse which had 
been treated with phenylhydrazine to induce anaemia (see Methods and Materials).
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(data not shown), it still remains a possibility that expression of the gene has become 
deregulated by an as yet undetected genetic alteration.
9.3: SCF, c-kit and the generation of stromal cell-independent viability.
These results suggested that SCF may be involved in maintaining the long­
term viability of D#6 cells. To examine this possibility, Ostertag and his colleagues 
(Itoh et al, 1993) performed two sets of experiments, one using anti-kit and anti-SCF 
antibodies to block SCF/c-kit interaction, and the second using mutant Sl/Sld stromal 
cells that produce only the soluble form of the ligand (Flanagan et al, 1991; Brannan 
et al, 1991; Huang et al, 1992). They have demonstrated that whilst the antibodies do 
not prevent adhesion of D#6 cells to MS-5 cells, they do significantly reduce the 
growth of D#6 cells in a D#6/MS-5 coculture by greater than 75% relative to 
untreated controls. The SlfSld stromal cells, in a similar fashion to SCF-supplemented 
medium, are able to support transient, but not long-term growth of D#6 cells. It was 
concluded from these results that the TM SCF/c-kit interaction plays a crucial role in 
blocking cell death and promoting erythroid progenitor cell survival, an interaction 
which can not be adequately replaced by binding of the soluble form of SCF to c-kit
This raised the possibility that stromal cell-independent growth could arise as 
a consequence of a mutation that constitutively activates the signalling pathway 
stimulated by TM SCF/c-kit association. This could occur by the autocrine 
production of SCF, and indeed, growth factor production by leukaemic cells has been 
previously reported (Miyanomae et al, 1985; Sawada et al, 1986; McDonald et al, 
1987; Meeker et al, 1990). However, as shown in Figure 9. IB and C, cell lines 1-1,1- 
2,1-5 and 1-6 produce no SCF mRNA that is detectable by Northern blot and RT-PCR 
analysis. An alternative hypothesis involves the constitutive ligand-independent 
activation of the receptor by mutation. The only known oncogenic form of c-kit, v- 
kit, contains a large deletion which removes the portion known to encode the 
extracellular and membrane-spanning domains of the protein (Besmer et al, 1986). 
However, in the four stromal cell-independent cell lines tested (1-1,1-2, 1-5 and 1-6)
1 2 2
the Ikit and Ekit probes (Figure 9.2A) both hybridise to the full-length transcript also 
seen in D#6 cell RNA, effectively excluding similar deletions in the generation of 
stromal cell-independent mutants (Figure 9.2B and data not shown). Furthermore, no 
gross rearrangements are detected with either probe on Southern blots of ECo RI or 
Bam Hl-cleaved DNA from the 1-1 and 1-2 cell lines (data not shown). However, 
these preliminary experiments do not exclude the possibility that subtle point 
mutations, akin to those reported in the CSF-1 receptor in patients with acute 
myelogeneous leukaemia (Ridge et al, 1990), may cause ligand-independent 
signalling and promote stromal cell-independent survival.
CHAPTER 10: p53 status.
10.1: Detection of a p53 mutation in the ELM-D cells.
Studies of p53 genes in Friend cell lines have demonstrated that mutation, 
accompanied by loss of the remaining normal allele, appears to be an obligatory step 
in the progression of Friend erythroleukaemia, irrespective of whether it is induced 
with FV-A, FV-P or F-MuLV (reviewed in Ben-David and Bernstein, 1991). Friend 
cell lines usually exhibit three phenotypic characteristics: (a) high tumorigenicity in 
vivo, (b) an inability to differentiate in response to epo, and (c) stromal cell- and 
growth factor-independent growth in vitro. By examining the p53 status within the 
ELM system, which shows variation with respect to all these properties, it should 
prove possible to determine whether mutation of the gene correlates with the 
acquisition of a particular phenotype.
As an initial screen for mutation, Southern blots were performed to compare 
the structure of the p53 genes in the highly tumorigenic, differentiation-resistant 1-1 
cells in comparison normal spleen tissue. Similar experiments had successfully 
identified p53 mutations in Friend cell lines (Mowat et al, 1985; Rovinski et al, 1987; 
Hicks and Mowat, 1988; Munroe et al, 1988). However, using five different
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restriction enzymes and a full-length murine p53 cDNA probe, no differences were 
observed, demonstrating that no gross rearrangements or insertions had occurred at 
the p53 locus (data not shown). Furthermore, Northern blot analysis of RNA from a 
number of the ELM cell lines showed that a full-length transcript was being expressed 
at levels comparable to normal spleen tissue (data not shown).
To test for expression of the protein, ELM-D cells growing on a MS-5 cell 
layer, were stained with the anti-p53 antibody PAb 246 which recognises an epitope 
spanning amino acid residues 88 to 109 (Yewdell et al, 1986; Figure 10.2). The 
protocol employed a biotin-conjugated horseradish peroxidase moiety which deposits 
a brown stain at the position of p53:PAb 246 complexes when incubated with its 
substrate, diamino benzidine (see Methods). As shown in Figure 10.1 A, the nuclei of 
the ELM-D cells stain well, whilst the fibroblast-like MS-5 cells underneath are 
relatively unstained. In comparison, there was essentially only uniform background 
staining of cells in a control coculture which had been treated identically, except 
without the inclusion of PAb 246 (Figure 10. IB). The intensity of the ELM-D 
staining with this antibody is consistent with the production of a large quantity of p53 
by these cells, and although PAb246 is not specific for mutant p53 proteins, 
stabilisation and accumulation of p53 protein is an indication that it is in the mutant 
conformation (Oren et al, 1981; Finlay et al, 1988). This result justified a search for a 
mutation at the nucleic acid level.
In an attempt to identify a mutation in the coding region of the p53 gene, small 
portions of cDNA were amplified by RT-PCR from ELM-D RNA, and then 
sequenced. In each reaction, RNA from the spleen of a normal C3H mouse was used 
as a wild-type control. Initially, a reverse transcription reaction was performed, 
primed by an antisense oligonucleotide (p53 Dl) that hybridises to a sequence in the 
3' end of the p53 transcript (Figure 10.2). Small aliquots from this reaction were then 
subjected to PCR using the p53 Dl primer, and a sense primer p53 U1 (Figure 10.2), 
that hybridises near the 5' end of the p53 coding region. This generated a fragment, 
~1.15kb in length, containing nearly all the coding sequence of the gene, including
Figure 10.1: ELM-D cells stained with the anti-p53 antibody, PAb246.
A: ELM-D cells growing on MS-5 cells at approximately 75% confluence were fixed 
and treated with the anti-p53 antibody PAb246. The position of the p53:PAb246 
complexes was determined using horse anti-mouse antibodies linked to a horseradish 
peroxidase moiety: subsequent treatment with diamino benzidine deposits a brown 
stain as a result of enzymatic cleavage by the peroxidase (see Methods and Materials). 
The intense staining over the nuclei of the ELM-D cells is apparent, whilst the MS-5 
stromal cells growing underneath stain only very weakly.
B: Control cells treated identically, except that the incubation step with the PAb246 
antibody was omitted.
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Figure 10.1.
Figure 10.2: Position of p53 primers, 'hot-spots' and epitopes.
Primers: The position (indicated by the arrows) and the sequence of the five primers j 
(p53 Ul, U2, U3, D l and D2) used to generate and sequence a PCR product spanning j  
the ELM mutation. j
'Hot-spots': The position of the four regions of the p53 gene most commonly 
targeted for mutation in human tumours is represented by the four red boxes (from 
Hollstein etal, 1991).
Epitopes: The position of the epitopes for the two anti-p53 antibodies, PAb 240 and 
PAb246, are shown as black boxes (from Stephen and Lane, 1992, and Yewdell et aU 
1986)
The position of the 18bp deletion, identified in ELM cells in this thesis, is also shown.
The structure of the p53 cDNA and the sequence of the primers is from Bienz et al, 
1984.
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the four mutational 'hot-spots'. p53 Dl is unable to hybridise to the p53 pseudogene: 
this prevents amplification of this sequence from possible genomic DNA 
contamination in the RNA samples.
Aliquots from the p53 U1 /p53 Dl-primed reaction were then used as a 
template for a second round of amplification which employed 'nested' primers that 
hybridise to sequences between p53 U1 and p53 Dl. This generated relatively large 
quantities of specific regions of the coding region, which were then sequenced using a 
i  third primer that hybridised between the 'nested' primers. Initially, the mutation 'hot­
spots' were targeted, but neither 'hot-spot' 1 nor 3 (depicted in Figure 10.2) contained 
| a mutation in ELM-D cells. However, when the products of a further PCR reaction,
| primed by p53 U2 and p53 D2 (Figure 10.2), were run on a 3% agarose gel, the
i
| fragment from ELM-D RNA appeared to be smaller than the fragment from spleen
| RNA suggesting that it contained a small deletion (data not shown). This was
f
| confirmed by direct sequencing using the p53 U3 primer (Figure 10.2), which
[ demonstrated that 18bp had been lost from the ELM-D cDNA (Figure 10.3) between
j 'hot-spots' 2 and 3 and encoded by exon 6. The deletion maintained the reading frame
i and did not introduce a stop codon: therefore, a nearly full-length protein lacking
i\
| amino acid residues 206 to 211 should be produced by the transcript. The absence of
| any wtp53 sequence in the ELM-D PCR product suggested that no wtp53 mRNA was
| present in ELM-D cells. Interestingly, adjacent to each breakpoint of the deletion is
j
j  the sequence ACAG; short repeats of this kind are a common feature of spontaneous
deletion mutations, and are probably important in the mechanism of deletion
[
(Nalbantoglu et al, 1986). In fact, all short deletions of >2bp identified in the human 
p53 gene to date, contain direct repeats of between 2 and 8bp in the close vicinity of 
the deletion (Jego et al, 1993).
10.2: All cells of the ELM system are hemizygous for the mutation.
Fortunately, a Dra ID restriction site (recognition sequence: CACNNNGTG) 
is lost as a consequence of the deletion and this was exploited diagnostically to (a)
Figure 10.3: Sequence analysis of the p53 mutation present in ELM-D cells.
RT-PCR with primers p53 U2 and p53 D2 was used to generate a 394bp product 
spanning the central portion of the p53 cDNA from ELM-D and normal C3H spleen 
cells (see Methods and Materials for RT-PCR protocol). Each fragment was 
sequenced directly using the p53 U3 primer shown in figure 10.2, which hybridised to 
a region between the two primers used in the PCR reaction. The 18 base pairs present 
in the wild-type spleen PCR product, but deleted in the ELM-D product, are shown by 
the brackets to the left of the sequence gel autoradiograph and again in the sequence 
written below. The ACAG repeats are boxed, and the recognition site for the Dra ID 
restriction endonuclease (CACNNNGTG), present in the spleen product only, is 
marked. p53 amino acid sequence and numbering are from Bienz et aU 1984.
Spleen ELM-I)
G A I C G A I (
Deleted 
Sequence.
D ra  III site.
204 213
glu asp arg gin thr phe arg his ser val
GAA GjAC AG|G CAG ACT TTT CGC Cj\C AG'C GTG
GAA GAC AGC GTG 
glu asp ser val
s p l e e n
ELM-D
Figure 10.3.
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check the other ELM cells for the mutation, and (b) assess whether a normal allele 
was present. A Southern blot of Dra Hi-digested DNA from cells of the ELM system 
was prepared and hybridised to a radiolabelled probe from intron 7 of the p53 gene 
(Figures 10.4A and 10.5). This probe was generated by PCR from normal spleen 
DNA (see Materials and Methods) and has the advantage of not hybridising to the p53 
pseudogene, making interpretation of the results simpler. The probe hybridised to a 
single 5.8kb band in normal spleen DNA; a larger llkb band predominated in DNA 
from the ELM cells, whilst the 5.8kb band was absent (Figure 10.4A). Since an 
intron 2 probe from the 5' side of the Dra HI site (Figure 10.5) hybridised almost 
exclusively to a 5kb band in Dra Ill-cleaved spleen DNA (Figure 10.4B, extreme 
right-hand lane), it was assumed that the 1 lkb species represented alleles in which the 
Dra IH site was absent due to the 18bp deletion. The presence of this band in DNA 
samples from the in vivo passaged tumour cells and all in vitro cell lines demonstrates 
that the 18bp deletion in the p53 gene was an early event involved in generating the 
original erythroleukaemia, and is not associated with phenotypic changes of the cell 
lines in vitro. Likewise, the absence of the wild-type 5.8kb band shows that this 
mutation was accompanied by loss of the remaining normal allele before cells were 
established in culture.
However, an additional band of 7kb was also apparent in the DNA from 1-1 
and in vivo passaged tumour cells (Figure 10.4A). It seemed unlikely that this 
represented a second mutational event in the p53 gene that creates a Dra IH site in 
these cells, but a more plausible explanation was that it was an artefact generated 
during digestion of the DNA. One possibility was that there was a sequence, 
approximately 1.2kb 5’ to the Dra HI site of exon 6, that could be cut inefficiently by 
Dra III (Figure 10.5). This was confirmed by digesting several 20|ig aliquots of 
normal spleen DNA with increasing concentrations of Dra IH and preparing a 
Southern blot. Hybridising to a radiolabelled p53 intron 2 fragment, showed that as 
the concentration of Dra HI was increased, the predominant band shifted from 5kb to 
3.8kb (Figure 10.4B). In fact, there are two sequences in exon 4 (CACNNNATG and
Figure 10.4: Southern blot analysis of the p53 gene in Dra Hi-cleaved genomic 
DNA samples.
A: 20|ig of genomic DNA from C3H spleen, in vivo passaged ELM tumour cells 
(IVP ELM), ELM-D#6 cells growing on MS-5 stromal cells (D#6) and ELM-I-2, was 
cleaved with 100 Units of Dra IH and a Southern blot prepared according to the 
Methods and Materials. This was hybridised to intron 7 of the p53 gene previously 
isolated by PCR from spleen genomic DNA using primers and PCR conditions 
described in the Methods and Materials, section 6.12. Exposure time: 3 days. The 
position of molecular weight DNA markers electrophoresed adjacent to the DNA 
samples are shown to the right of the autoradiograph.
B: 20|ig samples of genomic DNA from C3H spleen digested with various
concentrations of Dra HI (given at the top of the autoradiograph) were used to prepare 
a Southern blot (see Methods and Materials). This was hybridised to intron 2 of the 
p53 gene previously isolated by PCR from spleen genomic DNA using primers and 
PCR conditions described in the Methods and Materials, section 6.12. Exposure time: 
5 days. The position of molecular weight DNA markers electrophoresed adjacent to 
the DNA samples are shown to the right of the autoradiograph.
A. . „
1()() Units o t  Dra  III.
IVP
1-2 D # 6  E L M  Spleen
Probe: Intron 7 o f  the pS3 uene
—  11 kb
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—  6kb
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Figure 10.4.
Figure 10.5: Genomic organisation of the p53 gene showing the position of 
primers, probes and Dra in cleavage sites important in this study.
Primers: The position and sequence of the p53 U4 and p53 D4 primers are shown. 
These were used in the PCR reactions involved in the generation of Figure 10.6. 
Probes: The intron 2, intron 7 and Sst II cDNA probes are shown in red. These 
were used on various Southern blots performed in this study (see text for further 
details).
Dra III cleavage sites: The site of known Dra III cleavage sequences is shown above 
the gene structure, along with the size of the fragments formed upon digestion. The 
putative weak Dra HI site in exon 4, identified in this study (see text), is also shown.
The position of the exons and introns (coding; filled boxes: non-coding; empty boxes) 
is derived from Bienz et al, 1984. This reference was also used to provide the 
sequence for the two primers.
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CTCNNNGTG), which are approximately 1.2kb 5’ to the Dra III site in exon 6, which 
have 8/9 homology to the Dra III recognition sequence (CACNNNGTG), and may 
possibly act as weak Dra in  cleavage sites. The variation in the intensity of the 7kb 
band in the ELM samples in Figure 10.4A, was probably due to different salt 
concentrations in the DNA preparations which was known to affect the efficiency of 
i cleavage at Dra in sites (data not shown). Alternatively, DNA methylation variations 
I between samples may affect the ability to cleave these putative Dra IH sites.
PCR has been used to confirm the conclusions drawn from the Southern blot 
analysis. Primers p53 U4 and p53 D4, which anneal to sequences either side of the 
deletion and not to the pseudogene (Figure 10.5), were used to generate a 2.3kb 
fragment from DNA from cells in the ELM system. lOOng was then incubated with 
or without Dra III, electrophoresed on a 1% agarose gel and blotted onto a nylon
j membrane. Hybridisation with an intron 2 probe, radiolabelled with 32P, shows that
\
I none of the PCR products from any of the ELM cells were cleaved by Dra HI, whilst
!
the same fragment from normal spleen DNA digested completely to the expected
1.8kb product (Figure 10.6). (The small amount of D#6 product that was cleaved 
(-10-15%) was most probably due to contaminating feeder cell DNA in the D#6 
j genomic DNA preparation). In a control experiment using an equimolar mixture of 
spleen and ELM PCR products, 50% digested as expected, a result which 
demonstrates that lack of cleavage by Dra III was due to loss of the recognition site, 
and not because of inhibition of the enzyme by contaminants in certain PCR product 
( preparations (data not shown). A smaller band of low intensity was seen comigrating 
I with the 400bp marker in all the cleaved products. Again, this was probably a 
consequence of digestion at the weak Dra IH site identified by Southern blotting.
Loss of the normal allele from a developing tumour cell can occur by a 
number of distinct mechanisms (Hansen and Cavanee, 1987) that produce one of two 
results: (a) homozygosity i.e. two copies of the same mutant allele, or (b) 
hemizygosity, when only one copy of the mutant allele remains. To distinguish 
between these two possibilities the Southern blot originally probed with intron 7
Figure 10.6: Southern blot analysis, after incubation with or without Dra III, of 
PCR products spanning the ELM deletion in the p53 gene.
PCR reactions, primed with the p53 U4 and p53 D4 oligonucleotides (Figure 10.5), 
were performed, as described in Methods and Materials, using genomic DNA from 
the following cells:
1-1 and 1-2:- Stromal cell-independent clones 1-1 and 1-2.
D#6:- ELM-D#6 cells growing on live MS-5 cells (6 ELM-D#6 cells per MS-5).
IVP ELM:- In vivo passaged ELM tumour cells.
C3H spleen:- Normal C3H mouse spleen.
lOOng of the PCR product from each sample was incubated with or without 15 Units 
Dra HI for 2 hours, electrophoresed on a 1% (w/v) agarose gel and a Southern blot 
prepared. This was hybridised to a p53 intron 2 probe. Exposure time: 12 hours. The 
position of molecular weight DNA markers electrophoresed adjacent to the DNA 
samples are shown to the right of the autoradiograph.
1-2 1-1 D#6
+ + +
IVP ELM
+
C3H
Spleen
+ 15 Units of 
D ra  III
2kb
1.6kb
lkb
5(K)bp
4(K)bp
3(X)bp
Probe: Intron 2 of the p53 gene.
F igure  10.6.
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(Figure 10.4A) was stripped and reprobed with a Sst II fragment from the 3’ region of 
the p53 cDNA (Figure 10.5 shows the position of the probe; Figure 10.7A shows the 
autoradiograph of the blot). This generated a result identical to Figure 10.4A, except 
that the pseudogene band is also apparent (Figure 10.7A). Scanning densitometry of 
this autoradiograph, using the pseudogene band as an internal loading control, and 
combining the intensity of the llkb and 7kb bands in the ELM lanes, demonstrated 
that the ELM cells are hemizygous: only one mutant allele is present (Figure 10.7B). 
The higher gene/pseudogene ratio observed in the IVP ELM and D#6 samples is 
probably a consequence of a small number of contaminating normal spleen cells and 
MS-5 cells, respectively.
Thus, in conclusion, all cells of the ELM system are hemizygous for a p53 
allele containing an 18bp deletion. Mutation of the p53 gene is not directly 
responsible for any of the phenotypic differences between in vitro ELM cell lines, but 
was probably an important step in the evolution of the original erythroleukaemia. The 
deletion described here does not disrupt the reading frame of the transcript, or 
introduce a stop codon, thus a nearly full-length protein will be translated that lacks 
amino acid residues 206 to 211, inclusive. In-frame deletions are a relatively unusual 
mode of p53 inactivation: any deletions that do occur usually shift the reading frame 
of the transcript and translate to a truncated protein lacking the important carboxy- 
terminal oligomerisation domain (Hollstein et al, 1991; Caron de Fromentel and 
Soussi, 1992; Jego et al, 1993). Also, the deletion is outside the previously defined 
mutational 'hot-spots' of the p53 gene, although point mutations and frameshifts have 
been identified in the region of the gene deleted in ELM cells. Interestingly, the ELM 
deletion removes part of the epitope for the PAb 240 antibody which becomes 
exposed, presumably as a result of a conformational change, in a large number of 
different p53 mutant proteins (Figure 10.2; Stephen and Lane, 1992). One would 
assume, therefore, that the structural integrity of this region is necessary for wtp53 
function.
Figure 10.7: p53 copy number analysis in the ELM system.
A: The Southern blot previously probed with intron 7 of the p53 gene (Figure 10A) 
was stripped of the radioactivity and hybridised to a 32P-radiolabelled Sst II fragmat 
from the 3' end of the p53 cDNA (see Figures 10.2 and 10.5 for the position of te 
fragment). Exposure time: 3 days. The invariant pseudogene band is indicated. A\ 
bands have been given a number, shown with an arrow to the left of te 
autoradiograph, to permit easy cross-reference with the scanning densitometry tale 
shown in B. The position of molecular weight DNA markers electrophoresd 
adjacent to the DNA samples are shown to the right of the autoradiograph.
B: The autoradiograph shown in panel A was subjected to scanning densitomety, 
and a value calculated for each band representing the optical density multiplied by te 
area of the band under study. These figures were then used to determine the ratio )f 
gene copies to pseudogene copies. This ratio, by comparison to the spleen samjle 
which was assumed to have two p53 genes per cell, gave an estimate as to the numbr 
of copies present in the various ELM cells. The position of the gene bands observd 
in the Dra HI Southern in panel A determined whether they were mutant or nomal 
alleles.
100 Units o f  Dra 111.
IVP
Spleen ELM D # 6  1-2
Pseudogene.
Probe: 3' end o f  p53  c D N A  (Sst II fragm en t) .
B.
Optical density (OD) x Band area (mm2).
Band. Spleen. IVP ELM. D#6. 1-2.
A.
(pseudogene). 6.30 8.49 6.47 4.39
B.
(mutant). 0 3.65 10.83
6.04
C.
(mutant). 0
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D.
(wild-type). 18.67 0
0 0
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Pseudogene
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CHAPTER 11: The role of ete-related genes in the ELM system.
11.1: Screening 1-1 and 1-2 for ets proteins.
Studies on Friend erythroleukaemia have highlighted the importance of ets- 
related genes in the disruption of normal erythropoiesis. Induction with SFFV
invariably causes the deregulated expression of the Spi-1 gene (Moreau-Gachelin et
al, 1988, 1989, 1990), whilst erythroleukaemias developing in newborn mice infected
| with F-MuLV are associated with over-expression of the related Fli-1 gene (Ben-
David et al, 1991); in both cases this is due to the selection during tumour progression 
of a particular retroviral integration event at a position upstream of their promoter 
sequences. However, the exact role of these genes in the manifestation of the 
leukaemic phenotype is not known. The ELM system, which displays a number of
l
| phenotypic variants with respect to differentiation and growth properties, may permit
| a correlation to be drawn between the acquisition of a particular phenotype and
I expression of ett-related genes.
i
j Since the ELM erythroleukaemia was reportedly generated by irradiation (Itoh
I et al, 1988a), the close correlation between infection with a specific retrovirus and
i
I deregulated expression of Spi-1 or Fli-1 may not be observed. In fact, expression of
\
| other ete-related genes may be activated in their place to serve a similar function. TofiI
j screen for this, three ets-specific oligonucleotides, PEA3, PU-1 and E74 (see table 6.4
i
| in the Methods section), were used in electrophoretic mobility shift assays (EMSAs).
These oligonucleotides, which bind to a wide spectrum of ets proteins, were used to 
give a profile of ets DNA binding activity present within the ELM system. PEA3 is
I
I derived from the oncogene responsive domain of the polyoma virus enhancer 
(Wasylyk et al, 1989), and in EMSAs is known to bind to in v/rro-translated murine c- 
ets-1, c-ets-2 and elk-1 proteins, and also to the product of the recently cloned PEA3 
gene (Wasylyk et al, 1990; Rao and Reddy, 1992; Xin et al, 1992). The PU-1 
sequence, derived from the SV40 enhancer (Klemsz et al, 1990), binds to the product 
of the PU-1 gene which proved to be identical to Spi-1 (Goebl et al, 1990). The
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product of the closely-related Spi-B gene is also able to bind to the PU-1 sequence in 
vitro (Ray et al, 1992). The E74 oligonucleotide contains the consensus sequence 
required for binding to the Drosophila E74 protein (Umess and Thummel, 1990); it 
also binds to the human erg protein, but not c-ets-1 or c-ets-2 (Reddy and Rao, 1991). 
In all of these cases, if an ets gene product shows an ability to bind to a particular 
sequence in EMSAs, then exogenous over-expression of that gene in vivo is able to 
activate transcription from a promoter containing tandem repeats of the sequence 
(Klemsz etal, 1990; Reddy and Rao, 1991; Ray etal, 1992; Xin etal, 1992).
Nuclear protein extracts were prepared from the 1-1 and 1-2 cell lines (see 
Materials and Methods), chosen because of their different routes of isolation and 
phenotypic variation: a similar preparation was generated from Spi-1-expressing F4- 
12 cells to be used as a control. To determine the quality of these extracts, and to give 
a rough estimate of protein concentration, they were tested in an EMSA for the 
presence of proteins able to bind to the aP3A oligonucleotide, containing the CCAAT 
box of the mouse a-globin promoter (see Materials and Methods; Plumb et al, 1989). 
This sequence is able to bind to a protein which is thought to be present in a large 
number, if not all, cell types (Cohen et al, 1986). The three extracts generated a 
retarded complex in this assay, although 1-1 was approximately threefold more 
intense than F4-12 and 1-2 (data not shown): hence, in subsequent EMSAs, for every 
lp.1 of 1-1 protein used, 3|il of the 1-2 and F4-12 extract was used. In the following 
experiments, retarded complexes that were ’specific' for the labelled oligonucleotide 
were defined as those that could be successfully competed out by the inclusion of 
excess unlabelled oligonucleotide in the reaction.
When EMSAs were performed with the PU-1 or PEA3 sequences, no specific 
retarded complexes were observed with the 1-1 and 1-2 extracts (Figure 11.1): the low 
mobility band (labelled 'NS') was not efficiently competed by unlabelled 
oligonucleotides (data not shown). However, a single specific band (FI) was seen 
when F4-12 nuclear proteins were used with either of these oligonucleotides: the F2 
and F3 bands are thought to be proteolytic degradation products of the FI complex,
Figure 11.1: EMSAs using the PEA3 and PU-1 oligonucleotides.
Nuclear protein extract was isolated from 1-1, 1-2 and F4-12 cells and ^^-end- 
labelled double-stranded PU-1 and PEA3 oligonucleotides prepared (see Methods and 
Materials). Binding reactions, using 500pg of labelled oligonucleotide and equal 
quantities of nuclear protein, and the non-denaturing polyacrylamide gel 
electrophoresis were performed as described in the Methods and Materials. Gels were 
dried and exposed to X-ray film for 12 hours. The labelled oligonucleotide used in 
each reaction is shown at the top of the figure, below which are the unlabelled 
competitor oligonucleotides incorporated into the binding reaction: (-) indicates no 
competitor, (+++) indicates 200-fold excess (lOOng) of competitor. The nuclear 
protein extract used in each experiment is given under the competitors.
High mobility, non-specific binding, which is not competed by unlabelled 
oligonucleotide, is indicated by 'NS'. Specific complexes are named FI, F2 and F3, 
and are discussed in the text. Free oligonucleotide, which has not been bound by any 
proteins in the extracts, is seen at the bottom of the autoradiograph.
Oligonucleotide sequences:
PEA3: GATCCTCGAGCAGGAAGTTCGAGATC 
(Wasylyk etal, 1990).
PU-1: GATCCATAACCTCTGAAAGAGGAACTTGGTTAGGTGATC 
(Klemsz et al, 1990).
Radiolabelled oligonucleotide.
PEA3
PU- PEA3
Competitor.
+++
PU-1 +++
Nuclear  
protein extract. 1-1 1-2 F4 F4 1-1 1-2 F4 F4
Free oligonucleotide.
Figure  11.1.
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since their intensity varies with the quality of the nuclear protein preparation (M. 
Grove and M. Plumb, personal communication). The FI complex with the PU-1 
sequence is almost certainly due to binding of Spi-1 and/or a closely-related protein 
since this sequence appears to preferentially bind these proteins (Klemsz et al, 1990; 
Ray et al, 1992): the comigration of the PEA3 band with this complex suggested that 
this too was probably due to the same protein(s) (Figure 11.1). This result shows that 
not only are Spi-1 and Spi-B absent from 1-1 and 1-2, but also c-ets-1, c-ets-2, elk-1 
and PEA3 are probably not present, since there is no PEA3 binding activity in these 
cells. To support this hypothesis, a number of Northern blots were performed using 
RNA samples from the ELM system. The first probe used was a Spi-1 cDNA 
containing the full coding region of the gene, generated by RT-PCR from spleen 
mRNA (see Materials and Methods), cloned into pUC19 and partially sequenced to 
verify its identity. Hybridising this sequence to a Northern blot demonstrated that 
Spi-1 mRNA was undetectable in the in vivo passaged ELM tumour cells and all the 
cell lines derived from them (data not shown). However, more sensitive RT-PCR 
analysis of RNA samples suggested that a small amount of Spi-1 mRNA was present 
in the ELM cell lines (data not shown): this probably represents the low level of 
expression apparent in normal erythroid progenitors (Galson et al, 1993). The F4-12 
cell line, derived from a SFFV-induced erythroleukaemia, was shown to express a 
large amount of Spi-1 mRNA as expected (data not shown). The lack of c-ets-1 and 
c-ets-2 gene expression was also shown by Northern analysis (data not shown), thus 
confirming the assumption made from the EMSA data with the PEA3 
oligonucleotide.
Next, EMSAs were performed using the E74 oligonucleotide. All three of the 
cell lines under examination contained proteins that specifically bound to the E74 
oligonucleotide. 1-1 and 1-2 gave one major band (A), two minor complexes (B1 and 
B2) and a band arising from non-specific binding to the oligonucleotide (C), whereas 
only the non-specific band C was observed using a mutated E74 oligonucleotide 
(E74(mut)) lacking the GGAA motif (Figure 11.2A and B). The only difference
Figure 11.2: EMSAs demonstrating the presence of E74 oligonucleotide binding 
activity in nuclear protein extract from erythroleukaemia cell lines.
Nuclear protein extract was isolated from 1-1, 1-2 and F4-12 cells and 32P-end- 
labelled double-stranded E74 oligonucleotides prepared (see Methods and Materials). 
Binding reactions, using 500pg of labelled oligonucleotide and equal quantities of 
nuclear protein, and the non-denaturing polyacrylamide gel electrophoresis were 
performed as described in the Methods and Materials. Gels were dried and exposed 
to X-ray film for 12 hours. The labelled oligonucleotide used in each reaction is 
shown at the top of each figure, below which are the unlabelled competitor 
oligonucleotides incorporated into the binding reaction: (-) indicates no competitor, 
(+) indicates 10-fold excess (5ng), (++) indicates 50-fold excess, (+++) indicates 200- 
fold excess (lOOng).
Panel A: Nuclear protein extract from ELM-I-1 cells.
Panel B: Nuclear protein extract from ELM-I-2 cells.
Panel C: Nuclear protein extract from Friend virus-induced erythroleukaemia F4-12 
cells.
Low mobility, non-specific binding, which is not competed by unlabelled 
oligonucleotide, is indicated by the letter 'C'. Specific complexes are named A, Bl, 
B2, D, FI, F2 and F3, and are discussed in the text. Free oligonucleotide, which has 
not been bound by any proteins in the extracts, is seen at the bottom of the 
autoradiograph.
Oligonucleotide sequences:
PE A3: GATCCTCGAGCAGGAAGTTCGAGATC 
(Wasylyk et al, 1990).
PU-1: GATCCATAACCTCTGAAAGAGGAACTTGGTTAGGTGATC 
(Klemsz etal, 1990).
E74: GATCTCTAGCTGAATAACCGGAAGTAACTCATCCTAGGATC 
(Reddy and Rao, 1991).
E74(mut):GATCTCTAGCTGAATAACCCAAGTAACTCATCCTAGGATC 
(Reddy and Rao, 1991).
' •  Nuclear extract: KI M I I.
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between the two cell lines is the position of the weak band D. In 1-1 it has a higher 
mobility than complex C: in 1-2 its mobility is slightly less than C. However, band D 
may simply be due to proteolytic degradation of one of the lower mobility complexes. 
The retarded complexes were only competed efficiently by unlabelled E74, although a 
significant reduction in the formation of the A, B2 and D complexes was seen using
I,000-fold excess of the PE A3 oligonucleotide. The same pattern of bands was seen 
using F4-12 proteins (Figure 11.2C), although additional complexes were also 
observed which comigrate with the bands seen when F4-12 proteins were incubated 
with the labelled PEA3 and PU-1 oligonucleotides (Figure 11.1) and are competed 
with a low excess of unlabelled PU-1 oligonucleotide (Figure 11.2C): these, as before, 
are probably due to binding of Spi-1 and/or a closely-related protein. Recently, 
Zhang et al (1993) have demonstrated that Spi-1 is indeed able to bind to E74 when 
the protein is produced in bacteria fused to glutathione S transferase.
II.2: Fli-1 binds to the E74 sequence in vitro.
The EMSA results, confirmed by Northern analysis, showed that the Spi-1, c- 
ets-1 and c-ets-2 genes are not involved in the ELM system. However, 1-1 and 1-2 
contain an E74 binding activity that does not bind well to the PU-1 and PEA3 
sequences. The loss of binding to E74 when the GGAA motif is disrupted (E74(mut) 
sequence), and the weak competition observed with the PEA3 oligonucleotide is an 
indication that some, if not all, of the complexes formed with E74 are due to the 
binding of ets-related proteins present in the nuclear extracts. Currently, the only 
protein known to exhibit the DNA binding specificity observed in the 1-1 and 1-2 
extracts is the human erg protein (Reddy and Rao, 1991). However, the extensive 
amino acid homology between erg and murine Fli-1, which is 98% over the putative 
DNA binding domain (Ben David et al, 1991), suggests that Fli-1 may exhibit the 
same specificity. Thus, experiments were performed to define the DNA binding 
specificity of Fli-1, using protein synthesised in vitro.
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A cDNA fragment containing the Fli-1 coding region was generated by RT- 
PCR from murine spleen RNA, cloned into the pBluescriptll KS+ vector (to create a 
plasmid termed pFli) and partially sequenced to verify its identity. Fli-1 mRNA was 
then generated by transcription with T7 RNA polymerase from the pFli plasmid 
linearised with Sal I. This was translated in a reticulocyte lysate system and aliquots 
used directly in EMSAs. From its homology with erg, it seemed unlikely the Fli-1 
would bind to the PE A3, or the Spi-1-specific PU-1, oligonucleotides, and indeed, 
this proved to be the case (data not shown). However, using the E74 sequence, a 
complex was formed with Fli-1 (Figure 11.3) which comigrated with bands B1 and 
B2 observed in the I-1, 1-2 and F4-12 EMSAs (Figure 11.2). The higher mobility 
complex, indicated by the lower arrow, was probably due to the binding of degraded 
or incompletely synthesised Fli-1. Both bands were competed out by unlabelled E74, 
and no binding was detected with the GGAA mutant oligonucleotide, E74(mut). 
Some oligonucleotide retardation was seen using a mock translation reaction that had 
not been primed with the Fli-1 transcripts: this is presumably due to a low level of 
E74 binding activity present in the reticulocyte lysate. Thus, the Fli-1 and erg 
proteins produced in vitro, and nuclear proteins from the 1-1 and 1-2 cell lines, exhibit 
similar binding specificities. This result, in combination with the previously 
published EMSA data with the erg protein (Reddy and Rao, 1991), suggested that erg 
and Fli-1 were likely candidate ets genes expressed in the ELM system. However, it 
must be remembered that the DNA binding specificity of a protein produced in an 
unphosphorylated state in vitro, in the absence of other transcription factors, could 
exhibit completely different properties in the context of a total nuclear protein extract 
prepared from growing cells. Indeed, a recurring theme with many ets proteins is that 
their ability to recognise certain DNA sequences is altered by phosphorylation and 
protein:protein interaction with non-ets-related transcription factors (discussed in the 
Introduction, sections 3.2 and 3.3).
Figure 11.3: EMSA showing binding of in vi/re-translated Fli-1 to the E74 
oligonucleotide.
The translation reaction and EMSA were carried out as described in Methods and 
Materials, using 500pg of the E74 or E74(mut) oligonucleotide as indicated at die top 
of the figure. 5 pi (denoted by '+') or IOjj.1 (denoted by '++') from the trarelation 
reaction containing Fli-1 protein, or from a mock translation reaction not primed 
with Fli-1 mRNA, were included in the EMSA reaction where shown. The single 
reaction containing 50ng (100-fold excess) of unlabelled E74 oligonucleotide is 
marked with a V. Arrows indicate the position of retarded complexes: the lower 
complex is probably due to binding of incompletely synthesised or degraded Fli-1 
protein. Free oligonucleotide, which has not been bound by any proteins, is seen at 
the bottom of the autoradiograph.
E74 E74(mut) R a d io la b e l l c d  o l igonu c leo t ide .
4  + +  + +
4- 4 +
Unlabelled E74 (lOOx excess) 
Fli-1 protein 
Mock translation.
■ i  , I
— Free oligonucleotide.
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11.3: Fli-1 is only expressed in the differentiation-resistant 1-1 cell line.
To test whether the erg or Fli-1 genes are in fact expressed in the ELM 
system, a series of Northern blots were performed. These experiments also allowed a 
comparison to be made of the various phenotypically-distinct cell lines of the ELM 
system. First, the insert from the pFli plasmid was used as a probe. The reduction in 
Fli-1 mRNA in mouse spleen upon stimulation of erythropoiesis by induction of 
anaemia with phenylhydrazine (Methods and Materials), suggests that Fli-1 is only 
expressed at low levels, if at all, in developing erythroid cells (Figure 11.4). Only a 
very small quantity of Fli-1 mRNA was found to be present in leukaemic spleens 
containing ELM cells which had been continually passaged in vivo since the 
development of the original malignancy. This is consistent with it being expressed 
solely in a small number of contaminating normal spleen cells. An RNA sample from 
a very early passage of the cells was also extremely low in Fli-1 transcripts, implying 
that deregulated expression of this gene was not involved in the evolution of this 
erythroleukaemia. ELM-D and D#6 cells, growing in contact with stromal cells, also 
expressed the gene to a very low level (data not shown) which was thought to be due 
to the presence of contaminating stromal cell RNA in the RNA sample. To confirm 
this, D#6 cells were separated from the MS-5 cells by centrifugal elutriation, and 
RNA extracted (see Methods and Materials): Fli-1 mRNA was undetectable in this 
pure population of D#6 cells (Figure 11.4). Interestingly, Fli-1 mRNA was absent 
from all the fifteen stromal cell-independent cell lines tested, with the exception of I- 
1, where it was highly abundant (Figure 11.4 and data not shown). Since this cell line 
is unable to differentiate in response to epo, this property may be the result of Fli-1 
over-expression. However, the lack of Fli-1 mRNA in the fourteen other stromal cell- 
independent cell lines, indicates that expression of this gene is not a prerequisite for 
stromal cell-independent growth.
The presence of Fli-1 mRNA in the 1-1 cells, and the results obtained using in 
vitro-translated Fli-1, raised the possibility that some of the E74 binding activity in 
the nuclear extract prepared from this cell line was due to binding of the Fli-1 protein.
Figure 11.4: Northern blots showing that Fli-1 gene expression is restricted in 
the ELM system to the differentiation-resistant cell line, ELM-I-1.
20pg of total cellular RNA was electrophoresed, blotted and hybridised to a 32P- 
labelled full-length Fli-1 cDNA probe (Methods and Materials). Exposure time: 12 
hours. Molecular weight markers are given, in kb, between the autoradiographs. The 
blot was stripped and reprobed with an actin cDNA to assess the relative levels of 
RNA loading.
Tissues and cell lines examined were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
D#6 elutriated at 0.3ml/sec:- Pure ELM-D#6 cells prepared by centrifugal elutriation 
from a freshly-harvested ELM-D#6/MS-5 coculture (Methods and Materials).
MS-5:- Stromal cell line, MS-5.
IVP ELM:- In vivo passaged ELM tumour cells:
Late passage (5 passages since the evolution of the ELM tumour).
Early passage (1 passage since the evolution of the ELM tumour).
See Figure 5.1 in the Introduction.
Spleen:- Normal C3H mouse spleen.
Anaemic spleen:- Erythropoietically-active spleen from a C3H mouse which had 
been treated with phenylhydrazine to induce anaemia (see Methods and Materials).
The IVP ELM (late passage) sample was included on both blots to permit 
comparisons to be made between the two autoradiographs.
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Furthermore, the F4-12 cell line also expresses the Fli-1 gene at a low level (data not 
shown), and generated a banding pattern with the E74 sequence that was very similar 
to the 1-1 cell line. However, the lack of Fli-1 gene expression in 1-2 cells questions 
this assumption, since a virtually identical banding pattern is observed between the 
E74 sequence and 1-2 nuclear extract. Bearing in mind the similar size and DNA 
binding specificities of Fli-1 and erg, it seemed worthwhile to test whether 1-2 cells 
expressed the murine homologue of the human erg protein which may cause the 
similarity observed in the EMSAs.
11.4: Correlation between stromal cell-independent growth and expression of the 
erg gene.
11.4.1: Cloning part of the murine erg cDNA.
Rather than use a human erg DNA probe which may not be able to cross- 
hybridise to the putative murine homologue, a cDNA fragment spanning the ets 
domain of murine erg was cloned. A single-stranded DNA template was generated 
by reverse transcription from various RNA samples primed with a poly-T 
oligonucleotide. This was then subjected to PCR using two primers designed from 
the human erg sequence (Rao et al, 1987) from regions that show strong cross-species 
conservation between other ete-related genes (Figure 11.5 A). Three fragments were 
produced from mouse spleen RNA: one had the expected size of 426bp, but a larger 
(~500bp) and a smaller (~340bp) product were also generated (Figure 11.5B). The 
same bands were synthesised from 1-2 RNA, but were absent from D#6 and F4-12 
samples. It must be remembered, however, that since the PCR primers used were 
designed from the human erg sequence, the absence of an amplified product from 
mouse cell RNA does not necessarily mean that the mouse homologue is not 
expressed in these cells: it may be expressed at a level lower than 1-2 which prevents 
efficient amplification. Incidentally, the 426bp and 500bp fragments were also 
amplified from RNA from the human T cell line, Jurkat, which is known to express 
erg (Rao et al, 1987) and was used here as a positive control: the 340bp product was
Figure 11.5: Cross-species RT-PCR analysis of erg expression in selected murine 
cells.
A: Human erg cDNA structure (Rao et al, 1987) showing the position of the erg U1 
and erg D1 primers used in the RT-PCR reaction shown in panel B. The sequence of 
the primers is shown in table 6.2 in the Methods and Materials. The ETS domain is 
represented as a shaded box.
B: Ethidium bromide stained gel, photographed under UV illumination, of RT-PCR 
reactions for erg. RT-PCR was performed as described in the Methods and Materials, 
using the primers shown in panel A; half the reaction was electrophoresed on a 1% 
(w/v) agarose gel. Molecular weight DNA markers are shown to the left of the gel 
photograph. The presence (+) or absence (-) of reverse transcriptase (RT) during the 
cDNA production is indicated at the top of the gel.
Cell lines and tissues tested were Jurkat cells, a human T cell line (used as a positive 
control), Friend virus-induced erythroleukaemia F4-12 cells, ELM-I-2 cells, ELM- 
D#6 cells on MS-5 stroma (ratio of 6 D#6 per MS-5), and C3H spleen.
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absent. Control reactions in which the reverse transcriptase had been omitted from 
the cDNA production step, were all negative.
Attempts were made to clone the three products using the TA cloning kit (see 
Materials and Methods), but this was only successful for the 500bp and 426bp 
products, generating the p500erg and p426erg plasmids. The insert of p426erg was 
sequenced, translated, and aligned with human erg and murine Fli-1 amino acid 
sequences (Figure 11.6). Unsurprisingly, like other ets proteins, erg is highly 
conserved between species, with only four amino acids variant in the region cloned; it 
is also closely related to Fli-1, as previously described for the human homologues 
(Watson et al, 1992). Interestingly, the differences between Fli-1 and erg found in the 
putative DNA binding domain reside in a cluster of serine residues, possible targets 
for covalent modifications. The 500bp and 426bp inserts were identical, but 500erg 
contained sequence coding for a further 24 amino acids amino-terminal to the ets 
domain, and probably arises as a result of alternative splicing of the erg mRNA 
(Figure 11.6). This region of erg and Fli-1 adjacent to the ets domain is the least 
conserved part of the protein and may be involved in altering the DNA binding 
activity and specificity of the two proteins in vivo by mediating protein-protein 
interactions, or by acting as targets for specific post-translational modifications. The 
equivalent portion of several other ets-related proteins is believed to behave in this 
manner (c-ets-1 (Wasylyk et al, 1992); Spi-1 (Pongubala et al, 1992, 1993); elk-1 
(Janknecht and Nordheim, 1992; Rao and Reddy, 1992b); SAP-1 (Dalton and 
Treisman, 1992); GABP-a (Thompson etaly 1991)).
11.4.2: Expression of the erg gene in the ELM system.
The erg cDNA fragment in the p426erg plasmid was excised, labelled with 
32P and hybridised to Northern blots of RNA samples from the cells of the ELM 
system (Figure 11.7). As with Fli-1, the reduction of erg mRNA in mouse spleen 
upon stimulation of erythropoiesis by induction of anaemia with phenylhydrazine 
(Methods and Materials), suggests that erg is only expressed at low levels, if at all, in
Figure 11.6: Amino acid sequence comparison of part of the human (h) and 
murine (m) erg and Fli-1 proteins.
Conserved amino acids, relative to the human erg sequence, are represented by a dash 
(-); absent amino acids are indicated by a dot (.). The ETS domain, the putative DNA 
binding portion of the protein, is contained between the two brackets ([]), with the 
conserved tryptophan residues highlighted with an asterisk (*).
The sequence of the murine erg was derived by translating the nucleotide sequence 
generated from the insert of the p426erg plasmid, although the insert of the p500erg 
plasmid was identical except that a region encoding a further 24 amino acids (shown 
at the base of the figure) is present at the point marked 'alt' (see text for the derivation 
of the two erg plasmids). The erg U1 and erg D1 primers, used in the PCR reactions 
to generate murine erg cDNA fragments, are shown.
The sequence and amino acid numbering of the other proteins shown here was 
derived from the following references:
Rao et al, 1987 (Human erg).
Watson et al, 1992 (Human Fli-1).
Ben-David et al, 1991 (Murine Fli-1).
erg (h) DKALQNSPRLMHARNT DLPYEPPRRSAWTGHGHPTPQSKAAQPS 2 5 9
426erg (m) er9ul Primer alt--------------- S_L----------
Fli-1 (h) TSHTDQ-S— ..SVKE -PS-DSV— G— GNNMNSGLNKSPPLGG 24 6
Fli-1 (m) TSHTDQ-S— ..NVKE -PS-DSV— G— NNNMNSGLNKSPLLGG 246
[ *
erg (h) PSTVPKTEDQRPQLDPYQILGPTSSRLANPGSGQIQLWQFLLELLS 305
426erg (m) — A---------------------------------------------
Fli-1 (h) AQ-IS-NTE----P-----------------------------------292
Fli-1 (m) SQ-MG-NTE----P-----------------------------------292
*  *
erg (h) DSSNSSCITWEGTNGEFKMTDPDEVARRWGERKSKPNMNYDKLSRA 351
426erg (m)  N---------------------------------------
Fli-1 (h) — A-A-------------------------------------------- 338
Fli-1 (m) — A-A-------------------------------------------- 338
]
erg (h) LRYYYDKNIMTKVHGKRYAYKFDFHG 377
426erg (m) — ergDl primer
Fli-1 (h)  364
Fli-1 (m)  364
Alternatively spliced into 'alt' in 500erg: 
GGAAFIYPNTSVYPGATQRITTRP
FIGURE 11.6.
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developing erythroid cells. More importantly, these experiments showed the erg 
mRNA to be barely detectable in the in vivo passaged tumour cells from either early 
or late passages, or in the D#6 cell line and two other stromal cell-dependent clones 
(D#2 and D#3) (Figure 11.7A). However, in contrast, it was relatively abundant in 
thirteen of the fourteen stromal cell-independent cell lines tested (Figure 11.7A and 
B). Once differences in the loading have been normalised using the actin control, 
scanning densitometry revealed that these cell lines express erg at levels on average 
approximately 20-fold higher (ranging between 4- and 48-fold) than the D#6 cells 
from which most of them were derived. Thus, there appeared to be a strong 
correlation between increased expression of the erg gene and stromal cell- 
independent growth in the ELM system.
In interpreting this experiment, account must be taken of the level of MS-5
| contamination in the coculture. Before harvesting the D#6/MS-5 coculture, it was
| estimated that there were six leukaemic cells per stromal cell. This figure was
generated by counting the number of D#6 cells adhered to approximately twenty 
stromal cells from a representative patch of all the tissue culture flasks from which 
RNA was isolated. Contamination of roughly 15%, was confirmed by the p53 PCR
i
I from genomic DNA, and subsequent Dra III cleavage, shown in Figure 10.6.
I
| However, it remained a possibility that MS-5 cells contribute a disproportionate
[
i  quantity of RNA when harvested with D#6 cells.
One way to test for this is to probe the Northern blots with either an MS-5- or 
a D#6-specific cDNA probe, such as SCF or c-kit, respectively, but these experiments 
may be subject to enror since coculture of the two cell types may alter the expression 
of any such markers. Indeed, this point was implied from earlier work examining 
SCF expression which demonstrated that a D#6/MS-5 culture with a low ratio of 
leukaemic to stromal cells, expresses this growth factor gene at a level considerably 
greater than MS-5 cells alone, indicating a possible up-regulation of this gene as a 
consequence of coculture (data not shown). Instead, various ratios of freshly- 
harvested 1-1 and MS-5 cells were mixed and RNA immediately extracted. This
Figure 11.7: Northern blots demonstrating that expression of the erg gene is 
restricted to the stromal cell-independent clones within the ELM system.
20pg of total cellular RNA was electrophoresed, blotted and hybridised to a 32P- 
labelled erg cDNA fragment excised from the p500erg plasmid (Methods and 
Materials). Exposure time for both blots was 6 days. Molecular weight markers are 
given, in kb, to the right of the autoradiographs. The blot was stripped and reprobed 
with an actin cDNA to assess the relative levels of RNA loading: exposure time was 6 
hours. The intensity of all the actin and erg bands on both blots was determined by 
scanning densitometry. The figures for the erg bands were then modified to take into 
account the differences in RNA loading determined by the actin bands, setting the 
D#6 on MS-5 (6:1) sample to 1.0: the adjusted values are given below the 
autoradiographs.
Tissues and cell lines examined were:
In panel A:
D#3 on MS-5 (5:1):- ELM-D#3 cells growing on live MS-5 cells (5 ELM-D#3 cells 
per MS-5 cell, as determined by visually counting the cells prior to RNA extraction). 
D#2 on MS-5 (6:1):- ELM-D#2 cells growing on live MS-5 cells (6 ELM-D#2 cells 
per MS-5 cell, as determined by visually counting the cells prior to RNA extraction). 
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
D#6 on MS-5 (6:1):- ELM-D#6 cells growing on live MS-5 cells (6 ELM-D#6 cells 
per MS-5 cell, as determined by visually counting the cells prior to RNA extraction). 
MS-5:- Stromal cell line, MS-5.
IVP ELM:- In vivo passaged ELM tumour cells:
Late passage (5 passages since the evolution of the ELM tumour).
Early passage (1 passage since the evolution of the ELM tumour).
See Figure 5.1 in the Introduction.
C3H spleen:- Normal C3H mouse spleen.
C3H spleen (anaemic):- Erythropoietically-active spleen from a C3H mouse which 
had been treated with phenylhydrazine to induce anaemia (see Methods and 
Materials).
In panel B:
D#6 on MS-5 (6:1):- ELM-D#6 cells growing on live MS-5 cells (6 ELM-D#6 cells 
per MS-5 cell, as determined by visually counting the cells prior to RNA extraction). 
1-1 and 1-2:- Stromal cell-independent clones 1-1 and 1-2.
Ten ELM-I lines derived from D#6 in the presence of GM-CSF. These were 
cloned from ELM-D#6 in the presence of GM-CSF, but subsequent analysis 
demonstrated that they were not dependent on GM-CSF for long-term survival 
without stromal cell contact (see Figure 5.1, and text in section 5.4, in the 
Introduction).
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avoids interactions between the two cell types, thus preventing contact-dependent 
alterations in gene expression. For comparison, samples containing different ratios of 
I-l/MS-5 RNA were also created by mixing the appropriate amounts of RNA from 
pure 1-1 and MS-5 preparations. A Northern blot was generated using all these 
samples, plus samples of pure MS-5 and 1-1 RNA as controls, and probed with a full- 
length Fli-1 cDNA (Figure 11.8). After exposure to X-ray film, the filter was stripped 
of the Fli-1 probe and hybridised to an actin cDNA to assess the relative loading 
between the samples. Both autoradiographs were then subjected to scanning 
densitometry and the levels of Fli-1 adjusted relative to the pure 1-1 sample (given as
I.0 in Figure 11.8). By a direct comparison between the cell and RNA mixes, it was 
concluded that MS-5 cells may contain slightly more RNA than ELM cells. 
However, the effect of dilution of D#6 by MS-5 cells insufficient to account for the 
differences in erg mRNA level observed between a D#6/MS-5 coculture and the 
stromal cell-independent clones, which can be up to 48-fold higher (Figure 11.7).
II.5: Up-regulation of the erg gene in D#6 cells upon separation from MS-5 cells.
To determine whether this up-regulation of erg mRNA is due to adaptation to 
loss of stroma cell contact, or only found in truly stromal cell-independent mutants, 
pure populations of D#6 cells were obtained, either by taking D#6 cells that had 
detached from the stromal cells in a high density coculture, or by cleanly separating 
attached D#6 cells from MS-5 cells by trypsinisation, followed by elutriation and then 
short-term culture (~2-3hrs) (see Methods and Materials). Subsequent Northern blot 
analysis of RNA samples extracted from these cells revealed 4-9 fold higher levels of 
erg mRNA in the pure populations of D#6 cells compared to the 6:1 D#6/MS-5 
cocultures. This compares with the 14-40 fold higher levels in the three ELM-I 
mutants analysed at the same time (Figure 11.9). Further experiments confirmed that 
the pure populations of D#6 cells were not capable of long-term growth in the 
absence of MS-5 stromal cells, but died out within 1-2 weeks (data not shown). As 
before, these differences in the level of gene expression are too large to be accounted
Figure 11.8: Dilution of Fli-1 mRNA by MS-5 RNA.
The indicated ratios of freshly-harvested 1-1 and MS-5 cells were mixed and RNA 
immediately extracted to avoid an interaction between the two cell types, thus 
preventing contact-dependent alterations in gene expression. Samples containing the 
same ratios of RNA were also created by mixing the appropriate amounts of RNA 
from pure 1-1 and MS-5 preparations. A Northern blot was generated (see Methods 
and Materials) using 20p.g of these mixes, plus a 20fig sample of pure MS-5 and 1-1 
RNA. This was probed with a full-length Fli-1 cDNA. Exposure time: 16 hours. 
Molecular weight markers are given, in kb, to the right of the autoradiograph. The 
filter was stripped of the Fli-1 probe and hybridised to an actin cDNA to assess the 
relative loading between the samples. Exposure time: 3 hours. The intensity of all 
the actin and Fli-1 bands the autoradiograph was determined by scanning 
densitometry. The figures for the Fli-1 bands were then modified to take into account 
the differences in RNA loading determined by the actin bands, setting the pure 1-1 
sample to 1.0: the adjusted values are given below the autoradiograph.
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Figure 11.9: Separating ELM-D#6 ceils from stromal ceils induces expression of 
the erg gene.
20pg of total cellular RNA was electrophoresed, blotted and hybridised to a 32P- 
labelled erg cDNA fragment excised from the p500erg plasmid (Methods and 
Materials). Exposure time: 6 days. Molecular weight markers are given, in kb, to the 
right of the autoradiographs. The blot was stripped and reprobed with an actin cDNA 
to assess the relative levels of RNA loading: exposure time was 6 hours. The 
intensity of all the actin and erg bands was determined by scanning densitometry. 
The figures for the erg bands were then modified to take into account the differences 
in RNA loading determined by the actin bands, setting the D#6 on MS-5 (6:1) sample 
to 1.0: the adjusted values are given below the autoradiograph.
Cell lines examined:
One of the ELM-I lines derived from D#6 in the presence of GM-CSF (shown 
previously in Figure 11.7).
1-5 and 1-6:- Stromal cell-independent clones 1-5 and 1-6.
D#6 elutriated at 0.3ml/sec:- Pure ELM-D#6 cells prepared by centrifugal elutriation 
from a freshly-harvested ELM-D#6/MS-5 coculture, followed by a brief period of 
culture (2-3 hours) (see Methods and Materials, section 6.6.1, for a detailed 
description of procedure).
D#6 suspension cells:- ELM-D#6 cells taken from the medium of a dense ELM- 
D#6/MS-5 coculture.
MS-5:- Stromal cell line, MS-5.
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for by dilution of the erg mRNA level by the 15% MS-5 stroma cells in the D#6/MS- 
5 coculture. These results, therefore, strongly suggest that erg mRNA is up-regulated 
in response to loss of stroma cell contact, but that this is not sufficient per se to allow 
the long-term stroma cell-independent growth characteristic of the ELM-I mutants.
11.6: Effect of MS-5 contact on the level of erg gene expression in 1-2 and 1-5 
cells.
D#6 cells survive for several days in the absence of stromal cell contact and 
during this period are capable of limited proliferation (Itoh et al, 1993). It was 
postulated from the results described above that this may, at least in part, be due to the 
expression of the erg gene in the D#6 cells. Moreover, it is therefore possible that 
constitutive expression of the erg gene could indefinitely extend this period of stromal 
cell-independent growth, in other words generating ELM-I clones. To examine 
whether erg expression in the ELM-I clones is no longer subject to the same controls 
as that observed in D#6 cells, the following experiment was devised to assess the 
effect of stromal contact on the expression of the gene in the 1-2 and 1-5 cell lines. 
MS-5 cells were seeded at 50% and 80% confluence in fresh medium, a six-fold 
excess of 1-2 or 1-5 cells was added, and the coculture incubated for three days at 
37°C. Both the ELM-I cell lines used, like the ELM-D cells, adhered strongly to the 
MS-5 monolayer (data not shown). ELM-I cells remaining in suspension were 
discarded prior to harvesting the cells, the ratio of ELM-I to MS-5 cells was 
determined and total cellular RNA extracted. As controls, parallel cultures of MS-5 
cells alone were grown for three days, harvested, mixed with the same ratio of 1-2 or 
1-5 cells as determined for the cocultures, and the RNA immediately extracted. Fresh 
samples of pure 1-2 and 1-5 RNA were also prepared. A Northern blot was generated 
with all these preparations, and probed first with the erg cDNA fragment excised 
from the p500erg plasmid, and then with an actin cDNA fragment to assess the 
relative loading of the samples (Figure 11.10). This blot showed that culture with 
MS-5 cells had no effect on the level of erg mRNA in either the 1-2 or the 1-5 cell
Figure 11.10: Northern blot demonstrating that contact between MS-5 ceils and 
the stromal cell-independent cell lines 1-2 and 1-5, has no effect on erg gene 
expression.
1-2 and 1-5 cells were harvested and incubated to a six-fold excess in contact with a 
50% or 80% confluent MS-5 monolayer for three days: RNA was then extracted. The 
same mixes were prepared using pure MS-5 cells and 1-2 or 1-5 cells, but RNA was 
extracted immediately without incubation, and before the cells became adhered to one 
another. RNA was also prepared from pure 1-5 and 1-2 cells. 20|ig of each RNA 
sample was electrophoresed, blotted and hybridised to a 32P-labelled erg cDNA 
fragment excised from the p500erg plasmid (Methods and Materials). Exposure time: 
6 days. Molecular weight markers are given, in kb, to the right of the 
autoradiographs. The blot was stripped and reprobed with an actin cDNA to assess 
the relative levels of RNA loading: exposure time was 6 hours. The intensity of all 
the actin and erg bands was determined by scanning densitometry. The figures for 
the erg bands were then modified to take into account the differences in RNA loading 
determined by the actin bands, setting the 1-2 only sample (lane furthest right) to 1.0: 
the adjusted values are given below the autoradiograph.
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50 80 50 80 50 80 50 80 MS-5 (% confluence).
+ +
+ + +
+  1-2 .
-  1-5.
6-fold excess 
over MS-5.
Relative levels o f
4.7 4.6 0.9 0.9 5.6 5.4 5.1 1.2 1.0 1.0 erg after calibration
with actin.
Figure 11.10.
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lines, which remained well above the level observed in a coculture of MS-5s with 
either D#2, D#3 or D#6 (Figure 11.7A).
These observations suggest that the mutation(s) responsible for the generation 
of stromal cell-independent growth and long-term viability contrive to prevent normal 
regulation of the erg gene in response to stromal cell contact. Although yet to be 
proven, this deregulated erg expression may be a crucial step in the development of 
stromal cell-independence and will be discussed in further detail in section 13.4.
11.7: Evidence for the presence of another ets-related protein in the ELM 
system.
Northern blot analysis of the ELM cell lines has demonstrated that the 1-1 cell 
line expresses both the erg and the Fli-1 genes, whilst 1-2 only produces erg mRNA. 
These genes encode highly homologous proteins both of which are able to bind to the 
E74 sequence when they are produced in in vitro translation systems and used in 
EMSAs: nuclear protein extract from 1-1 and 1-2 cells contain proteins that bind to the 
E74 oligonucleotide in the same assays. However, without performing 'super-shift1 
experiments with Fli-1 or erg anti-sera (which are currently unavailable), it is not 
possible to conclude that the E74 binding activity in the 1-1 and 1-2 extracts is due to 
the erg and Fli-1 proteins: other ets-related proteins may be responsible. To examine 
this problem further, EMSAs were performed using nuclear extract from MS-5 cells, 
which Northern blot analysis had demonstrated expressed no detectable erg mRNA 
and only an extremely low level of Fli-1 (Figures 11.4 and 11.7A). Despite 
presumably containing little, if any, Fli-1 or erg protein, they still contained a 
complex series of E74-binding activities which exhibited some similarities and some 
differences from the 1-1 and 1-2 E74 complexes (Figure 11.11). The bands labelled A 
and B2 seen in the ELM-I and MS-5 EMSAs comigrated and exhibited very similar 
competition with the E74, E74(mut), PEA3 and PU-1 oligonucleotides. It seems 
likely, therefore, that these complexes are formed by the same or highly homologous 
protein(s) in these extracts, and is strongly indicative that other, possibly unknown,
Figure 11.11: EMSA showing E74 oligonucleotide binding activity in the stromal
cell line, MS-5.
Nuclear protein extract was isolated from 1-2 and MS-5 cells and 32P-end-labelled 
double-stranded E74 oligonucleotides prepared (see Methods and Materials). Binding 
reactions, using 500pg of labelled oligonucleotide and equal quantities of nuclear 
protein, and the non-denaturing polyacrylamide gel electrophoresis were performed as 
described in the Methods and Materials. Gels were dried and exposed to X-ray film 
for 12 hours. The labelled oligonucleotide used in all reactions was E74; the 
unlabelled competitor oligonucleotides incorporated into the binding reaction are 
shown above the autoradiograph: (-) indicates no competitor, (+) indicates 10-fold 
excess (5ng), (+++) indicates 200-fold excess (lOOng).
Low mobility, non-specific binding, which is not efficiently competed by unlabelled 
oligonucleotide, is indicated by the letter 'C. Specific complexes are named A, Bl, 
B2 and B3, and are discussed in the text. Free oligonucleotide, which has not been 
bound by any proteins in the extracts, is seen at the bottom of the autoradiograph.
Oligonucleotide sequences:
PEA3: GATCCTCGAGCAGGAAGTTCGAGATC 
(Wasylyk et al, 1990).
PU-1: GATCCATAACCTCTGAAAGAGGAACTTGGTTAGGTGATC 
(Klemsz etal, 1990).
E74: GATCTCTAGCTGAATAACCGGAAGTAACTCATCCTAGGATC 
(Reddy and Rao, 1991).
E74(mut):GATCTCTAGCTGAATAACCCAAGTAACTCATCCTAGGATC 
(Reddy and Rao, 1991).
Radio la belied ol igonucleotide:  H74.
HLM-I-2. MS-5.
+++ + — L74.
+++ + -  -  E74(mut
+++ PI-A3. 
+++ PU-l .
I<'nla belled eompeti ioi
ol igonucleotide.
<■ £
A.
B3.
Bl.
B2.
-  C .
Free o 1 i uo n uc leo t ide.
Figure 11.11.
140
ets-related proteins are present in the 1-1 and 1-2 extracts along with the Fli-1 and erg 
proteins. These are not specific for the stromal cell-independent ELM cells since they 
are also formed in EMSAs using nuclear proteins from D#6 cells growing in contact 
with MS-5 stromal cells, or freshly-separated from MS-5 cells by centrifugal 
elutriation (Figure 11.12). The protein(s) in band A appears to be widely expressed in 
various human and murine cell lines and tissues since a complex with identical 
mobility and competition profile is observed in murine foetal liver, human K562 
myeloid leukaemia cells, C5 cells derived from murine embryonic epithelium, human 
cervical and liver tumour cell lines and murine STO fibroblasts (J. O'Prey, personal 
communication).
The B1 band observed with the 1-1 and 1-2 extracts (Figure 11.2A and B) was 
not present in the MS-5 EMSAs, although a lower mobility complex, termed B3, was 
formed (Figure 11.11). Unlike Bl, B3 is competed using a large excess of the PEA3 
sequence: Bl and B3, therefore, are probably formed by distinct proteins present in 
each cell type. Bl may be formed by Fli-1 or erg, and coincidentally, this complex 
does comigrate with E74 bound to in Wrro-translated Fli-1 protein shown in Figure
11.3. However, Bl is not formed with nuclear extract from D#6 cells grown either 
with or without MS-5 contact, both of which express the erg gene to some extent 
(Figure 11.12).
In summary, it is possible to draw a number of conclusions from these E74 
EMSA results. First, they imply the presence of ets-related protein(s) in the ELM 
system in addition to Fli-1 and erg, the expression of which appears not to correlate 
with stromal cell-independent growth. Second, they question the validity of using in 
virro-translated ets proteins to determine their sequence specificity. Fli-1 and erg 
both bind E74 in these assays, yet it has proven very difficult to demonstrate binding 
of these proteins to this sequence in nuclear protein preparations from cell lines 
expressing the genes. In particular, the inability to detect any differences in E74 
binding activity in the Fli-1-expressing 1-1 cell line compared to the 1-2 cells, implies 
that when Fli-1 is produced in vivo, in a state subject to post-translational
Figure 11.12: EMSA showing E74 oligonucleotide binding activity in the ELM-
D#6 cells growing with or without MS-5 contact.
Nuclear protein extract was isolated from a ELM-D#6/MS-5 coculture (ratio of 6 
ELM-D#6 cells per MS-5), and also from a pure population of ELM-D#6 cells 
prepared by centrifugal elutriation (see Methods and Materials). 32P-end-labelled 
double-stranded E74 oligonucleotides were synthesised as described in the Methods 
and Materials. Binding reactions, using 500pg of labelled oligonucleotide and equal 
quantities of nuclear protein, and the non-denaturing polyacrylamide gel 
electrophoresis were performed as described in the Methods and Materials. Gels were 
dried and exposed to X-ray film for 12 hours. The labelled oligonucleotide used in 
all reactions was E74; the unlabelled competitor oligonucleotides incorporated into 
the binding reaction are shown above the autoradiograph: (-) indicates no competitor, 
(+++) indicates 200-fold excess (lOOng).
Low mobility, non-specific binding, which is not competed by unlabelled 
oligonucleotide, is indicated by the letter 'C'. Specific complexes are named A and 
B2, and are discussed in the text. Free oligonucleotide, which has not been bound by 
any proteins in the extracts, is seen at the bottom of the autoradiograph.
Oligonucleotide sequences:
PE A3: GATCCTCGAGCAGGAAGTTCGAGATC 
(Wasylyk etal, 1990).
PU-1: GATCCATAACCTCTGAAAGAGGAACTTGGTTAGGTGATC 
(Klemsz et al, 1990).
E74: G ATCTCT AGCTG A AT A ACCGG A AGTA ACTCATCCTAGG ATC 
(Reddy and Rao, 1991).
E74(mut):GATCTCTAGCTGAATAACCCAAGTAACTCATCCTAGGATC 
(Reddy and Rao, 1991).
Radiolabelled oligonucleotide: E74.
D#6 on MS-5 (6:1). 
+++
+++
D #6 elutriated  
at 0 .3m l/sec.
+ ++ - 
-  + + +  -
++ + E74.
E 74(m ut).
PEA 3.
PU-1.
Unlabelled com petito r
oligonucleotide.
Free oligonucleotide
Figure 11.12.
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modifications and hetero-oligomer formation, the sequence specificity of the protein 
is altered. There are precedents for this with the elk-1 and SAP-1 proteins that are 
only able to bind to the recognition sequence in the serum response element after 
interaction with a SRF dimer (Dalton and Treisman, 1992; Janknecht and Nordheim, 
1992; Rao and Reddy, 1992b). However, alternative possibilities are that (a) the Fli-1 
and erg mRNAs are not translated in the ELM cell lines, or (b) the Fli-1/E74 and 
erg/E74 complexes are part of the low mobility band A seen in the EMSAs. To 
answer these questions, erg and Fli-1 anti-sera must be developed.
CHAPTER 12: Characterisation of a rearrangement at the Fli-1 
locus.
12.1: Southern blot analysis of the erg and Fli-1 loci.
Inappropriate, deregulated expression of a gene in a developing tumour cell 
can occur either indirectly, as a consequence of alterations in the transcription factor 
profile of the cell, or directly, by the acquisition of a mutation(s) in the cis regulatory 
sequences of the gene. There are several possible mechanisms whereby a mutational 
event can increase the expression of a particular gene. For example, transposing a 
transcriptional enhancer to a position adjacent to the promoter of a gene will alter its 
normal regulation. In human leukaemias, translocation events have been well 
characterised and show proto-oncogenes becoming controlled by a cellular enhancer 
highly active in the cell type the leukaemia is derived from (Sawyers et al, 1991). In 
retrovirally-induced leukaemias studied in animal model systems, insertion of the 
viral genome into a particular site in the host DNA may confer a selective advantage 
during tumour progression, since the viral LTR deregulates the expression of a 
particular gene, either by transcriptional read-through or by enhancer insertion 
(reviewed in Peters, 1990). These kind of mutations disrupt the gross structure of the 
DNA and are readily detectable by Southern blot analysis. Smaller, more subtle
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mutations in the normal regulatory domains of a gene could possibly have a similar 
effect on transcription: these are unlikely to be found by such experimentation.
The murine erg cDNA probe (426erg) generated in section 11.4.1 was used to 
probe a series of Southern blots of ELM DNA digested with five different restriction 
endonucleases {Bam HI, ECo RI, Kpn I, Nco I and Xba I). No structural differences, 
either amplification or rearrangement, were detected between the normal C3H spleen 
control and any of the ELM cell lines tested (ELM-D, D#6,1-1,1-2,1-5 and 1-6) (data 
not shown). However, this does not unequivocally exclude the possibility of a 
mutation directly deregulating erg expression in cells of the system in view of the 
probe being only a partial cDNA derived from the middle of the mRNA.
Similar studies were also performed for Fli-1. The Fli-1 locus has been well 
characterised by others investigating common retroviral integration sites in MuLV- 
induced leukaemias (Ben-David et al, 1990a, 1991; Bergeron et al, 1991). A map of 
the region, showing the location of these integrations and a number of relevant 
restriction enzyme cleavage sites, was compiled from these studies (Figure 12.1C). 
Interestingly, this demonstrated that the orientation of the inserted provirus varies, 
depending upon which particular MuLV (F-MuLV or Cas-Br-E) was used to induce 
the leukaemia., The position of the SU-9 genomic probe obtained from Dr. E. Rassart 
is also shown. This was used to look for a rearrangement at the Fli-1 locus in the Fli- 
7-expressing 1-1 cells, using C3H spleen as a normal control. Genomic DNA was 
digested with five restriction enzymes, electrophoresed on a 0.8% agarose gel, blotted 
onto a nylon membrane and probed with radiolabelled SU-9 (Figure 12.1 A). Three of 
the enzymes (Pst I, ECo RI and Bam HI) produced identical banding patterns in the 
two DNA samples. However, with Xba I and Hind HI, an additional band is apparent 
in the 1-1 DNA, accompanied by a reduction in the intensity of the normal band. This 
is consistent with one Fli-1 allele having undergone a rearrangement, with the 
breakpoint localised between an Eco RI and a Hind III site, as shown in Figure 12.1C.
Since the SU-9 probe is approximately 5kb from the breakpoint of the putative 
rearrangement, an attempt was made to confirm the result using a second probe closer
Figure 12.1: Detection of a rearrangement in one Fli-1 allele in ELM-I-1 cells by 
Southern blot analysis.
A and B: Genomic DNA was isolated from ELM-I-1 cells (denoted by T-l') aid 
normal C3H spleen tissue (denoted by ’S') and 20|ig aliquots digested with the five 
restriction endonucleases shown above the autoradiographs. A Southern blot was 
prepared of these cleaved DNA samples and probed initially with a 32P-labelled SU-9 
probe (Bergeron et al, 1991) as described in Methods and Materials. A 3 day 
exposure of this blot is shown in panel A; the position of molecular weight DNA 
markers electrophoresed adjacent to the DNA samples are shown to the right of the 
autoradiograph. The blot was then stripped and probed with a probe from the ncn- 
coding region of the Fli-1 gene, generated by PCR from spleen genomic DNA (see 
Materials and Methods). A 6 day exposure of this blot is shown in panel B; the 
position of molecular weight DNA markers electrophoresed adjacent to the DNA 
samples are shown to the right of the autoradiograph. The background signal on this 
autoradiograph is particularly high: this is probably a consequence of the short length 
of the probe (~210bp) used in this experiment. The minor 4kb band seen in the Bam 
HI digest is thought to be a consequence of partial DNA cleavage.
C: Restriction map of the normal Fli-1 locus for the enzymes used in the Southern 
blot analysis (derived from Bergeron et al, 1991, and Ben-David et al, 1990a, 1991). 
Abbreviations used for the restriction sites are: P - Pst I; X - Xba I; H - Hind III; E - 
ECo RI; B - Bam HI. Also shown as black boxes are the regions where retroviral 
insertions occur in F-MuLV and Cas-Br-E-induced leukaemias; the orientation of 
the integrated viruses is also shown. The empty boxes show the position of the SL-9 
probe (from Bergeron et al, 1991), the location of the non-coding region of the Fli-1 
gene (as determined from the Southern blot analysis shown in panel B) and the regbn 
involved in the rearrangement identifed in the ELM-I-1 cells (labelled 'ELM 
breakpoint').
A .  P s t l  X b a  I H in d  III  E C o  RI /*am HI
1-1 S 1-1 S 1-1 S 1-1 S 1-1 s
P s t l  X b a  I H in d  III E C o  RI Bam  HI
1-1 S 1-1 S 1-1 S I-l S 1-1 s
F-MuLV Cas-Br-E  
y m m  y  y u  y
ELM — >^i—) i —  Fli-1  non-cod ing  
Breakpoint reg ion .
Figure 12.1.
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to this region. Ben-David and his colleagues (1991) have stated that the 5' end of the 
Fli-1 cDNA is able to hybridise to a region adjacent to the retroviral insertion sites, 
between the ECo RI and Bam HI sites shown in Figure 12.1C. PCR from genomic 
DNA was therefore used to generate a short 210bp cDNA probe containing the 5’ 
non-coding sequences of Fli-1, which was then hybridised to the blot previously 
probed with SIJ-9. With all the restriction enzymes shown, except ECo RI, 1-1 DNA 
contained an additional band absent from the spleen control (Figure 12. IB). Thus, the 
5' non-coding region of Fli-1 maps very close to the breakpoint found in 1-1 DNA, 
between the ECo RI and Pst I sites shown on Figure 12.1C. In conclusion, these 
results demonstrated that a rearrangement had occurred in one Fli-1 allele in 1-1 cells 
adjacent to the putative first exon of the Fli-1 gene. The assumed absence of 
exogenous and endogenous retroviral involvement in the generation and progression 
of the cells of the ELM system (Itoh et aU 1988a), made this rearrangement 
particularly interesting since it may indicate the presence of a translocation between 
the Fli-1 locus and the regulatory regions of another cellular locus.
12.2: Cloning and characterisation of the rearranged Fli-1 allele.
To elucidate the nature of the rearrangement at Fli-1, a genomic library was 
constructed from 1-1 DNA digested with Sau 3AI and ligated into ?iGEMll (see 
Methods and Materials). Initially, the library was amplified (section 6.16.4) and 
7.5xl05 plaques were screened with a radiolabelled SU-9 probe: no positive- 
hybridising plaques were found, despite the fact that, theoretically, the number of 
plaques screened had an -99% probability of containing the required insert 
(Sambrook et al, 1989). The presence of 1-1 DNA in the library was confirmed by 
hybridising to 32P-labelled mouse genomic DNA, and furthermore, three plaques 
were found that hybridised to the Fli-1 cDNA fragment excised from the pFli 
plasmid. However, these were unable to bind to SU-9 (data not shown). These 
results implied that the breakpoint region was under-represented in the library, an 
effect that may possibly be the result of amplification. Thus, a fresh library was
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constructed and used immediately without amplification. This was screened with SU- 
9, and two positive clones (A and B) were isolated. The 5' non-coding Fli-1 cDNA 
probe was not used in these initial screens because, even though it maps closer to the 
breakpoint, its short size makes hybridisation more difficult, a point that is illustrated 
by the intensity of the background signal observed in Figure 12.IB. However, once 
DNA had been isolated from the two positive clones, this probe was used to show that 
the clone B insert did not span the breakpoint region. Further analysis of this clone 
showed that it contained an ~15kb 1-1 genomic DNA insert (Figure 12.2A) that was 
unable to hybridise to any part of the Fli-1 cDNA, implying the presence of a large 
first intron (at least 18kb) in the Fli-1 gene. However, it is possible that alternative- 
spliced exons not present in the Fli-1 cDNA cloned in chapter 11 are encoded within 
this portion.
The cleavage sites for a number of different restriction enzymes were mapped 
for clone A, using Southern blot analysis and the SU-9 and Fli-1 5' non-coding 
probes, and also by transcription labelling from the SP6 and T7 promoters adjacent to 
the insert (see Methods, section 6.16.7). Fortunately, this demonstrated that the insert 
in this 'phage did span the breakpoint and was derived from the rearranged allele. Of 
the 12.5kb insert in clone A, 10.5kb had a restriction map identical to the wild-type 
Fli-1 allele (Figure 12.2A). Three restriction fragments around the breakpoint were 
excised from the clone and subcloned into the pBluescriptll KS+ plasmid to create the 
pCBlO, pCB20 and pCB30 vectors (Figure 12.2A). These inserts were partially 
sequenced using primers which hybridise to a region in the pBluescriptll KS+ 
plasmid adjacent to the cloning site. This showed that the whole 5' non-coding region 
of the gene and the first six codons, which presumably comprise the first exon of the 
gene, are found approximately 900bp from the breakpoint, and are transcribed away 
from this alteration (Figure 12.2B). Interestingly, the viral integrations described by 
Bergeron et al (1991) are all in this first exon, and in the same transcriptional 
orientation as the gene. Thus, they probably activate Fli-1 expression by a 
transcriptional read-through mechanism: this has recently been confirmed (Bergeron
Figure 12.2: Characterisation of a 'phage clone spanning the breakpoint at the 
Fli-1 locus.
A library was prepared from the genomic DNA of the ELM-I-1 cells and the 
XGEM11 bacteriophage vector, and screened with the SU-9 probe (Methods and 
Materials). Two positive hybridising clones (A and B) were isolated and DNA 
extracted.
A: Restriction map of clone A. Using a combination of SU-9, the non-coding region 
probe from the Fli-1 gene and probes prepared by transcription labelling from the SP6 
and T7 promoters in the 'phage arms, restriction maps for a number of enzymes were 
prepared for the two clones (Methods and Materials). Preliminary analysis 
determined that clone B did not span the breakpoint and was not subjected to any 
further analysis: its position is shown above the map for clone A. Abbreviations used 
for the restriction sites are: P - Pst I; X - Xba I; H - Hind III; E - ECo RI; B - Bam HI; 
S - Sst I; Bg - Bgl II; N - Nco I; Nsi - Nsi I. The positions of the SU-9 probe 
(Bergeron et al, 1991), and the BP1 probe used in later experiments, are denoted by 
red boxes; the right and left arms of the 'phage vector are given as green boxes. The 
position of the breakpoint is labelled accordingly. The three DNA fragments which 
were subcloned into pBluescriptll KS+ for further sequence analysis (Methods and 
Materials) are shown as double-headed arrows, adjacent to which is the name of the 
vector formed (pCBlO, pCB20 or pCB30) and the restriction enzyme used to cleave 
the fragment from the 'phage clone.
B: Sequence of the putative first exon of the Fli-1 gene, as derived from the pCBlO 
and pCB30 vectors. Sequence reactions and denaturing polyacrylamide gel 
electrophoresis are described in the Methods and Materials. The region between the 
two arrows had already been published (Ben-David et al, 1991): no nucleotide 
differences were apparent between the sequence from this reference and the one 
shown here. The first six codons are indicated by the bold letter beneath them which 
represent the amino acid for which they code: the putative splice site is shown. The 
Pst I restriction site in this region is underlined. Nucleic acid numbering takes the 
adenine residue of the initiating ATG as +1. The dinucleotide repeat is labelled with 
(A G )23 .
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et al, 1992). However, the F-MuLV integrations discovered by Ben-David and his 
colleagues (1990a) are further upstream outside the exon and in the opposite 
orientation. In this case, the gene presumably becomes over-expressed by an 
enhancer insertion mechanism. Twenty bases upstream from the beginning of the 
published sequence for Fli-1 was found a region consisting of 23 repeats of the 
dinucleotide, AG. The function of dinucleotide repeats of this kind is unclear, 
although in vitro DNA fragments consisting solely of these sequences are able to form 
left-handed double helical structures, termed Z-DNA (reviewed in Hill, 1991). 
Whether this occurs in vivo remains an issue of some controversy, but it has been 
proposed that these structures are involved in recombination and transcriptional 
control. The position of the AG repeat in the Fli-1 locus adjacent to the first exon of 
the gene, implies that it may play a role in regulating Fli-1 gene expression.
Sequence from the 2kb portion of clone A from the other side of the 
breakpoint, derived from the regions X, Y and Z of the pCBlO and pCB20 plasmids 
(Figure 12.3A), was compared with known sequences in the GenBank data-base, 
using GCG sequence analysis software (Devereux et al, 1984). The best match, of 
nearly 100%, was with the LTR and gag gene of the exogenous F-MuLV retrovirus 
strain FB29 (Figure 12.3B), the sequence of which had been published by Perryman 
et al (1991). It remained a possibility, however, that the provirus inserted at the Fli-1 
locus is derived from endogenous retroviral sequences, since in a number of radiation- 
induced leukaemias endogenous viruses become active, and are involved in 
deregulating genes necessary for tumour progression (Janowski and Boniver, 1986). 
To test for the presence of exogenous F-MuLV insertions in the genomic DNA of 1-1 
cells, a DNA probe specific for the env gene of the virus (termed ENV; see Table 6.1 
in the Methods and Materials) was hybridised to a Southern blot of Bgl H-cleaved 
DNA from these cells, using C3H mouse spleen DNA as a control. The combination 
of the ENV probe and the Bgl II digest will create junction fragments between the 
virus and the host DNA, allowing the number of proviruses to be calculated. No 
hybridisation to spleen DNA was observed, as expected, but three bands were
Figure 12.3: Comparative analysis of sequence derived from the rearranged Fli- 
1 allele isolated from ELM-I-1 cells, and the retrovirus F-MuLV.
A: Restriction map of the left-hand end of clone A depicted in Figure 12.2.
Abbreviations used for the restriction sites are: P - Pst I; H - Hind III; E - ECo RI; B - 
Bam HI; S - Sst I; Bg - Bgl II. The left arm of the 'phage vector is given as a stippled 
box. The position of the breakpoint is labelled accordingly. Two DNA fragments 
which were subcloned into pBluescript for further sequence analysis (Methods and 
Materials) are shown as double-headed arrows, adjacent to which is the name of the 
vector formed (pCBlO or pCB20) and the restriction enzyme used to cleave the 
fragment from the 'phage clone. The three boxes labelled X, Y and Z are the regions 
of these two vectors which were sequenced.
B: Sequence from regions X, Y and Z compared to F-MuLV (strain FB29)
(Penyman et al, 1991). The sequence from the 'phage subclones is the top line in 
each case with F-MuLV below. A dash (-) indicates nucleic acid identity, an asterisk 
(*) shows where a base is missing in the F-MuLV sequence, and bases missing from 
the clone A sequence but present in F-MuLV are given below both sequences with a 
line showing where the difference lies.
A.
IT S  pCB20. W |Break- f-----L1^ —
Stfl “ point. 1<—   --------
S S E Bg S
M , _________  '   I  ^  j,_______________ ____
Left arm: H ' ! B B
T7 pol. p  p
prom.   >
—>  pCBlO.
621 Pst I.
B. Z
X
CTTCCCTCACTAAGTCTCCTAAGGTCCTGCTCTTCAAATCTTCTAACCGCTCTAACTTTCG  
---------------------------------------------------------------T -----------------T ---------------------------------------------------------------
CCCGATATCCGGGGCGGACTGCCAGATGAATGACATGGCCACATTGGTTTCTTGCCCTGGG
TCCTCAGGGTCATAAGGAGTGTATCTGCGATAGGCCTCCTTGAGTCTCTCTAAAAAGGCTG
AGGGAGACTCATTAGGTCCCTGGGTTATCCCTTTTACCTTGGCCAAATTGGTGGG  
Compared to the gag gene of F-MuLV (strain FB29).
Y
CCTGTGGTCGTAGTACCTGGCAGGTCTCAGATCCGGACGAGCCCAAATGAAAGACCCCCGAG
 ! ] f --------------------------------------
AG C CC
ACGGGTAGTCAATCACTCTGAGGAGACCCTCCCAAGGAACAGCGAGACCACAAGTCGGATGC  
----------------------------------------------------------------------------------------------------------------------------G-------------------
AACAGCAAGAGGC T T TAT T GGATACACGGTACCCGGGCGACACAGTC TATCGGAGGAC TGGC
   * G--------------------------------- T ------------------------------------------------
GA
GCGCCGAGTGAGGGGTTGTGGGCTCTTTTATAGAGCTC  
 A -----------------------------------------
Compared to the F-MuLV (strain FB29) LTR.
M  GCTTCGGCTCCAAACCGAAAGCAAAAATTTAGACGGGGGCGGAAACCGTTTCAGCCCTCCG
TCCCCTACCAGAACCACATACCCCTCCTCTAAAGGGTGTGCACCAAAGAGTCCAAAACGAT  
----------------------------------------------------------------------------- G-------G------------------------------------------------------G -
CGGGATATTTGGACTCTGGCCGGGCCACAAAAATGGCCCCCGAAGTCCCTGGGACGTCTCC  
--------------GG------------------------------------------------------------------------------------------------- T -----------------------------
CAGGGTTGCGGCCGGGTATCCGAACTCGTCAGTTCTACCACGGGTCCGCCAGATACAG  
Compared to the 5' end of the gag gene, and part of the LTR, of F-MuLV (strain FB29).
Figure 12.3.
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detected in the 1-1 DNA, implying that three F-MuLV proviruses were present in this 
cell line (Figure 12.4). This result confirmed that exogenous virus was present in 
these cells. It appears, therefore, that Fli-1 became expressed in the ELM-I-1 cell line 
as a consequence of the insertion of F-MuLV. Since the viral genome is in the 
opposite transcriptional orientation to Fli-1, the LTR presumably acts as an enhancer 
for the normal Fli-1 promoter.
12.3: Retroviral expression and integration in the ELM system.
The presence of F-MuLV in 1-1 was surprising since the history of the 
development of the original ELM tumour and the cell lines within the system contains 
no mention of a viral involvement (Itoh et al, 1988a, 1988b, 1993). Thus, the RNA 
and DNA of the other cells in the system was tested, to examine when infection 
occurred. When RNA was hybridised to the ENV probe by Northern blot analysis, it 
was obvious that all the ELM-D and ELM-I cell lines, and indeed the in vivo passaged 
tumour cells, expressed variable amounts of viral gene transcripts (predominantly 
lOkb and 4kb species) that were absent from the normal C3H mouse tissue controls 
(Figure 12.5). The nature of the 9kb transcript restricted to the D#6, 1-5 and 1-6 
samples, is unknown, but may represent the presence of recombinant retroviruses 
formed between exogenous and endogenous retroviral sequences. Not only are viral 
transcripts produced, but it is also possible to observe virus budding from ELM cells 
under the electron microscope (Ostertag, personal communication). Exactly how 
virus infection occurred is not known, but the viral gene expression in the in vivo 
passaged tumour cells suggests that it was involved in generating the ELM tumour, in 
a similar way to erythroleukaemias previously described by Ben-David and his co- 
workers (1990a, 1991). This implied that the ELM leukaemia was not induced solely 
by X-ray irradiation, as originally thought (Itoh et al, 1988a), but suggested that F- 
MuLV infection was probably also involved in leukaemic development and 
phenotypic change within the cell lines. However, SFFV, the other component of the 
Friend virus complex, was not present in the ELM system. This was shown by
Figure 12.4: Southern blot demonstrating the presence of exogenous F-MuLV- 
like retroviruses in the ELM-I-1 cell line.
Genomic DNA was isolated from ELM-I-1 cells (denoted by T-l') and normal C3H 
spleen tissue ('spleen') and 20|ig aliquots digested with Bgl II. A Southern blot was 
prepared of these cleaved DNA samples and probed with a 32P-labelled ENV probe 
derived from the envelope gene of F-MuLV as described in Methods and Materials. 
A 3 day exposure of the blot is shown; the position of molecular weight DNA markers 
electrophoresed adjacent to the DNA samples are shown to the right of the 
autoradiograph.
Bgl  II cleaved.
Probe: F-MuLV enx gene.
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6kb
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Figure 12.4.
Figure 12.5: Expression of mRNAs hybridising to the F-MuLV envelope gene in 
the ELM system.
20fig of total cellular RNA was electrophoresed, blotted and hybridised to a 32P- 
labelled probe derived from the envelope gene of F-MuLV (Methods and Materials). 
Exposure time: 12 hours. Molecular weight markers are given, in kb, to the right of 
the autoradiograph. The position of the four different transcripts which hybridise to 
this probe are indicated by the arrows to the left of the autoradiograph, with an 
approximation of their size. The blot was stripped and reprobed with an actin cDNA 
to assess the relative levels of RNA loading. Exposure time: 4 hours.
Tissues and cell lines examined were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
D#6:- ELM-D#6 cells growing on live MS-5 cells (ratio 6 ELM-D#6 cells per MS-5). 
MS-5:- Stromal cell line, MS-5.
IVP ELM:- In vivo passaged ELM tumour cells.
Spleen:- Normal C3H mouse spleen.
Anaemic spleen:- Erythropoietically-active spleen from a C3H mouse which had 
been treated with phenylhydrazine to induce anaemia (see Methods and Materials). 
F4-12:- Friend virus-induced erythroleukaemia cell line, F4-12.
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Northern and Southern blot analysis using a DNA probe from the gp55 gene of the 
virus (see Table 6.1 in the Methods section). Although the probe hybridised to 
endogenous retroviral sequences, compared to normal C3H spleen there was neither 
any detectable novel integrations nor any significant increase in the expression of the 
gp55 gene in the in vivo passaged ELM cells or in the cell lines D#6,1-1,1-2, and 1-6: 
F4-12 DNA, used as a positive control, contained a number of integrated SFFV 
proviruses and exhibited a large over-expression of the gp55 gene. However, as will 
be described below, the 1-5 cell line may contain recombinant viruses formed with 
endogenous g/?55-like sequences.
Surprisingly, further Southern blot analysis with the F-MuLV ENV probe 
showed that the number of insertions varied between the different ELM cells: two 
insertions occur in the in vivo passaged tumour cells, but this increases up to nine in 
the cell lines derived from them (Figure 12.6). The two stromal cell-dependent cell 
lines tested had seven proviruses each; 1-1 only three; 1-2 and 1-5 had eight each and 
1-6 had nine. The additional integrations possibly arise as a consequence of re­
infection of the cells with F-MuLV produced either by the leukaemic cells, or by the 
MS-5 stromal cells which also surprisingly express low amounts of F-MuLV mRNAs 
(Figure 12.5). (The origin of MS-5 viral infection is also unknown: these cells were 
reportedly generated by irradiating long-term bone marrow cultures (Itoh et al, 
1989)). Furthermore, since the restriction endonucleases used will cleave the DNA to 
create junction fragments between the provirus and the host, it is apparent that only 
one site remains constant throughout the whole system (labelled ’common band' in 
Figure 12.6), although 1-5 and 1-6 contained all the same bands as the D#6 cell line 
from which they were derived (see also Figure 5.1 in the introduction, chapter 5). 
Thus, the additional insertion sites in 1-5 and 1-6 may be involved in generating 
stromal cell-independent growth.
Another interesting observation is that the 1-1 cells contain only one 
integration that is present in the cells from which they were derived (ELM-D and in 
vivo passaged tumour cells) (Figures 12.6 and 12.9B). Furthermore, it would appear
Figure 12.6: Retroviral integrations in the ELM system detected by Southern 
blot analysis of DNA cleaved with restriction enzymes which create junction 
fragments.
Genomic DNA was isolated from the ELM cells, cleaved with either Bgl II (panel A) 
or Nco I (panel B) and Southern blots prepared according to Methods and Materials. 
Both blots were hybridised to a probe derived from the envelope gene of the F-MuLV 
retrovirus and exposed to X-ray film for four days. The position of molecular weight 
DNA markers electrophoresed adjacent to the DNA samples are shown to the right of 
the autoradiographs. The 'common band', which is present in all the samples, is 
labelled with an arrow shown to the left of the autoradiograph. Spleen DNA from a 
normal C3H mouse contains no sequences which hybridise to the F-MuLV envelope 
probe (Figure 12.4) was omitted from the blot.
Tissues and cell lines examined were:
IVP ELM:- In vivo passaged ELM tumour cells.
D:- ELM-D cells growing on live MS-5 cells (ratio 6 ELM-D#6 cells per MS-5).
D#6:- ELM-D#6 cells growing on live MS-5 cells (ratio 4 ELM-D#6 cells per MS-5). 
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
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that 1-1 has actually lost some of the inserted proviruses in ELM-D cells. 
Alternatively, 1-1 may have been derived from ELM-D at a time when it too only had 
three insertions, but that continued passage on F-MuLV-infected MS-5 cells caused a 
gradual re-infection. However, it is difficult to explain why these integrations appear 
to be present in all ELM-D cells, unless one assumes that they confer a growth 
advantage. A further contributory factor that may explain these differences is 
genomic rearrangement, or deletion, of the provirus. In this way, the position of 
bands observed in one particular cell line could be shifted, or lost, in another. This 
would not be surprising since tumour cells often have particularly unstable genomes, 
a property which may, in part, be due to mutation of the p53 gene (Kastan et al, 1992; 
Yin et al, 1992; Livingstone et al, 1992). Recombination between exogenous 
retroviruses and endogenous retroviral sequences occurs in many malignancies 
induced by viral infection and may be important in the progression of the tumour due 
to the production of more leukaemogenic viral subtypes. For example, in F-MuLV- 
induced neoplasms, Friend mink cell focus-forming viruses (F-MCF) are formed 
which are thought to produce envelope proteins which are able to activate the 
erythropoietin receptor in a fashion similar to the gp55 protein of SFFV (Ruscetti et 
al, 1981; Chesebro et al, 1983, 1984; Li and Baltimore, 1991). In order to examine 
the ELM system for similar recombination events, two DNA probes were obtained 
from Ostertag and his colleagues. The first, termed F-MCF ENV, is able to hybridise 
to a wide variety of endogenous retroviral sequences, including those involved in 
forming Friend-MCF virus in F-MuLV-infected cells (Table 6.1 in Methods and 
Materials; Oliff et al, 1983). No extra bands were observed in the ELM system, that 
were distinct from those found in C3H spleen DNA, when Southern blots of DNA 
digested with either Bgl II or Xba I were hybridised to the probe (data not shown). 
However, the second probe, a 600bp fragment derived from the gp55 gene of SFFVp, 
binds to numerous fragments present in Bgl H-cleaved C3H spleen DNA, but 
interestingly an additional band is apparent in 1-5 DNA cleaved with the same 
enzyme that is absent from the other ELM cell lines tested (Figure 12.7A). A similar
Figure 12.7: Southern and Northern blot analysis of the ELM system using an 
endogenous retroviral probe derived from SFFV.
A: Genomic DNA was isolated, cleaved with Bgl II and a Southern blot prepared 
according to Methods and Materials. This was hybridised to a probe derived from the 
gp55 envelope gene of the SFFV retrovirus (see table 6.1 in the Methods and 
Materials) and exposed to X-ray film for four days. The position of molecular weight 
DNA markers electrophoresed adjacent to the DNA samples is shown to the right of 
the autoradiograph. The I-5-specific fragment is labelled with an arrow to the right 
of the autoradiograph at ~2.9kb. Novel integration sites of SFFV are apparent in the 
SFFV-induced erythroleukaemia cells, F4-12.
B: 20fig of total cellular RNA was electrophoresed, blotted and hybridised to a ^2P- 
labelled probe derived from the gp55 envelope gene of SFFVp (Methods and 
Materials). Exposure time: 72 hours. Molecular weight markers are given, in kb, to 
the right of the autoradiograph. The transcript observed in all the cells examined, 
including normal C3H spleen, is labelled with the letter 'A' and an arrow. The 
additional transcript seen in 1-5 RNA is labelled with the letter 'B' and an arrow. The 
blot was stripped and reprobed with an actin cDNA to assess the relative levels of 
RNA loading. Exposure time: 4 hours.
Cell lines and tissues tested were:
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
MS-5:- Stromal cell line, MS-5.
D#6:- ELM-D#6 cells growing on live MS-5 cells (ratio 6 ELM-D#6 cells per MS-5). 
IVP ELM:- In vivo passaged ELM tumour cells (late passage).
Spleen RNA from a C3H mouse.
F4-12:- Friend virus-induced erythroleukaemia cell line, F4-12.
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result is seen when the DNA is cleaved with Nsi I or Nco I (data not shown). F4-12 
cells also had an additional band but in a different position (~4.5kb), presumably due 
to insertion of the SFFV retrovirus that was used to generate this cell line.
The significance of the I-5-specific band is unclear. It seems highly unlikely 
that this cell line alone became infected with SFFV, and a more plausible explanation 
is that it arose as a result of a recombination event between endogenous g/?55-like 
sequences and, possibly, the exogenous F-MuLV. Interestingly, a Northern blot 
hybridised to the same probe showed that 1-5 produced significantly more of the ~4kb 
gp55-like mRNA than the other ELM cell lines and normal spleen tissue, although it 
was considerably less than the SFFV-infected F4-12 cells (Figure 12.7B). 1-5 cells 
also produce a larger transcript of approximately ~10kb that is absent from all the 
other ELM cell lines tested.
The 1-5 cell line is unique in the ELM system, in that it is still able to 
differentiate in response to epo, but is highly tumorigenic. Whether this is due to 
some extent to the alterations in the expression of g/?J5-like transcripts is not known: 
it is possible that the production of MCF-like viruses could enhance the splenomegaly 
induced by inoculation of 1-5 cells by infecting and stimulating the proliferation of 
host erythroid cells. This could be examined by testing whether the cells in the 
enlarged spleens all contain the 18bp deletion in the p53 gene characteristic of ELM 
cells.
12.4: A full-length F-MuLV provirus is inserted into the Fli-1 locus in all ELM 
cells.
The discovery of inserted F-MuLV proviruses in the cells of the ELM system 
raises a number of important questions concerning the generation of the ELM 
leukaemia, and its progression to various phenotypically-distinct cell types in vitro. 
The clonality of the in vivo passaged tumour cells with respect to its two integration 
sites, implies that these are important for the tumorigenicity of these cells in vivo, and 
were probably involved in its generation. Furthermore, the conservation of the
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integrity of one of these integrations throughout the ELM system suggests that this 
particular insertion is necessary to maintain the viability of the ELM cells in vitro. 
Obviously, identifying the position of this insertion and determining which gene(s) 
are affected by the provirus was of interest to further understand the development and 
progression of murine erythroleukaemias.
One possibility was that F-MuLV insertion into the Fli-1 locus was an early 
event in the ELM system that was maintained throughout the various cell lines. This 
seemed unlikely since the Fli-1 gene was only expressed in the 1-1 cell line. 
Surprisingly, however, by using radiolabelled BP1 probe isolated from clone A (see 
Figure 12.2A), it was demonstrated by Southern blot analysis that the same genomic 
rearrangement is detectable at the Fli-1 locus in all the ELM cells (Figure 12.8 and 
12.9A). Despite the restriction of Fli-1 expression to the 1-1 cell line, no gross 
structural differences were apparent between this and the other cell lines with the 
three restriction endonucleases used, Bgl II, Nco I and Nsi I. Since Nsi I, does not 
cleave within the published sequence of F-MuLV (Perryman et al> 1991), the fact that 
it produced a rearranged band approximately 9-9.5kb larger than the wild-type band 
(Figure 12.9A) suggests that a full-length F-MuLV provirus (~9.25kb) is present at 
the Fli-1 locus in all ELM cells. When this blot is stripped of the BP1 probe, and 
hybridised with radiolabelled F-MuLV ENV (Figure 12.9B), the common ELM 
insertion site described above, was found to comigrate with the rearranged band 
detected with BP1 (Figure 12.9A). This suggested that the invariant insertion is the 
one at Fli-1, a conclusion that is supported by the Bgl II and Nco I blots probed with 
ENV (Figure 12.6). This is illustrated in Figure 12.10 which shows a hypothetical 
map of a full-length F-MuLV provirus in the Fli-1 locus with the relevant restriction 
sites marked. The ENV probe should theoretically hybridise to a 9kb Nco I junction 
fragment and 5.8kb fragment upon cleavage with Bgl II. These are the sizes of the 
invariant band seen in the ELM system on the Nco I and Bgl II blots (Figure 12.6).
Thus, in summary, it appears that a full-length F-MuLV provirus is inserted 
into the Fli-1 locus in ELM tumour cells that have been passaged in vivo and in all the
Figure 12.8: Southern blot analysis demonstrating that the retrovirus inserted in 
the Fti-l locus is present in all the cells of the ELM system.
The two blots previously hybridised to the F-MuLV envelope probe (Figure 12.6) 
were stripped and probed with the BP1 fragment derived from 'phage clone A (Figure 
12.2). This probe maps very close to the integration site identified in one Fli-1 allele 
in ELM-I-1 cells. Blots were exposed for four days. The position of the 'normal 
allele' bands was determined from previous Southern blots of Bgl II- and Nco I- 
cleaved C3H spleen genomic DNA which are not shown here: the 'rearranged allele' 
bands are also labelled. The differences in the intensity of the bands between lanes is 
due to variation in DNA loading: the differences apparent within a single lane (D and 
D#6) are due to the stromal cell contamination in these samples. The position of 
molecular weight DNA markers electrophoresed adjacent to the DNA samples are 
shown to the right of the autoradiographs.
Tissues and cell lines examined were:
IVP ELM:- In vivo passaged ELM tumour cells.
D:- ELM-D cells growing on live MS-5 cells (ratio 6 ELM-D#6 cells per MS-5).
D#6:- ELM-D#6 cells growing on live MS-5 cells (ratio 4 ELM-D#6 cells per MS-5). 
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones I-1,1-2,1-5 and 1-6.
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Figure 12.9: Southern blot analysis of Nsi l-cleaved DNA suggests that there is a 
full-length retrovirus inserted at the Fli-1 locus, whose structure remains 
unchanged throughout the ELM system.
Genomic DNA was isolated from various cell lines and tissues, cleaved with Nsi I and 
a Southern blot prepared according to Methods and Materials. The blot was first 
hybridised to 32P-labelled BP1 probe derived from clone A (Figure 12.2) and exposed 
to X-ray film for four days (panel A) The position of molecular weight DNA markers 
electrophoresed adjacent to the DNA samples are shown to the right of the 
autoradiographs. The position of the 'normal allele' and 'rearranged allele' bands are 
labelled. The difference in the intensity of the bands between the ELM cell DNA 
lanes is due to variation in DNA loading: the differences apparent within a single lane 
(D and D#6) are due to the stromal cell contamination in these samples.
The blot was stripped and reprobed with a 32P-labelled DNA fragment from the 
envelope gene of the F-MuLV retrovirus and exposed to X-ray film for four days 
(panel B). The 'common band', which is present in all the samples, is labelled with a 
line shown at both sides of the autoradiograph. The position of molecular weight 
DNA markers electrophoresed adjacent to the DNA samples are shown to the right of 
the autoradiograph.
Tissues and cell lines examined were:
C3H spleen:- Normal spleen from a C3H mouse.
IVP ELM:- In vivo passaged ELM tumour cells.
D:- ELM-D cells growing on live MS-5 cells (ratio 4 ELM-D#6 cells per MS-5).
D#6:- ELM-D#6 cells growing on live MS-5 cells (ratio 6 ELM-D#6 cells per MS-5). 
1-1,1-2,1-5 and 1-6:- Stromal cell-independent clones 1-1,1-2,1-5 and 1-6.
As mentioned in the text, when the two autoradiographs shown here are superimposed 
the 'rearranged allele’ band in panel A, and the 'common band' in panel B, are 
coincident.
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cell lines derived from these original tumour cells, despite the fact that the Fli-1 gene 
is only expressed in 1-1 cells. No structural differences, detectable by Southern blot 
analysis, are apparent between the different ELM cell lines. Therefore, unlike the 
other integration events in the ELM tumour cells, the integrity of the provirus at the 
Fli-1 locus appears to remain constant throughout the system. Possible explanations 
for all the phenomena described in this section are discussed in further detail in Part 4.
Figure 12.1G: Restriction map of the Fli-1 locus, with and without a full-length 
F-MuLV provirus.
The restriction map of the 'normal allele' shown here has been constructed from 
known sites identified in 'phage clone A and from Southern blot analysis of C3H 
spleen DNA probed with the BP1 probe (shown as a dark blue box). The 
hypothetical 'disrupted allele' shown above this uses the restriction map for the 
normal allele and the map of the F-MuLV retrovirus (Perryman et al, 1991). 
Abbreviations used for the restriction sites are: B - Bgl II; N - Nco I; Nsi - Nsi I. The 
location of the F-MuLV env probe in the retrovirus is indicated with a dark blue box. 
The direction of transcription initiation mediated by the retroviral LTRs are 
represented by the arrows above the black boxes. The position and direction of 
transcription of the first exon of the Fli-1 gene is also indicated in the normal and 
disrupted maps.

PART 4: DISCUSSION.
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CHAPTER 13: General Discussion.
13.1: The ELM system as a model for normal and malignant erythropoiesis.
The ELM erythroleukaemia is a very attractive model in which to investigate 
erythropoiesis and erythroleukaemia, initially for the following reasons. First, its 
origins appeared to be unique as it was reportedly induced with X-ray irradiation, 
which usually generates leukaemias derived from other blood cell lineages (Janowski 
and Boniver, 1986; Mole, 1986; Itoh et al, 1988a). There was no detectable 
endogenous or exogenous retroviral involvement, as assayed by reverse transcriptase 
activity and leukaemogenic virus production (Itoh et al> 1988a), unlike the previously 
described Friend virus- and radiation-induced leukaemias (Janowski and Boniver, 
1986). Secondly, unlike the retrovirally-induced models it generated cell lines (ELM- 
D and its clonal derivatives, ELM-D#6, ELM-D#2 and ELM-D#3) which appeared to 
be much less advanced in terms of their loss of normal erythroid progenitor 
characteristics: that is, they required direct contact with a bone marrow-derived 
stromal cell layer to maintain long-term viability and prevent cell death (Itoh et al, 
1988b, 1993). Identifying the growth factors and regulatory molecules produced by 
the stroma, and defining their role in supporting the growth of ELM-D cells, has 
obvious implications in our understanding of the control of normal and malignant 
erythropoiesis and the nature of stroma/progenitor cell interactions. However, the use 
of such tissue culture cell lines obviously requires that the interacting cells can 
proliferate in culture. This may cause a problem in terms of the relevance of the 
results to the in vivo situation, if in fact one function of stroma is to keep 
haemopoietic progenitor cells dormant and provide long-term maintenance until 
demand for a specific cell type arises. Clearly such an in vitro proliferating 
haemopoietic cell/stromal cell system may have lost an important aspect of the 
normal function. Nevertheless, the work presented in this thesis concerning SCF, 
along with the extensive studies performed by our collaborators in Dr. Ostertag's 
group (Itoh et al, 1993), have begun to reveal the complexity of these interactions in
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controlling cell growth. Furthermore, this work demonstrated that mutant clones 
arose from these ELM-D cell lines, at a rate consistent with a mutational event, which 
had lost their stromal cell-dependence and were able to proliferate indefinitely in 
serum-containing medium alone. Defining the mutations responsible for this 
transition should give an insight into the nature of the intracellular signalling 
pathways which mediate the stromal cell-derived survival messages, and possibly 
further our knowledge of erythroleukaemia progression in the mouse. Significantly, 
the work described in this thesis has strongly implicated the ets family of transcription 
factors in preventing the cell death observed in ELM-D cells after separation from 
stroma.
13.2: Biological characterisation of the ELM system.
The initial experiments identified other phenotypic differences between the 
various cell lines of the system, namely their sensitivity to physiological 
differentiation inducers and their tumorigenicity in immunosuppressed syngeneic 
mice. All the cell lines tested, except ELM-I-1, could be induced to express globin 
mRNA and produce haemoglobin by incubation with erythropoietin, either alone, or 
in combination with IL-3, an effect which appears not to be due to differences in the 
expression of the erythropoietin receptor gene. The same differences in 
differentiation were observed in vivo, with only the ELM-I-1 cell line causing obvious 
anaemia, and an accompanying splenomegaly, upon injection. However, the ELM-I- 
5 cell line also induced a rapid splenomegaly, usually to a greater extent than ELM-1- 
1, but the cells were still capable of differentiation. Thus, the ELM cell lines can be 
categorised into four distinct phenotypic classes: the differentiation-sensitive, stromal 
cell-dependent cells and stromal cell-independent cells that (a) differentiated and had 
low tumorigenicity (ELM-I-2 and ELM-I-6), (b) differentiated, but had a much higher 
tumorigenicity (ELM-I-5), or (c) were differentiation-resistant in vitro and in vivo and 
also highly tumorigenic (ELM-I-1). Interestingly, the ELM-I-1 cell line shares all the 
characteristics attributable to Friend virus-induced erythroleukaemia cell lines
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(section 2.3.4). Thus, by identifying correlations between particular mutations and 
certain phenotypes, and then demonstrating an effect of the mutation by introducing it 
into a phenotypically less advanced cell type, it should be possible to answer a 
number of questions concerning murine erythroleukaemias.
13.3: The role of SCF in stromal cell-associated erythropoiesis.
The acute anaemia observed in Steel and W mice, and the demonstration of a 
potent synergistic effect on erythroid 'burst' formation exerted by soluble SCF in 
combination with other growth factors, has strongly implicated this protein in stromal 
cell-derived stimulatory signals acting during erythropoiesis (see Introduction section 
1.3.6). It was therefore an obvious candidate to study in the ELM-D#6/MS-5 
coculture system, and in fact a form of SCF mRNA, which contains the region 
encoding the proteolytic cleavage site, is highly abundant in MS-5 cells. This results 
in the production of both the soluble and transmembrane (TM) form of the ligand 
(Itoh et al, 1993). On the other hand, the ELM tumour and all in vitro cell lines tested 
express the SCF receptor gene, c-kit, and interestingly, the evolution of the original 
ELM leukaemia appears to have resulted in a selective expansion of cells expressing 
this gene.
Soluble SCF is unable to permit the long-term growth of ELM-D#6 cells in 
the absence of stromal cells (Itoh et al, 1993), but it seemed possible that the TM 
form of the ligand could be a crucial part of the microenvironment established by the 
stromal cells, and required by ELM-D#6 cells. To test this, Ostertag and his group 
attempted to block the SCF/c-kit interaction by incubation with antibodies raised 
against the ligand and the receptor. These antibodies did not prevent the adherence of 
the two cell types, but did significantly reduce the growth of ELM-D#6 cells (>75%) 
compared to untreated controls (Itoh et ah 1993). These results suggested that TM 
SCF was indeed a necessary component of the stroma, a conclusion confirmed by 
experiments in which the MS-5 cells were replaced with defective stromal cells 
derived from a Steel-Dickie (SUSld) mutant mouse. These mice are unable to produce
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the transmembrane form of the ligand, although the soluble form is present at levels 
equivalent to wild-type animals (Flanagan et al, 1991; Brannan et al, 1991; Huang et 
al, 1992). The ELM-D#6 cells are unable to survive longer than a few weeks on these 
stromal cells, exhibiting similar properties to erythroleukaemic cells grown in soluble 
SCF without MS-5 cells (Itoh et al, 1993). Whilst it remains to be demonstrated that 
this effect is solely due to the absence of TM SCF, the result emphasises the 
importance of this alternative form of the ligand.
In summary, ELM-D#6 cells, despite being leukaemogenic, still have a 
requirement for TM SCF/c-kit interaction for optimum long-term growth in vitro; 
abrogating this interaction reduces viability and induces cell death, even in the 
presence of other erythropoietic growth factors. Whether TM SCF alone is sufficient 
for ELM-D#6 cell survival, remains to be tested. Other interactions established 
between the two cell types may also be involved, and even though IL-3, GM-CSF and 
epo are not produced by the stromal cells (Itoh et al, 1993), other erythropoietic 
regulators or components of the extracellular matrix may play a part in preventing 
ELM-D#6 cell death (see chapter 1 in the Introduction). This hypothetical 
combinatorial stimulation is perhaps analogous to the situation with mature T cells in 
which stimulation through CD4, CD8 and the TCR-CD3 complex cooperate to elicit 
maximal proliferation (reviewed in Rudd, 1990). However, it is possible that TM 
SCF may exhibit different properties than the soluble form which enable it to permit 
long-term viability. Indeed, this has been proposed by other workers (Dolci et al, 
1991; Steel et al, 1992; Toksoz et al, 1992) who find that soluble SCF, unlike the TM 
form, is restricted in its ability to support the long-term viability of several SCF- 
responsive cell types. Moreover, this would explain the typical Steel phenotype of 
Steel-Dickie mice that appear to lack only the TM form (Flanagan et al, 1991; 
Brannan et al, 1991; Huang et al, 1992). However, recent unpublished data from 
Prof. Ostertag's laboratory suggests that under certain conditions long-term viability 
of ELM-D#6 cells can be supported, albeit less efficiently, by stromal cells derived 
from homozygous Steel (Sl/Sl) embryos which produce no SCF at all. It is not yet
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known what factors these embryonic cells produce which support ELM-D#6 growth 
in the coculture. However, in conjunction with the results from the Sl/Sld stroma, this 
observation has led to the tentative hypothesis that TM SCF is required to provide a 
fine tuned balance between cell survival, and cell death induced by soluble factors 
such as soluble SCF. Such a hypothesis presupposes that different intracellular 
signals are elicited through the same receptor upon binding to slightly different forms 
of ligand. Experiments are being initiated to test this idea, employing expression 
vectors carrying the various forms of SCF to attempt to change the nature of SCF 
production in SI/SI stromal and their subsequent efficiency at supporting long-term 
ELM-D#6 cell viability.
The stromal cell-independent mutants have lost the requirement for stromal 
contact, but this is due neither to the endogenous production of SCF by these cells, 
nor to v-kit-like truncations of the SCF receptor (Besmer et al, 1986). However, a 
mutation in an ELM-D cell which mimics the stromal cell-derived signal would 
presumably be sufficient to permit the stromal cell-independent growth of that cell. 
Bearing in mind the dominant effect of IL-3, GM-CSF and epo, which induce clonal 
extinction or differentiation respectively even when this survival signal is continually 
present in a ELM-D#6/MS-5 coculture (Itoh et al, 1993), it remains a possibility that 
these growth factors could elicit the same effect on ELM-I cells containing the 
aforementioned mutation. This is the case with epo since all the cell lines, except 
ELM-I-1, differentiate. Very preliminary data suggest that ELM-I-2 undergoes a 
considerable reduction in cell proliferation in response to IL-3, unlike the highly 
tumorigenic ELM-I-1 and ELM-I-5 cell lines: this can not be adequately explained in 
terms of variations between the cell lines with respect to the extent of differentiation 
induction (see Figure 8.2 in the Results section). Although this observation requires 
confirmation, it may represent a further phenotypic difference within the ELM 
system, and possibly provide a clue as to the nature of the mutation responsible for 
stroma-independence in the various ELM-I mutants, i.e. ELM-I-2 may have 
constitutively activated the stromal cell-stimulated survival pathway(s), whilst ELM-
158
1-1 and ELM-I-5 may contain mutations which prevent programmed cell death at a 
point further downstream that can not be overcome by IL-3. One would assume that 
the ELM-I clones isolated in the presence of GM-CSF, but not dependent on GM- 
CSF for survival (see Figure 5.1 in the Introduction) would fit into the latter category.
13.4: Mutation of the p53 gene in murine erythroleukaemias.
wtp53 is absent from all the erythroleukaemias arising after infection with 
Friend retroviruses (Ben David and Bernstein, 1991), and the ELM erythroleukaemia 
is no exception. Only one allele remains in all the ELM cells, and this contains an 
18bp in-frame deletion which removes amino acid residues 206 to 211, inclusive, 
from the mature protein. The mutation is outside the previously defined 'hot-spots' 
identified by analysis of a wide variety of p53 mutations, but small deletions and 
insertions have been reported in this region (Hollstein et al, 1991; Caron de Fromentel 
and Soussi, 1992). Interestingly, adjacent to the breakpoints of the deletion is a direct 
repeat of the sequence ACAG: similar repeats are seen in most other deletion 
mutations identified in the p53 gene (Jego et al, 1993), and probably play an 
important part in the mechanism governing these types of mutations. The 18bp 
deletion removes part of the epitope recognised by the PAb 240 antibody which 
becomes exposed in a large number of p53 mutants that have lost their suppressor 
function (Gannon et al, 1990; Stephen and Lane, 1992). The fact that these 
mutations, which are dispersed throughout the gene, alter the conformation of this 
central region of the protein, implies that a mutation within this region would also 
result in the loss of wt properties. Therefore, although it has not been confirmed by 
transformation assays, it is highly likely that the mutant p53 protein present in ELM 
cells is unable to perform its normal functions.
Cells containing this mutant still undergo cell death in the absence of stromal 
cells in vitro and are able to differentiate in response to erythropoietin. The mutation 
is, therefore, unable to block differentiation or cell death. These observations appear 
to conflict with several recent publications that demonstrate apoptotic induction in
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various cell types by the reconstitution of wtp53 expression (Yonish-Rouach et al, 
1991; Shaw et al, 1992; Ryan et al, 1993; Johnson et al, 1993). Of particular 
relevance, is the fact that when p53-negative Friend cells are transfected with wtp53 
expression vectors their cell cycle arrests at the Gl/S boundary, apoptosis is induced 
exhibiting the distinctive characteristic of DNA fragmentation, and there is a marginal 
increase in the level of spontaneous differentiation (Ryan et al, 1993; Johnson et al, 
1993). The differentiation induction in this case, and in other examples of wlp53- 
induced maturation (Feinstein et al, 1992; Shaulsky et al, 1991), may simply be the 
consequence of cell cycle arrest, since many chemical inducers of leukaemic cell 
differentiation block cell cycle progression by interfering with DNA replication (for 
example, the DMSO-induced differentiation of Friend cells (Terada et al, 1977)). 
Interestingly, the viability of wtp53-expressing Friend cells is restored by the addition 
of epo and differentiation returns to the normal background level (Johnson et al, 
1993). Epo is known to prevent cell death in normal erythroid progenitors which then 
progress to form mature erythrocytes (Koury and Bondurant, 1990), but in Friend 
cells, even those expressing wtp53, other mutations involved in the development of 
the leukaemia probably contrive to inhibit differentiation. These wtp53 reconstitution 
experiments led their authors to conclude that this gene induces death in erythroid 
progenitors, and therefore that p53 mutations in developing erythroleukaemic cells 
prevents this process and increases their life-span. However, ELM-D#6 cells undergo 
cell death in the absence of MS-5 cells, even though they lack wtp53 proteins.
This paradox can be explained by assuming there are two forms of cell death 
in erythroid progenitors: one, wtp53-dependent, exhibiting classical apoptotic 
characteristics; the other, wtp53-independent, inhibited by stromal cell interaction. 
The latter process may occur by a separate mechanism and may be the reason why it 
has been difficult to demonstrate DNA fragmentation in ELM-D#6 cells (Ostertag, 
personal communication). Furthermore, this would explain the normal erythropoietic 
proliferation, cell death and differentiation that occurs in p53-null mice (Donehower 
et al, 1992). The current working model for p53 as a DNA damage-regulated
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proliferation inhibitor (Lane, 1992; Figure 4.2 in the Introduction) has proposed that 
the wtp53 protein induces cell death only when the genome is disrupted by mutagenic 
agents. This would suggest that mutation of the p53 gene in developing 
erythroleukaemia cells has no direct influence on cell proliferation or differentiation 
per se, but rather that it permits the survival of cells that have undergone DNA 
damage, a consequence of which will be the accumulation of oncogenic mutations 
and the loss of other tumour suppressor genes. It is these secondary mutations which 
are the probable cause of differentiation arrest and immortality. When wtp53 
expression is reconstituted in these Friend cells (Ryan et al, 1993; Johnson et al, 
1993) this damage is detected, the cell cycle arrests and apoptosis is induced. In 
ELM-D#6 cells, cell death is the consequence of growth/survival factor deprivation 
and not a damage-induced apoptosis. One would hypothesise that this latter process 
would occur even in the presence of wtp53 gene expression in normal erythroid 
progenitors, and thus may be more relevant to the production of erythrocytes and the 
progression of erythropoiesis, than the protective death induced by the wtp53 
expression.
13.5: The role of ete-related genes in the ELM system.
13.5.1: Expression of Spi-1 and Fli-1.
Previous studies on Friend virus-induced erythroleukaemia cell lines 
demonstrated that if the original tumour was induced with SFFV or the Rauscher 
virus then the Spi-1 gene became activated (Moreau-Gachelin et al, 1988, 1989,
1990), whereas use of the F-MuLV retrovirus caused deregulated expression of the 
Fli-1 gene (Ben-David et al, 1990a, 1991; Sels et al, 1992). In the ELM system, 
which has putative F-MuLV involvement, Spi-1 mRNA is only detectable using 
sensitive reverse transcription-PCR protocols and the protein is undetectable in 
EMSAs. This low level probably represents the expression seen in normal erythroid 
progenitors which has been reported by other groups (Tsai et al, 1991b; Galson et al, 
1993). Fli-1, on the other hand, is expressed only in the ELM-I-1 cell line, the only
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ELM cell line which is unable to differentiate in response to epo. In fact, this cell line 
is phenotypically very similar to the Fli-1- or Spi-1-expressing Friend cell lines. This 
supports the hypothesis that deregulated expression of Fli-1 blocks erythroid 
differentiation: the ELM system presents an ideal opportunity to test this idea by 
ectopically expressing the gene in either other ELM-I cells or in the stromal cell- 
dependent clones, all of which are genetically very similar to the ELM-I-1 cell line. 
The lack of Fli-1 mRNA in all the other ELM-I cell lines suggests it is not necessary 
for stromal cell-independent growth.
The ELM system maintains the correlation of Fli-1 expression with F-MuLV 
infection, with Spi-1 deregulation restricted to SFFV-transformed cells, observations 
which Ben-David and Bernstein (1991) have suggested may be due to differences in 
the structure of the LTRs of the two viruses. Both contain putative ets binding sites, 
and it seems plausible that one effect of ets gene deregulation may be the potentiation 
of retroviral expression. This would increase production of SFFV and F-MCF 
envelope proteins which are known to bind to, and constitutively activate, the epo 
receptor in the absence of ligand (Ruscetti et al, 1990; Li et al, 1990; Li and 
Baltimore, 1991), and could therefore be viewed as an advantageous step in 
leukaemic progression. Interestingly, the F-MuLV envelope gene is expressed to a 
much higher level in the Fli-1-expressing ELM-I-1 cells compared to the other ELM 
cells. However, a recent publication demonstrates, paradoxically, that Spi-1, but not 
Fli-1, is able to bind to the F-MuLV LTR (Zhang et al, 1993).
13.5.2: Erg expression and stromal cell-independence.
The presence of proteins in nuclear extracts from the ELM system that are 
able to bind to the E74 oligonucleotide in EMSAs, instigated an investigation into the 
expression of erg, an ete-related gene highly homologous to Fli-1 which, when 
translated in vitro, codes for an E74 binding protein (Ben-David et al, 1991; Reddy 
and Rao, 1991). A portion of the previously undescribed murine erg gene was 
generated by reverse transcription-PCR reactions using primers designed from the
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human gene (Rao et al, 1987) and the fragment sequenced. This demonstrated that 
(a) the protein is strongly conserved between species (only four amino acids out of 
142 vary in the region analysed), (b) the -85 amino acid ets domain, the putative 
DNA binding portion of the protein, is nearly identical to the equivalent region of the 
Fli-1 protein (three amino acids vary in a cluster of serine residues), and (c) the erg 
gene is probably subject to alternative splicing in a region adjacent to the ets domain, 
which plays an important role in other ets proteins in regulating DNA binding and 
transactivation properties (Janknecht and Nordheim, 1992; Rao and Reddy, 1992b; 
Dalton and Treisman, 1992; Pongubala et al, 1992; Wasylyk et al, 1992). Duterque- 
Coquillaud et al (1993) have very recently shown that this alternative splicing event is 
also seen in the human erg mRNA, and contributes to the formation of at least five 
transcript variants.
Analysis of the ELM system, using the erg cDNA fragment to probe Northern 
blots, demonstrated that whilst erg mRNA was very low in in vivo passaged tumour 
cells and three separate stromal cell-dependent clones, there was a significant (4-48- 
fold) up-regulation in all the fourteen stromal cell-independent cell lines. Mixing 
experiments have shown that this difference can not be explained simply by 
contaminating stromal cells (erg mRNA-negative) diluting the erg-hybridising signal 
on the blot, although this of course will contribute slightly to the observed changes. 
Interestingly, expression of the erg gene appears to be subject to stromal cell 
regulation in the ELM-D#6 cell line, whereas this is lost in the ELM-I cells. This is 
implied by the fact that ELM-D#6 cells separated from stroma have a 5-10-fold 
increased level of erg mRNA . (These pure populations of ELM-D#6 cells are viable 
for between one to two weeks in the absence of stroma, but then undergo cell death). 
However, when the cell lines ELM-I-2 and ELM-I-5 are allowed to adhere to MS-5 
cells and grow in coculture for 72 hours, the erg gene is not down-regulated. Thus, 
the expression of the gene in the ELM-D#6 cells may be an essential component of a 
response to loss of stromal cell contact which temporarily elicits an ELM-I-like 
phenotype on the cells, and allows short-term survival. However, the cells will
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eventually undergo cell death, unless the pathway becomes constitutively active. One 
way this could possibly happen is by direct deregulation of the erg gene as a result of 
a mutational event, such as proviral insertion, and whilst I have been unable to detect 
either rearrangement or amplification at the erg locus in four ELM-I cell lines, this 
may be a consequence of only a partial cDNA probe being available at present. 
Further analysis using a full-length cDNA may reveal these types of mutations: 
cDNA library screening is underway to isolate such a probe. This would also allow 
the hypothesis that erg alters stromal cell-dependence to be tested by its ectopic 
expression in ELM-D cells.
In summary, there is a correlation between expression of the Fli-1 gene and a 
block in erythropoietin-induced differentiation, and erg expression and stromal cell- 
independent survival and proliferation. Future experiments designed to verify the 
validity of these observations are discussed in chapter 14.
13.5.3: Detection of ets proteins in the ELM system.
At the outset of this part of the project, erythroleukaemia cell lines were 
screened for the expression of ets proteins by using three oligonucleotides, each 
known to bind to a subset of different ets proteins. With ELM-I-1 and ELM-I-2, no 
detectable binding was apparent with the PU-1 and PEA3 oligonucleotides, thus 
effectively excluding Spi-1, c-ets-1 and c-ets-2, a conclusion confirmed by Northern 
blot analysis. However, a complex pattern of bands was observed when the E74 
oligonucleotide was used: erg had previously been shown to recognise this sequence 
(Reddy and Rao, 1991) and gene expression was subsequently analysed. The 
homology between erg and Fli-1 over their putative DNA binding domains prompted 
experiments to examine the DNA binding specificity of Fli-1 protein produced in a 
reticulocyte translation system. In fact, this protein exhibited similar specificity as 
erg, a result confirmed by Zhang et al (1993), who extended the studies to 
demonstrate a modest increase in the transcription of a reporter gene linked to tandem 
arrays of the E74 oligonucleotide co-transfected with a Fli-1 expression vector. The
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E74 binding activity in the ELM-I-1 and ELM-I-2 extracts could, therefore, 
conceivably be due to the Fli-1 and erg proteins, although this can only be confirmed 
by performing 'super-shift' EMSAs with Fli-1- or erg-specific antisera. However, the 
E74 oligonucleotide must be able to bind to other ets proteins. First, MS-5 cells 
which are erg-negative and only express Fli-1 at very low levels, give retarded bands 
with E74 some of which have identical mobility and are subject to the same pattern of 
competition with other ets binding sites as those seen with ELM-I-1 and ELM-I-2. 
Second, comparison of ELM-D#6 EMSAs with the ELM-I results identifies few, if 
any, significant differences in the bands formed, despite the obvious differences 
apparent at the mRNA level with respect Fli-1 and erg expression. These results have 
led to two tentative conclusions: (a) other E74-binding ets-related protein(s) are 
probably expressed in the ELM system, the identification of which may be important 
in understanding the role of deregulated ets genes in erythroleukaemia as these may 
interfere with processes controlled by other ets proteins; and (b) DNA binding 
specificity and affinity determined using in vitro-produced ets proteins may not 
necessarily mirror the in vivo situation. Bearing in mind that the sequences 
recognised by other ets proteins are altered by post-translational modifications and 
hetero-oligomerisation, this is not a trivial point. However, this presupposes that the 
Fli-1 and erg transcripts are translated in ELM-I-1 and ELM-I-2 cells, which needs to 
be confirmed with antibodies when they become available.
13.6: The effect of retroviral integration at the Fli-1 locus in the ELM system.
The restriction of Fli-1 expression to the ELM-I-1 cell line suggested that 
transcription of this gene had become deregulated, possibly as the consequence of a 
mutational event. Using a genomic probe from the Fli-1 locus, and a probe from the 
5' end of the Fli-1 cDNA, a rearrangement was detected in one allele in the DNA of 
ELM-I-1 cells. Cloning the rearranged Fli-1 allele revealed that the rearrangement 
was caused by the insertion of a F-MuLV-like provirus at a position identical to those
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previously described by Ben David and his colleagues (1990a, 1991); that is, 
upstream of, and in the opposite orientation to, the Fli-1 gene.
The sequence data presented here from the Fli-1 locus has defined the position 
of the putative first exon of the gene, which in the ELM cells is approximately 900bp 
from the proviral insertion site. This exon contains the previously defined 5' non­
coding portion of the gene and the first six codons (Ben David et al, 1991). 
Interestingly, the Cas-Br-E integration sites identified by Bergeron et al (1991) all 
appear to lie within this first exon, and unlike the F-MuLV integrations are in the 
same transcriptional orientation as the gene: this has recently been confirmed 
(Bergeron et al, 1992). Thus, it seems likely that Fli-1 is activated by two distinct 
mechanisms, depending on the retrovirus used to induce the leukaemia; enhancer 
insertion with F-MuLV, but transcriptional read-through with Cas-Br-E. The 
preliminary analysis of the Fli-1 gene also identified a dinucleotide repeat ((AG)23) 
just upstream of the start of the first exon. The exact role of this sequence, if any, in 
the transcriptional regulation of Fli-1 is not known, but it has been suggested that 
formation of left-handed double-helical Z-DNA by these sequences may increase the 
rate of formation of unwound DNA required during transcriptional initiation 
(reviewed in Hill, 1991). Moreover, it has also been proposed that they act as targets 
for recombination and insertion events, and it is tempting to hypothesise that the 
dinucleotide repeat at Fli-1 may play a part in retroviral integration at this locus in 
haemopoietic cells.
An intriguing and novel aspect of this work was the detection of the F-MuLV 
integration at Fli-1 in the in vivo passaged tumour cells and all the derivative cell 
lines, despite the restricted expression of the gene to the ELM-I-1 cells. This raises 
important questions concerning (a) the role of F-MuLV integrations at the Fli-1 locus 
in the ELM cells and other erythroleukaemia cell lines, and (b) the mechanism 
whereby Fli-1 becomes expressed in ELM-I-1 cells. Currently, there is no definitive 
answer to either of these questions, but several hypotheses will be considered, some 
of which are supported by experimental observations.
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The fact that the tumour cells are monoclonal with respect to this insertion 
implies that it was selected for during tumour development. There are precedents in 
other systems for such insertions being selected due to activation or inactivation of 
adjacent genes (reviewed in Peters, 1990). However, in the ELM leukaemia 
inactivation seems unlikely since there is no evidence for Fli-1 expression in normal 
erythroid progenitors, and furthermore, only one allele appears to be affected by 
mutation in the ELM tumour. Also, other work with a number of independently- 
isolated leukaemia cell lines, strongly implies that insertions at the Fli-1 locus 
deregulate expression of the Fli-1 gene (Ben-David et al, 1991; Bergeron et al, 1992). 
There seem to be two plausible interpretations of the ELM data involving gene 
activation by retroviral insertion. First, Fli-1 could have been activated in the original 
tumour but then become inactivated during subsequent passage in vivo, i.e. Fli-1 
expression was required for initiation of the leukaemia but not for its subsequent 
maintenance. However, if this hypothesis is correct, inactivation of Fli-1 must have 
occurred very early since tumour cells obtained from the very first passage of the 
original leukaemic spleen only express levels of Fli-1 mRNA consistent with 
contamination by normal spleen cells. An alternative explanation is that the retroviral 
insertion upstream of the Fli-1 gene activates the expression of another gene nearby, 
and it is the expression of this gene which encourages leukaemic progression. Fli-1 is 
known to be linked to c-ets-1 (Ben David et al, 1991), but this is not expressed in the 
ELM tumour or its derivative cell lines (data not shown). However, it remains 
possible that other genes in the vicinity of the integration site become ectopically 
expressed and are advantageous in tumour progression: possible candidates are the 
mouse homologues of PLZF and ALL1, genes closely related to known Drosophila 
developmental genes and which are the targets for translocations involving llq23 in 
human leukaemias and lymphomas (Tkachuk et al, 1992; Gu et aly 1992; Djabali et 
alt 1992; Ziemin van der Poel et al, 1992; Chen et al, 1993). (Human llq23 is 
syntenic with the position on mouse chromosome 9 where Fli-1 and c-ets-1 reside).
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The second question concerns the mechanism whereby Fli-1 becomes 
expressed in ELM-I-1. No structural differences have been detected between ELM-I- 
1 and other ELM cell lines using Southern blot analysis of the Fli-1 locus, although it 
can not be excluded that small sequence changes, in either the normal or the 
rearranged alleles, or other alterations outwith the region screened in this study, may 
be affecting expression of the Fli-1 gene. Alternatively, ELM-I-1 may express 
transcription factors absent from other ELM cell lines, that permit Fli-1 transcription 
which again may be either from the rearranged or the normal allele. This putative 
alteration in the transcription factor profile of ELM-I-1 cells, possibly as a 
consequence of mutational events, may be responsible for the different phenotype of 
ELM-I-1 cells. One possibility is that the reported resistance of C3H mice to F- 
MuLV-induced neoplasms (Ruscetti et al, 1981) may be due to an inability of the 
LTR to be appropriately activated in the haemopoietic cells of this strain: expression 
in ELM-I-1 cells may reflect a loss of this genetic control. A third hypothesis is that 
DNA methylation at CpG dinucleotide sequences, a process often associated with the 
transcriptional silencing of cellular and viral promoters (Bird, 1992; Orend et al,
1991), inactivates Fli-1 expression in all but the ELM-I-1 cells. Preliminary evidence 
derived from the comparative analysis of the banding patterns of Southern blots of 
DNA digested with Msp I (recognition sequence: CCGG) or its methylation-sensitive 
isoschizomer Hpa n, have suggested that several CpG sites around the breakpoint are 
hypomethylated in the ELM-I-1 cell line (data not shown). What effect, if any, these 
differences have on Fli-1 expression is unknown: in any case, as is often the problem 
with these kind of studies, it is difficult to conclude whether hypermethylation is the 
cause, or the consequence, of gene silencing (Bird, 1992). However, it may be 
significant that the expression of F-MuLV sequences is significantly higher in the 
ELM-I-1 cells than in any of the other ELM cell lines, which suggests that the activity 
of the retroviral LTR varies between the cell lines and this in turn could explain the 
Fli-1 expression differences. One way to distinguish between these possibilities 
would be to introduce an expression plasmid containing a reporter gene linked to the
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F-MuLV LTR and Fli-1 promoter (available from clone A) into the various cell lines 
of the system. If, for example, this reveals that only the ELM-I-1 cells are capable of 
transcription from such a promoter, it would imply that only these cells contain the 
appropriate transcription factor profile required to mediate Fli-1 expression.
13.7: Radiation and retroviruses.
i The work presented here questions the non-viral origin of the ELM leukaemia,
i}
| since the in vivo passaged tumour cells, and all the cell lines derived from them,
[ contain (a) expressed exogenous retroviral sequences which hybridise to the env gene
iI
| of F-MuLV, and (b) genomic LTR and gag sequences nearly 100% homologous to
f
I the published sequence derived from a F-MuLV strain (Perryman et al, 1991).
t
j  Furthermore, it is possible to observe viral particles budding from cultured ELM cells
I under the electron microscope (Ostertag, personal communication). Exactly when,
and how, retroviral infection occurred remains a mystery, but the presence of 
retroviral sequences in the earliest in vivo ELM cells available suggests that it 
probably played a major part in the evolution of the tumour. Thus, although radiation 
may have been a contributory factor, it was almost definitely not the sole etiological 
agent. Interestingly, since F-MuLV has only been reported to induce leukaemias in
! newborn mice (Troxler and Scolnick, 1978; MacDonald et al, 1980; Oliff et al, 1981),
I
j and only in Balb/c and NIH/Swiss strains (Ruscetti et al, 1981), the radiation may
have been necessary to encourage the progression of this erythroleukaemia in a C3H 
background, which did not appear until the mouse was over one year old (Itoh et al, 
1988a).
! A further complication arose when the number and structure of the F-MuLV
i
proviruses was investigated by Southern blot analysis. By using the appropriate 
restriction endonucleases and a retroviral probe, junction fragments between the host 
DNA and the provirus were assessed. This revealed that not only did the number of 
proviruses vary from between two to nine in the ELM cells, but also that only one 
maintained its structural integrity throughout the system. As was discussed earlier,
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this insertion appears to be at the Fli-1 locus. The generation of new insertions may 
be the consequence of superinfection by F-MuLV retroviruses or recombinants 
produced either by the ELM cells, or by the MS-5 stromal cells, which also 
surprisingly express F-MuLV transcripts. (Like the ELM erythroleukaemia, the MS-5 
cell line was reportedly generated by irradiation, in this case of a long-term bone 
marrow cultures (Itoh et al, 1989)). The apparent shifting of insertions, seen for 
example between the in vivo passaged tumour cells and the ELM-D cell line, may be 
a result of recombination events between F-MuLV and endogenous, or other F- 
MuLV, sequences present in these cells. However, there is little evidence to support 
any of these possible explanations which could only be effectively proven by cloning 
the proviruses from genomic libraries constructed from the DNA of the various cell 
types. Perhaps a more important goal is to determine whether the proviruses affect 
the structure or expression of tumour suppressors or proto-oncogenes. In particular, 
whilst it is known that one of the proviruses in the in vivo passaged tumour cells is 
inserted at the Fli-1 locus, the position of the second is unknown: since the cells are 
monoclonal with respect to this integration event, it seems likely that it conferred 
some advantage to the developing ELM tumour. Furthermore, the novel integrations 
apparent in the ELM-I-5 and ELM-I-6 cells, but absent from the ELM-D#6 cell line 
from which they were derived, may have been important in the evolution of stromal 
cell-independence.
There is no evidence for the presence of the other component of the Friend 
virus complex (SFFV) in the ELM system, demonstrated by the fact that (a) gp55- 
hybridising sequences are expressed at only a very low level equivalent to that seen in 
normal C3H spleen cells, and (b) no novel insertions are detectable in the DNA of the 
in vivo passaged tumour cells. However, genomic DNA from ELM-I-5 contains a 
novel g/?55-hybridising band arising not as the result of SFFV infection, but probably 
as a consequence of a genomic rearrangement within this cell line. Furthermore, 
using the same probe, Northern blot analysis suggested that the ELM-I-5 cells 
produce an increased amount of retroviral transcripts, and also produce a novel
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transcript absent in the other ELM cell lines. The significance of these observations 
is at present unclear, and it remains to be determined whether they influence the 
biological properties of the ELM-I-5 cell line in any way. One possibility, is that this 
putative rearrangement may generate a tumorigenic retrovirus, in a manner akin to 
that seen in other F-MuLV-induced malignancies (Ruscetti et al, 1981; Chesebro et 
al, 1984). Li and Baltimore (1991) have demonstrated that these retroviruses behave 
like SFFV, expressing envelope proteins capable of ligand-independent activation of 
the erythropoietin receptor. If the ELM-I-5 cell line does express a recombinant 
retrovirus of this type, then it may explain the increased splenomegaly caused by 
these cells since host erythroid cells could develop epo-independence as a result of 
cross-infection. Such an effect is readily tested by determining the ratio of ELM-I-5 
to host cells in the enlarged spleens which develop on ELM-I-5 injection.
CHAPTER 14: Future Prospects.
The data presented in this thesis have initiated two long-term avenues of 
research for subsequent study: (1) the elucidation of the molecular mechanisms 
involved in the critical stromal cell interactions which support long-term ELM-D 
growth, in particular the role of signalling through c-kit in response to binding to 
soluble or membrane-bound SCF; and (2) the investigation of the roles of the erg and 
Fli-1 genes in generating abnormal phenotypes in erythroid progenitor cells and the 
effect this has on erythroleukaemia progression. The results from these studies should 
provide a working model concerning intracellular signalling in response to survival 
and differentiation stimuli.
With respect to SCF, retroviruses expressing the various forms of the protein 
should be useful tools in determining if they have distinct functional properties. 
Experiments already underway in Prof. Ostertag's laboratory involve the use of such 
retroviruses to alter the SCF expression in Sl/Sl and Sl/Sld stromal cells and assay for
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changes in these cells to support long-term ELM-D growth. Alternatively, it may 
prove informative to infect the ELM-D cells themselves with these viruses to see if it 
increases the generation of stromal cell-independence. One possible problem with 
this experiment is that the expression of SCF, in particular the TM form, and c-kit in 
the same cell may prevent proper interaction. A different approach is to assess 
whether ELM-I mutants have mutations in c-kit that constitutively activate the 
receptor. This could be done by measuring the protein's kinase activity by assaying 
autophosphorylation after immunoprecipitation. Likewise, it may be interesting to 
introduce v-kit (Besmer et al, 1986) into ELM-D cells and again assess for alterations 
in the rate at which stromal cell-independent variants arise.
Crucial experiments to directly examine the putative role of erg and Fli-1 in 
the phenotypic differences in the ELM system can be performed by constitutively 
expressing Fli-1 or erg cDNAs in ELM-D or ELM-I cells. This will require the 
cloning of a full-length erg cDNA and the construction of expression vectors or 
retroviruses carrying the genes. Hypothetically, one might expect that Fli-1 will 
block differentiation in these assays, whilst erg may increase the rate of generation of 
stromal cell-independent variants. However, bearing in mind the high homology 
between the two ets proteins (almost 100% over the ets domain) (Ben-David et al, 
1991; Watson et al, 1992), it is possible that high ectopic expression of either gene in 
the ELM system may affect both survival and differentiation. The erythroid 
maturation observed in erg-expressing ELM-I clones, which were selected for stroma- 
independent growth rather than differentiation arrest, may be due to erg not being 
directly deregulated by mutation. In this way, epo may still override the 
constitutively active survival signal present in these cells, perhaps in a manner similar 
to the way that it overrides the stromal cell-derived signal. If erg or Fli-1 were to 
induce phenotypic change in ELM cells, it would prove interesting to introduce 
partially-deleted or mutated versions of the genes into these cells to define the 
domains required, and also suggest possible mechanisms, for each particular 
phenotypic change observed. For example, cDNAs encoding only the DNA binding
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domain of the proteins may act as dominant-negative inhibitors of Fli-1, erg or other 
ets proteins (such as the E74 binding protein identified in ELM-D cells).
The validity of any results obtained in these experiments would be reinforced 
by using erg and Fli-1 anti-sera to verify protein production. Further, these would 
allow the 'super-shift' experiments proposed in section 13.6.3 to be performed to 
compare the DNA binding specificities of these proteins when they are produced in in 
vitro translation systems as opposed to within live cells, where hetero-oligomerisation 
and post-translational modifications must be considered.
If up-regulation of erg and Fli-1 are responsible for generating some aspects 
of the leukaemic phenotype, these effects should be manifest by expressing the 
proteins in normal haemopoietic progenitors. Using retroviral expression vectors, 
these genes can be introduced into haemopoietic cells and the growth factor 
requirements and differentiation properties assessed using standard protocols, such as 
BFU-E and CFU-E assays, with or without stromal cells. Generation of leukaemic 
cells could be determined by transplantation in vivo or by direct infection of mice 
with the retroviruses. Since the ELM leukaemia cells contain p53 mutations, it might 
also prove informative to introduce these expression vectors into p53-null mice 
(Donehower et al, 1992) with the assumption that one genetic event which occurs 
during the progression of erythroleukaemias, is already present.
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